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Design, Combinatorial Synthesis, and Biological Evaluation of Novel α-Helical 
Mimetics Based on Functionalized Piperazines as Antagonists of p53/MDM2 
Interactions 
Melissa Topper 
Abstract 
The p53 protein promotes tumor eradication upon activation, making it an 
attractive target in cancer therapies. A reported 50% of all human cancers display 
aberrant activation of the MDM2 oncoprotein, which directly promotes tumorgenesis by 
inactivating the transcriptional activity of wild type p53, and is commonly associated 
with drug, chemo, and radio therapy resistance.  Previously reported crystallographic 
analysis of the p53/MDM2 complex infers that the p53 protein forms a 2.5 turn 
amphipathic alpha helix whose hydrophobic face interacts within a deep hydrophobic 
cleft in the NH2-terminal domain of the globular MDM2. This suggests that the synthesis 
of small molecular antagonists of p53/MDM2 binding interactions, capable of 
reactivating wild type p53 function, show a promising therapeutic strategy in 
pharmaceutical discovery.  The use of alpha helix mimics for the disruption of 
p53/MDM2 binding interactions has been amply documented in the literature; however, 
these compounds contain hydrophobic scaffolds that limit their usefulness as potential 
drug candidates.  Presented is the design, synthesis, and biological evaluation of novel 
non-peptidic, drug-like, small molecule inhibitors to target p53/MDM2 binding 
xiv 
 
interactions.  The mimetics are designed to bind to the NH2-terminal domain of MDM2 
protein leaving p53 unbound and capable of activation.  The inhibitor design is based on 
an alpha helix mimetic scaffold derived from functionalized piperazines, 
diketopiperazines, and/or pyrimides.  The mimetics are designed to have a comparably 
higher degree of solubility and notably facile synthesis yet still maintain the desired 
spacial arrangements of hydrophobic side chains in the ith, ith+4, and ith+7 positions of 
a natural alpha helix.  The small molecules are designed to act as antagonists of 
protein/protein interactions, tumor inhibitors, and potent p53 activators. 
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Chapter One: 
 
Cancer Formation and its Association with Proteins 
1.1 Cancer 
Cancer is a group of fundamentally genetic diseases that begin within the cell.  It 
is widely agreed upon that the formation of tumors (tumorigenesis) in humans is a 
complicated, multi-step, progressive process.(Busygina and Bale, 2006; Hanahan and 
Weinberg, 2000; Lengauer et al., 1998)  These steps, which display a succession of 
genetic alterations, are responsible for the progression of normal human cells, to 
abnormal cancerous cells, to a conglomerated mass of abnormal cells termed a 
tumor.(Hanahan and Weinberg, 2000) There are more than 100 different types of cancer 
and all of those various cancer cells are hallmarked by the same six essential alterations 
to otherwise normal cell physiology, as shown in Figure 1.1.   Cells, which will progress 
to human malignancies, have the acquired ability to induce and sustain angiogenesis, 
evade apoptosis, discount anti-growth signals, display limitless replication potential, are 
self-sufficient in growth signals, and are able to invade surrounding tissue and 
metastasize.(Genentech, 2008; Hanahan and Weinberg, 2000)    
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Figure 1.1: Acquired cellular capabilities of cancer 
 
Anyone one of these alterations is attributed to the mutation of a specific gene and 
a culmination of all six alterations enables the transformation of a normal functioning cell 
to cancerous cell.  The occurrence of gene mutation is a highly inefficient process.  The 
body is designed to maintain pristine genomic order by a complex array actions initiated 
by tumor suppressor (TS) genes, proto-oncogenes, and DNA repair genes.  The TS and 
proto-oncogenes, commonly referred to as the “gatekeepers”, regulate cell growth, 
proliferation, adhesion, and cellular death (apoptosis). (Busygina and Bale, 2006; Levitt 
and Hickson, 2002)  The DNA repair genes, also referred to as the “caretakers”, do not 
directly affect cell growth, but are directly involved in the maintenance of genomic 
stability by preventing superfluous mutations. (Busygina and Bale, 2006; Hanahan and 
Weinberg, 2000; Levitt and Hickson, 2002)  This is done through the actions of 
nucleotide-excision and DNA mismatch repair genes. (Lengauer et al., 1998)  Given the 
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high level of complexity and efficiency of the body’s natural maintenance process, it 
would be highly unlikely that all six aforementioned mutations could or would 
spontaneously occur in a single normal cell, resulting in cancer development.  This poses 
one of the greatest conundrums in modern medicine as cancer undoubtedly does develop 
in a substantial portion of the population, causing a world-wide health concern. 
(Busygina and Bale, 2006; Hanahan and Weinberg, 2000)  There were an estimated 
1,529,560 new cases of cancer reported in the United States alone in 2009, and cancer is 
the second leading cause of death in the United States (Figure 1.2). (American Cancer 
Society, 2010; Heron et al., 2009)  This overwhelming statistic would provide sound 
belief that the genomes of the caretakers, gatekeepers, or possibly both, have been 
compromised and therefore left susceptible to increased mutability to account for the high 
incident rate of cancer diagnoses. (Busygina and Bale, 2006; Hanahan and Weinberg, 
2000; Lengauer et al., 1998) 
 
Figure 1.2: Estimated new cancer cases and deaths in the United States for 2010 
 
1.2 Tumor Protein p53 
 Proper cell function is dependent upon a delicate balance between cell 
proliferation and cell death (apoptosis) (Figure 1.3).  An excess of apoptosis can result in 
embryonic defects and/or lethality, autoimmune diseases, and neurodegenerative 
diseases.  While an excess of cellular proliferation can result in tumorigenesis and 
metastasis. 
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Figure 1.3: Cellular homeostasis 
 
There are many signaling pathways within the body whose function is to maintain 
homeostasis between cellular proliferation and apoptosis.  The pathway most commonly 
regarded as compromised and implicated in tumorigenesis is the p53 signaling pathway.  
The primary function of this pathway is to induce cell cycle arrest or apoptosis to 
irreparably damaged cells.(Pogribny et al., 2009)  As depicted by Figure 1.4, p53 is the 
central component of this complex network, directly effecting ever gene and downstream 
signal within this pathway, documenting this protein’s paramount role in proper cell 
function. 
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Figure 1.4: p53 signaling pathway with the p53 protein circled in red 
 
 
Tumor suppressor protein 53, more commonly known as p53, is located at the 
core of an exceedingly complex network within the living cell and exists within the body 
in an α-helical N-terminal domain that binds to MDM2 and MDMX.(Laptenko and 
Prives, 2006)  The α-helix, first proposed by Pauling, et al., and later confirmed in 1951 
by Perutz, is the most abundant secondary conformation found in naturally occurring 
proteins (approximately 40%). (Han Yin, 2007; Hanahan and Weinberg, 2000)  An α-
helical state has been defined as a state in which the phi and psi display dihedral angles of 
approximately -60
o
, twisting repeatedly in the same right handed direction.  The distance 
separating each turn of the helix is 5.4 Å in a confirmation containing 3.6 amino acids per 
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turn of the helix, with a rise of 1.5 Å per amino acid, as shown in Figure 1.5.(Han Yin, 
2007; Woster, 2010) 
 
                                               Figure 1.5: Natural α-helix 
 
P53 is a transcription factor that directly effects tumor suppression, and acts as a 
checkpoint in the cell cycle, inducing cell cycle arrest or apoptosis to irreparable 
cells.(Sturzbecher and Deppert, 1994)  It has been described as “the guardian of the 
genome” and “the master watchman” due to its great importance in inhibiting genetic 
mutations.(Lane, 1992)  The p53 protein regulates expression of over one hundred 
different targets by acting as a sequence specific transcription factor.(Bai and Zhu, 2006)   
The p53 protein is a nuclear phosphoprotein with a molecular weight of 53 kDa and is 
located on the small arm of chromosome 17.(Bai and Zhu, 2006) It consists of 393 amino 
acids and occurs in the active form as a tetramer composed of four identical subunits 
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(Figure 1.6).(Bai and Zhu, 2006; Ren et al., 2005)  Each monomer contains several 
structural and functional domains: 
N-terminus 
 Amino-terminus domain (residues 1-42), required for transactivation activity, 
contains the MDM2 protein binding site  
 Proline rich region (residues 40-92) contains a series of repeating proline residues 
that are involved in p53 stability regulated by MDM2 
Central Core 
 DNA binding domain (residues 102-292) is the central domain of the p53 protein 
and is required for sequence specific DNA binding. 90% of p53 mutations are 
found in this region. 
C-terminus 
 Oligomerization domain (residues 324-355) consists of a beta-strand, followed by 
alpha-helix and this domain is necessary for p53 dimerization 
 Carboxy terminus (residues 363-393) is a strongly basic domain that is involved 
in the downregulation of DNA binding in the central domain and has been 
connected to the initiation of cell death 
 
Figure 1.6: Cartoon representation of the p53 protein 
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p53 is functionally activated by a wide array of cellular stress signals such as: 
DNA damage, UV radiation, hypoxia, and chemotherapeutic agents.(Scian et al., 2004)  
The biological repercussions following p53 activation include: cell cycle arrest, induction 
of programmed cell death (apoptosis), DNA repair, and cellular senescence (Figure 
1.7).(Bai and Zhu, 2006; Braithwaite and Prives, 2006; Laptenko and Prives, 2006; Scian 
et al., 2004)  Two key features of the p53 protein that are required for proper function are 
the ability to mobilize transcriptional co-regulators, and  the capacity to recognize and 
bind specific DNA sequences.(Laptenko and Prives, 2006) 
                  
Figure 1.7: Representation of p53’s activation and response 
 
 
In unstressed cells, p53 transcriptional activity is inert and its turnover rate is 
downregulated via the binding of specific proteins (such as MDM2, COP1, PIRH2 or 
JNK) that promote p53 degradation through ubiquitin-dependent proteasome 
pathways.(Alarcon-Vargas and Ronai, 2002)  The major regulator of p53 is MDM2.  
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When bound to p53, MDM2 inhibits the phosphorylation of p53 and ultimately results in 
the degradation and nuclear transport of p53.(Chen et al., 2005)  When cells receive a 
genotoxic stress signal, excess p53 is produced which stimulates the production of 
MDM2. These excess levels of MDM2 lower the p53 levels via a negative feedback 
reaction and the stress signal induces phosphorylation of serine residues within the 
activation domain of the p53 protein (Figure 1.8).(Hardcastle, 2007)   
 
Figure 1.8: Regulation of p53 by MDM2 
 
The phosphorylation of p53 prevents p53-MDM2 binding interactions.(Sturzbecher and 
Deppert, 1994)  Mitogenic signals then activate the p53 by induction of the ADP 
ribosylation factor (ARF) tumor suppressor which binds to MDM2 and further inhibits 
the ability of MDM2 to ubiquitinate p53.(Chen et al., 2005)  This activation allows for 
the p53 to induce apoptosis or cell cycle arrest of damaged cells.  After these actions are 
completed, the excess p53 is quickly dephosphorylated and destroyed by the 
accumulation of MDM2.  Levels of p53 must be strictly regulated for proper cell 
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function.(Chen et al., 2005; Sturzbecher and Deppert, 1994)  Mutations in the p53 gene 
have been reported in approximately 50% of all malignancies. (Bai and Zhu, 2006; 
Levine et al., 2004; Scian et al., 2004; Sturzbecher and Deppert, 1994) Inactivation of the 
p53 gene is often associated with increased malignancy, treatment resistance, and 
decreased survival rates.(O'Brien, 2007)   
1.3 MDM2 
Levels of p53 must be strictly regulated for proper cell function, and the 
predominanat regulator of p53 is cellular MDM2 oncoprotein.(Freedman et al., 1999; 
Kussie et al., 1996; Lu et al., 2001)  When bound to p53, MDM2 prevents 
phosphorylation and subsequent activation of p53. This binding interaction triggers the 
degradation of p53 via the ubiquitin system and promotes p53’s nuclear 
transport.(Alarcon-Vargas and Ronai, 2002; Chen et al., 2005; Sturzbecher and Deppert, 
1994)  A reported 50% of malignancies maintain wild type p53 expression and a large 
percentage of these tumors display compromised p53 function due to an overexpression 
of the MDM2 protein, as shown in Figure 1.9.(Shangary and Wang, 2009)  Over 
expression of MDM2 and excess p53/MDM2 binding interactions inhibits the p53 
protein’s activation capability to regulate the bodies cellular response to stress or damage, 
ultimately resulting in inhibition of apoptosis.(Freedman et al., 1999) This permits tumor 
formation by continued growth and division of damaged cells and can trigger a tumor’s 
progression from benign, to malignant, to metastatic.(Alarcon-Vargas and Ronai, 2002; 
Chen et al., 2005; Shangary and Wang, 2009)  Due to the paramount role that 
overexpression of MDM2 plays in the inactivation of wild type p53, therapeutically 
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targeting MDM2 for the development of anti-tumor agents, to disrupt p53/MDM2 
interactions and restore wild type p53 function is an attractive area in cancer 
research.(Klein and Vassilev, 2004) 
 
Figure 1.9: Cancers that commonly display overexpressed MDM2 
 
Initial validation of MDM2 as a potential drug candidate have been explored by 
several different approaches.(Klein and Vassilev, 2004) Microinjection of monoclonal 
antibodies directed against the p53 binding site on MDM2 resulted in the inhibition of 
p53/MDM2 binding interactions and subsequent activation and cellular accumulation of 
p53.(Blaydes et al., 1997; Bottger et al., 1996)  It was reported that inhibition of MDM2 
expression by antisense oligonucleotides resulted in activation of p53.(Chen et al., 1998; 
Chen et al., 1999; Chen et al., 2005; Zhang et al., 2003) 
1.4 Crystal structure of the p53/MDM2 complex 
Previously reported crystallographic analysis of the p53/MDM2 complex (Figure 
1.10) infers that there is a deep hydrophobic cleft in the NH2-terminal domain of the 
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globular MDM2 which contains the p53 binding activity.(Bartlett et al., 1990; Chen et al., 
2005; Kussie et al., 1996; Yin and Hamilton, 2005) The p53 peptide forms a 2.5 turn 
amphipathic α-helix whose hydrophobic face buries deep within the hydrophobic cleft of 
the MDM2 protein.(Kussie et al., 1996) It has been shown that a triad of hydrophobic and 
aromatic amino acids (phenalanine 19 (F19), tryptophan 23 (W23), and leucine 26 (L26)) 
are aligned along one face of the p53 helical peptide in the ith, ith+4, and ith+7 positions, 
are imperative for binding interactions to occur.(Kussie et al., 1996; Moisan et al., 2008; 
Yin and Hamilton, 2005) 
 
Figure 1.10: MDM2 protein bound to the helical domain of the p53 protein.  P53 (green) 
with key residues highlighted, F19 (yellow), W23 (pink), and L26 (blue). (PDB structure 
1YCQ)  
 
Studies report that the nature of interactions between p53 and MDM2 are 
primarily hydrophobic. The binding surface of p53 is dominated by a triad of amino acids 
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(F19, W23, and L26) that interact with a hydrophobic cleft in the binding domain of the 
MDM2 protein (Figure 1.10 and Figure 1.11).(Cummings et al., 2006; Kussie et al., 
1996; Yin and Hamilton, 2005) This interaction defined the corresponding F19, W23, 
and L26 pockets necessary for the p53/MDM2 interactions to occur. In this classification, 
the F19 pocket is defined by amino acid residues R65, Y67, E69, H73, I74, V75, M62, 
and V93, the W23 pocket is defined by S92, V93, L54, G58, Y60, and V93, and the L26 
pocket is defined by Y100, T101, and V53.(Kussie et al., 1996) 
 
Figure 1.11: Simplified image of the three key p53 binding residues. Labeled Leu, Trp 
and Phe domains in the MDM2 hydrophobic pocket  
 
1.5 α-Helix mimetics to disrupt the p53/MDM2 complex 
Numerous examples of α-helix mimetics developed to disrupt p53/MDM2 
binding interactions are reported in the literature.(Chen et al., 2005; Cummings et al., 
2006; Shangary and Wang, 2009; Yin et al., 2005a)  These small molecules were 
designed to directly mimic the α-helical region of the p53 peptide, containing key 
residues in the ith, ith+4, and ith+7 positions of a natural α-helix. (Figure 1.12).(Chen et 
al., 2005; Cummings and Hamilton, 2010; Kutzki et al., 2002; Yin and Hamilton, 2005)  
The synthetic targets were designed to bind to the hydrophobic cleft of the MDM2 
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protein and disrupt p53/MDM2 binding interactions.  The binding between the synthetic 
mimic and MDM2 would result in an unbound wild type p53. Leaving p53 capable of 
phosphorylation and activation for apoptosis induction, and disruption of the p53/MDM2 
complex inhibits p53 degradation, making the small molecules antagonists of 
protein/protein interactions, tumor inhibitors, and potent p53 activators.(Cummings and 
Hamilton, 2010) 
 
 
 
Figure 1.12: α-helix mimics based on Hamilton’s terphenyl scaffold with key 
substituent's in the ith, ith+4, and ith+7 positions  
 
Dr. Andrew Hamilton, from Yale University, pioneered the field of using α-helix 
mimics to efficiently disrupt protein/protein-binding interactions.(Chen et al., 2005; 
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Cummings and Hamilton, 2010; Kutzki et al., 2002; Yin et al., 2005b) His most 
recognizable contribution to the field is the design of the non-peptide based terphenyl 
scaffolds used to disrupt p53-MDM2 binding interactions.  Many variation of the 
terphenyl scaffold were synthesized and found to be biologically active.  Figure 1.13 
displays a particular terphenyl derivative, A-2, that was reported to disrupt the binding 
protein-protein interactions of the p53-MDM2 biological system in vitro (182 nM). (Chen 
et al., 2005; Yin and Hamilton, 2004; Yin and Hamilton, 2005)   Analysis conducted by 
heteronuclear multiple quantum coherence (HMQC) data showed that the side chains 
pointed in the desired ith, ith+4, and ith+7 positions of an ideal α-helix, as shown in 
Figure 1.14.(Yin et al., 2005a) 
 
Figure 1.13: Hamilton’s terphenyl scaffold, A-2 
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Figure 1.14: Overlay of the Hamilton terphenyl scaffold.  The p53 peptide (green) with 
the key hydrophobic side chains of F19, W23, and L26 shown in stick representations.   
 
Further evaluation of scaffold A-2 showed poor potency in ELISA assays of with 
a reported IC50 of 130 μM and the scaffold was not shown to activate p53.  It was 
reasoned that the poor biological activity was due to the scaffolds high degree of 
hydrophobicity which leads to poor solubility and limits their usefulness as potential drug 
candidates. Additionally, the overall synthesis was reported to be lengthy and low 
yielding.(Chen et al., 2005)    
1.6 Fluorescence Polarization Assay 
Fluorescence Polarization is a technique especially applied to the study of 
molecular interactions (receptor/ligand studies, protein/protein interactions, DNA/protein 
interactions, tyrosine kinase assays, and competitive immunoassays).(Knight et al., 2002; 
Perrin, 1926) Fluorescence polarization measurements are based on the assessment of the 
rotational motion of fluorescently labeled macromolecules, as shown in Figure 
1.15.(Kinoshita, 2010)  The fluorophore is attached to the small binding partner of the 
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desired interest and excited by polarized light.  Small molecules rotate quickly during the 
excited state, and upon emission, have low polarization values.  In contrast, upon 
excitation, large molecules display little movement the emitted light remains highly 
polarized.  A large molecule is formed by the binding of a second molecule to the 
fluorescently labeled small molecule, resulting in slowed tumbling during the lifetime of 
the excitation and a correspondingly high polarization value. The fluorescence 
polarization assay reports a direct, nearly instantaneous measure of the tracer`s 
bound/free ratio, and will be used for the specific analysis of the ability of our library of 
compounds to bind to the NH2 terminal domain of MDM2. 
 
Figure 1.15: Schematic of a fluorescence polarization assay 
 
 
1.7 ELISA 
The enzyme-linked immunosorbent assay (ELISA) is a plate-based assay that is 
used to determine if a particular peptide, protein, antibody, or hormone is present in a 
sample and quantify it.(Shurley et al., 2005) An ELISA can also be performed as a 
competitive assay when the targeted antigen is small and has only one antibody binding 
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site (Figure 1.16).(GenWay, 2010)  In this type of assay, a known antigen and unknown 
target compete for binding to the capture antibody. There is an inverse relationship 
between the signal obtained and the concentration of the unknown target in the sample 
therefore a decrease in signal indicates the presence an effective inhibitor.(Oldreive et al., 
2001)  
 
Figure 1.16: Schematic of a competitive ELISA assay 
 
1.8 Drug Discovery Process 
 Within our lab, a specific drug discovery protocol is followed.  The process 
begins with a strong knowledge base of the desired biological target and/or pathway.  
Following this, a rational retro-synthesis for a library of potential drug targets is 
proposed.  Molecular modeling studies are performed to increase the likelihood for hit 
generation.  Synthesis of the virtual hits is performed followed by analysis from in vitro 
biological assays.  Optimization of hits is performed until the molecules display the 
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desired pharmacological properties necessary for preclinical in vitro analysis.  Following 
successful preclinical trials are clinical trials, and then ultimately the approval of a new 
drug.  This is a lengthy and expensive process.  It was reported that the entire process 
takes 10-15 years to complete, costs $802 million dollars to develop one new drug, and 
only one molecule per every 100,000 tested will become a new drug.(DiMasi Joseph et 
al., 2003) 
Drug Discovery Process
Molecular 
Modeling
Hit Synthesis 
Optimization
Preclinical Trials
Clinical Trials
→
Structure Validation
Hit Generation
Drug
Knowledge Base 
Rational Design
Biological Assays
 Figure 1.14: Drug discovery protocol 
1.9 Goal and Objectives 
 In our lab, MDM2 was therapeutically targeted with the goal of restoring wild 
type p53 activity in cells overexpressing MDM2 by means of novel small molecule α-
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helix mimetic-based inhibitors.  We performed the design and synthesis of non-peptidic, 
drug-like, small molecule inhibitors to target p53/MDM2 binding interaction. The 
mimetics were designed to bind to the N-terminal domain of the MDM2 protein leaving 
p53 unbound and capable of activation.  The molecules were designed to directly mimic 
the α-helical region of p53’s MDM2 binding domain with key residues in the ith, ith+4, 
and ith+7 positions of an α-helical.  The small molecules were designed to act as 
antagonists of protein/protein interactions, tumor inhibitors, and potent p53 activators.  
Our approach toward the development of small molecule α-helix mimetic-based 
inhibitors is analogous to Hamilton’s design with the terphenyl scaffolds, however our 
design included the addition of polar functional groups to increase drug-like properties 
and potential therapeutic applications.   
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Chapter Two: 
Design and Synthesis of the Piperazine-2,5-Dione-Piperazine Hybrid Scaffold  
2.1 Introduction 
2.1.1 Terephthalamide Scaffold 
Research performed by Dr. Hamilton’s group at Yale in the development of α-
helical mimetics based on a terephthalamide scaffold (Figure 2.1) has been extensively 
investigated by our lab.(Yin et al., 2005)  This work was initially interesting due to the 
small nature of the molecules when compared with previously reported α-helix 
mimics.(Chen et al., 2005; Shangary and Wang, 2009; Volonterio et al., 2007)   
 
Figure 2.1: Terephthalamide (A) Generic terephthalamide helical mimetic superimposed 
on the ith, ith+4, and ith+7 position of an ideal α-helix (B) Terephthalamide scaffold 
shown to display potent inhibition of protein/protein interactions  
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These mimetics reportedly displayed a higher degree of solubility, notably facile 
synthesis, when compared to the first generation terphenyl derivates (Yin et al., 2005), 
yet still maintained the desired spacial arrangements of hydrophobic side chains in the 
ith, ith+4, and ith+7 positions despite their small size. The terephthalamide scaffold was 
reported to be a potent inhibitor of protein/protein interactions (Figure 4.2) with an IC50 = 
35.0 µM for Bcl-xL/Bax inhibition. Surprisingly, these derivatives were not reported to 
have activity against p53/MDM2 interactions and the paper reported a difficult linear 
synthesis and poor solubility of the terephthalamides.(Yin et al., 2005) 
2.1.2 Rational of the Piperazine-2,5-Dione-Piperazine Hybrid Scaffold  
The Hamiltion terephthalamide scaffold design (Figure 2.1) was used as the basis 
for our piperazine-2,5-dione-piperazine hybrid scaffold, as shown in Figure 2.2.  Our 
scaffold design replaced the hydrophobic phenyl ring, used in Hamilton’s 
terephthalamide scaffold, with functionalized 2,5-DKPs and piperazine units.  It was 
anticipated that the reported facile piperazine and DKP synthesis would improve the 
overall ease of synthesis of the scaffold.  The addition of polar functional groups was 
intended to increase the desired drug like properties of the parent terephthalamide 
scaffold while still maintaining the desired spacial arrangement of side chains in the ith, 
ith+3, and  ith+7 positions of a natural α-helix, shown in Figure 2.3.    This novel scaffold 
was designed to be a potent inhibitor of p53/MDM2 binding interactions. 
Piperazine and piperazinediones are common building blocks featured in many 
biologically active compounds such as: agonists acting at the δ-opioid receptors (Alfaro-
Lopez et al., 1999), inhibitors of MDA-MB-231 breast cancer cell proliferation (Ali and 
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Yar, 2007), and  in Gliotoxin (Balibar and Walsh, 2006). There are many documented 
facile syntheses of substituted piperazines (Dankwardt et al., 1995) and DKP’s (Gordon 
and Steele, 1995). 
 
Figure 2.2: Piperazine-2,5-dione-piperazine hybrid scaffold  
 
 
 
Figure 2.3: Schematic α-helix representations (A) a natural α-helix with the i-1, i, i + 4, i 
+ 7, and i + 11 residues, (B) 2D hybrid piperazine-2,5-dione-piperazine scaffold, (C) 3D 
hybrid piperazine-2,5-dione-piperazine scaffold. 
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2.1.3 Molecular Modeling Studies 
 
In efforts to validate potential novel inhibitors of p53/MDM2 binding interactions 
in a virtual screening mode, we conducted computational simulations with Shrodeinder 
software for variations of the proposed target hybrid scaffold (Figure 2.2) docked into the 
hydrophobic pocket in the N-terminal domain of the MDM2 protein derived from the X-
ray crystal structure of p53 bound to the hydrophobic pocket of MDM2 (PDB 
1YCQ).(Kussie et al., 1996)  Computational analysis of the proposed structures were 
ranked based on the docking GLIDE (Friesner et al., 2004) score and the top scoring 
structures were then synthesized.  Molecular modeling of the top GLIDE scoring 
structure of hybrid scaffold 2.13 (shown in Figure 2.5) suggested that the hybrid scaffold 
targeted the same surface area of MDM2 where p53 binds, inserting the side chains into 
the desired F19, W23, and L26 binding pockets, as shown in Figure 2.5. 
 
Figure 2.4: Top glide scoring proposed hybrid scaffold 2.13 
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Figure 2.5: Molecular docking of 2.13. Image is displaying the three aromatic side 
chains of the hybrid scaffold 2.13 occupying the key F19, W23, and L26 positions in the 
MDM2 hydrophobic pocket (image by Courtney DuBoulay) 
  
 
Further analysis of the hybrid scaffold 2.13 docked with the p53 protein in 
transparent light blue (Figure 2.7) displayed numerous hydrophobic interactions with the 
MDM2 protein, as shown in Figure 2.6. The phenyl group in the R1 position, ith position, 
displayed hydrophobic interactions with Y100 and L54, and the indole group in the R2, 
ith+3, position displayed hydrophobic interactions with V93, I99, and F91. The isopropyl 
group, in the R3, ith+7, position displayed hydrophobic interactions with Y67.  The 
model also revealed a hydrogen bond between the indoline NH and L57 which was 
considered optimal of activity.  The hydrophobic interactions of scaffold 2.13 with the 
MDM2 protein are all reported to be located within the p53 binding pocket.(Kussie et al., 
1996)   
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Figure 2.6: Schematic representations of 2.13 (A) 2D hybrid piperazine-2,5-dione-
piperazine scaffold (B) Hydrophobic interactions of the top scoring hybrid scaffold 2.13 
 
 
Figure 2.7: Overlay of the p53 protein (transparent light blue) with the proposed hybrid 
scaffold 2.13 docked in the MDM2 hydrophobic pocket (image by Courtney DuBoulay) 
 
 
The observed hydrophobic interactions at these positions were also observed in 
the binding of the p53 peptide and MDM2 (Kussie et al., 1996) demonstrating that the 
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hybrid scaffold 2.13 recognizes the MDM2 protein surface and adopts a similar 
conformation to the p53 peptide. 
2.2 Results and Discussion 
2.2.1 Retrosynthesis of the Piperazine-2,5-Dione-Piperazine Hybrid Scaffold 
By retrosynthetic analysis (Scheme 2.1), it was reasoned that two functional 
moieties could be introduced to the 2,5-DKP  by reacting an amino acid based orthogonal 
esters a and b, performing selectively hydrolysis d, followed by ring closure e and 
subsequent hydrolysis f to afford the desired dual functionalized 2,5-DKP A1-2 unit . 
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Scheme 2.1: Retrosynthesis of the piperazine-2,5-dione-piperazine hybrid scaffold 
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2.2.2 Synthesis of the Piperazine-2,5-Dione Dimers 
Synthesis of the piperazine-2,5-dione dimers (units A1-2, Scheme 2.1) began by N-
acylation of commercially available amino methyl esters 2.1a-d (Scheme 2.2) with 
bromoacetyl bromide in the presence of a biphasic system of benzene and saturated 
aqueous sodium bicarbonate to afford the pure products of 2.3a-d in good yields (60-
92%).(Maity and Koenig, 2008)  Compounds 2.3a-d where were then coupled with an 
orthogonal amino acid tert-butyl esters 2.2a-d in methanol and refluxed overnight, in the 
presence of TEA, to respectively yield the pure products 2.4a-h, again with high purity 
and in good yields as shown in Scheme 2.2.  
 
Entry R1 Yield 
 2.3a i-Pr 67% 
 2.3b i-Bu 62% 
2.3c Bn 90% 
2.3e 4-tert-butoxyphenyl 70% 
 
 
 
Scheme 2.2: Synthesis of compound 2.3a-d and 2.4a-h 
Entry R1 R2 Yield 
2.4a Bn i-Pr 60% 
2.4b i-Bu i-Pr 53% 
2.4c Bn Bn 64% 
2.4d i-Bu Bn 65% 
2.4e Bn i-Bu 82% 
2.4f i-Pr i-Bu 50% 
2.4g i-Pr s-Bu 63% 
2.4h Bn s-Bu    50% 
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Selective hydrolysis of esters 2.4 was carried out under basic conditions using aqueous 
3M sodium hydroxide and methanol at ambient temperatures to yield 5a-g as the pure 
products, shown in Scheme 2.3. 
 
Entry R1 R2 Yield 
2.5a Bn  i-Pr 90% 
2.5b i-Bu i-Pr 78% 
2.5c Bn Bn 42% 
2.5d i-Bu Bn 40% 
2.5e Bn i-Bu 56% 
2.5f i-Pr i-Bu 35% 
2.5g i-Pr s-Bu 60% 
Scheme 2.3: Synthesis of compounds 2.5a-g 
 
 
Cyclization of compounds 2.5a-g proved to be the most challenging portion of 
this synthetic scheme.  As depicted in Scheme 2.4, treatment with TEA or DIEA in 
MeOH or DMF by traditional and microwave heating did not result in the desired 
formation of 2.6a.  Additional attempts using HBTU and HATU with traditional and 
microwave heating were also unsuccessful at yielding 2.6a. (Montalbetti and Falque, 
2005)   
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Entry Reagents Conditions Results 
1 TEA MeOH, reflux, 24 h No rxn 
2 DIEA MeOH, reflux, 24 h No rxn 
3 DIEA DMF, 110 °C, 5 h No rxn 
4 HBTU, DIEA DMF, 110 °C, 18 h No rxn 
5 HBTU, DIEA DMF, 80 °C, 20 min No rxn 
6 HATU, DIEA DMF, 80 °C, 18 h No rxn 
Scheme 2.4: Attempted cyclization of 2.5a 
 
Successful cyclization of 2.5a was accomplished using pivalic anhydride, as a 
coupling agent, in the presence of TEA under reflux, forming 2,5-DKP 2.6a-g, as shown 
in Scheme 2.4. (Humphrey and Chamberlin, 1997; Montalbetti and Falque, 2005; 
Sobolev et al., 1991) Compounds 2.6a-g were subsequently hydrolyzed under acidic 
conditions with 4N HCl/Dioxane, yielding the target piperazine-2,5-dione dimers 2.7a-e 
(Scheme 2.5).   
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Entry R1 R2 Yield 
2.6a Bn  i-Pr 36% 
2.6b i-Bu i-Pr 59% 
2.6c Bn  Bn 38% 
2.6d i-Bu Bn 57% 
2.6e Bn i-Bu 54% 
2.6f i-Pr i-Bu 74% 
2.6g i-Pr s-Bu 61% 
 
Entry R1 R2 Yield 
2.7a Bn i-Pr 80% 
2.7b i-Bu i-Pr 59% 
2.7c Bn i-Bu  45% 
2.7d i-Pr i-Bu 95% 
2.7e i-Pr s-Bu 54% 
2.7f i-Bu Bn 85% 
Scheme 2.5: Synthesis of compounds 2.6a-g and 2.7a-e 
 
The reaction conditions followed for the synthesis of compounds 2.6a-g and 2.7a-
f were used with tert-butyl amino acid esters 2.2a-d as the starting materials as an 
alternative to amino acid methyl esters 2.1a-d. Synthesis of the piperazine-2,5-dione 
dimers began by N-acylation of commercially available tert-butyl amino acid esters 2.2a-
d (Scheme 2.6) with bromoacetyl bromide in a biphasic system of benzene and saturated 
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aqueous sodium bicarbonate to afford the pure products of 2.8a-d in good yields (80-
93%).  Compounds 2.8a-d were then coupled with an orthogonal amino acid methyl 
esters 2.1a-f in tert-butanol and refluxed overnight, in the presence of TEA, to yield the 
pure products 2.9a-k, in high purity and in good yields (50-80%), as shown in Scheme 
2.6. (Maity and Koenig, 2008)  
 
 
 
 
 
 
 
 
 
Scheme 2.6: Synthesis of compounds 2.8a-d and 2.9a-k 
 
 
Selective hydrolysis of esters 2.9a-k was carried out under acidic conditions with 4N 
HCl/Dioxane to yield 2.10a-i in good yields (50-99%) as the pure products, shown in 
Scheme 2.7. 
Entry R2 R1 Yield 
2.9a i-Pr   Bn 60% 
2.9b Bn  Bn  70% 
2.9c Bn  i-Bu   80% 
2.9d Bn  s-Bu 55% 
2.9e i-Bu i-Pr 70% 
2.9f i-Pr s-Bu 66% 
2.9g i-Pr 2-methyl-1H-indole  70% 
2.9h Bn 2-methyl-1H-indole  60% 
2.9i i-Bu 2-methyl-1H-indole  64% 
2.9k s-Bu 2-methyl-1H-indole  50% 
Entry R2 Yield 
2.8a Bn  83% 
2.8b i-Bu 88% 
2.8c i-Pr 93% 
2.8d s-Bu 80% 
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Entry R2 R1 Yield 
2.10a i-Pr  Bn 99% 
2.10b Bn  Bn  90% 
2.10c i-Bu Bn 95% 
2.10d Bn  s-Bu 99% 
2.10e i-Bu i-Pr 99% 
2.10f i-Pr 2-methyl-1H-indole  90% 
2.10g Bn 2-methyl-1H-indole  92% 
2.10h i-Bu 2-methyl-1H-indole  99% 
2.10i s-Bu 2-methyl-1H-indole  85% 
Scheme 2.7: Synthesis of compounds 2.10a-i 
 
Cyclization of compounds 2.10 was accomplished using pivalic anhydride, as the 
coupling reagent, in the presence TEA under reflux, forming 2,5-DKPs 2.11a-i, as shown 
in Scheme 2.7. (Humphrey and Chamberlin, 1997; Montalbetti and Falque, 2005) 
Compounds 2.11a-i were subsequently hydrolyzed under basic conditions using aqueous 
3M lithium hydroxide and CH3CN at ambient temperatures to yield 2.12a-i as the pure 
products (Scheme 2.7). (Balakrishnan et al., 2007) 
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Entry R2 R1 Yield 
2.11a i-Pr  Bn 36% 
2.11b Bn Bn 40% 
2.11c Bn i-Bu 85% 
2.11d i-Bu i-Pr 75% 
2.11e i-Pr 2-methyl-1H-indole  63% 
2.11f Bn 2-methyl-1H-indole  50% 
2.11g i-Bu 2-methyl-1H-indole  52% 
2.11h s-Bu 2-methyl-1H-indole  45% 
2.11i Bn s-Bu 40% 
 
Entry R2 R1 Yield 
2.12a i-Pr Bn 36% 
2.12b Bn Bn 49% 
2.12c i-Pr 2-methyl-1H-indole  59% 
2.12d s-Bu 2-methyl-1H-indole  40% 
2.12e i-Pr s-Bu 45% 
2.12f i-Bu i-Pr 40% 
2.12g Bn i-Bu 55% 
2.12h s-Bu Bn 50% 
2.12i Bn 2-methyl-1H-indole 44% 
Scheme 2.8: Synthesis of compounds 2.11a-i and 2.12a-i 
 
In conclusion, reaction conditions remained constant for the synthesis beginning 
with tert-butyl ester with a few minor changes. For the coupling to an orthogonal ester 
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(step b, Scheme 2.6), tert-butanol was used as the reaction solvent instead of the previous 
sly used MeOH in Scheme 4.2.  No reaction was observed to occur when MeOH, 
CH3CN, or THF were used as the reaction solvents (data not shown).  The basic 
hydrolysis (step b, Scheme 2.7) was performed using 3M LiOH and CH3CN, which 
resulted in shorter reaction times and a more facile work-up.  The overall reaction 
conditions and yields were comparable for both the amino acid methyl esters and the 
amino acid tert-butyl esters.   
X-ray crystal structure analysis of compounds 2.7e and 2.12c (Figure 4.7) were 
obtained by Dr. Frank Fronczek at Lousiana State University.  The crystal structures 
verified the s,s sterochemisty of the dimeric units which corresponded to the starting 
material use of L-amino acids.  
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Figure 2.8: X-ray crystal structures of compounds 2.7e and 2.11g 
 
2.2.3 Synthesis of Trimers 2.13 and 2.14 
Different synthetic routes were explored for the synthesis of the target trimer 2.13 
before an optimized synthesis was developed (Scheme 2.8).  The coupling of 2.12c with 
phenyl piperazine was attempted with EDC/HOBt (Fara et al., 2006; Kitamura et al., 
2001) and CDI (Nam et al., 2009; Paul and Anderson, 1960) resulting (in both cases) in 
very complicated mixtures of products and side-products.  The purification of these 
42 
 
mixtures was not successfully accomplished due to the complex composition of the crude 
material.  PyBroP
®
 was tried next for its reported use in difficult coupling with N-methyl 
amino acids and α,α-dialkylglycines with low levels of racemization. (Santagada et al., 
2001; Zapf et al., 2005)  These attempts also resulted in a complicated mixture of 
products and side-products.  
 
Entry Reagents Conditions Results 
1 EDC, HOBt DCM, rt, 24 h Multiple products 
2 CDI CHCl3, rt, 24 Multiple products 
3 PyBroP
®
, DIEA DCM, rt, 24 h Multiple products 
4 PyBroP
®
, DIEA THF, rt, 24 h Multiple products 
Scheme 2.9: Attempted synthesis of 2.13 
 
The successful synthesis of 2.13 and 2.14 was achieved using standard coupling 
conditions with EDC and DCM at ambient temperatures, shown in Scheme 2.9. 
(Montalbetti and Falque, 2005; Zhang et al., 2002) 
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Scheme 2.10: Synthesis of trimers 2.13 and 2.14 
 
2.2.4 ELISA Assays 
 A competitive ELISA assay to detect binding between immobilized His6-p53 and 
free GST-MDM2 was performed, at the Moffitt Center in the lab of Dr. Jiandong Chen, 
to determine if my compounds could disrupt p53/MDM2 binding interactions.(Chen et 
al., 2005)  A previously developed peptide optimized for binding to MDM2 termed pDI 
(Phan et al.) and the small molecule Nutlin-3 (Hu et al., 2006; Vassilev et al., 2004), a 
known in vitro inhibitor of p53/MDM2 binding interactions, were used as positive 
controls for the experiment.  As expected, Nutlin-3 and PDIW inhibited p53/MDM2 
binding with IC50 of ∼800 nm (Figure 2.9).(Chen et al., 2005; Hu et al., 2007)  In 
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comparison, my compounds were unfortunately unable to disrupt the MDM2-p53 
interactions at concentrations up to 100 μm, which is close to its solubility limit in the 
ELISA assay (Figure 2.10).(Hu et al., 2007)   
 
 
Figure 2.9: Nutlin-3 and PDI were used as test controls in an ELISA assay to detect 
binding between immobilized His6-p53 and GST-MDM2 
 
0
0.2
0.4
0.6
0.8
1
1.2
0 1 2 3 4 5 6
A
b
s
o
rb
a
n
c
e
 a
t 
4
5
0
 n
m
Concentration (μmol/L)
Nutlin-3 and PDI Controls
nutlin
PDIW
45 
 
 
 
 
Figure 2.10: ELISA results: Piperazine-2,5-dione-piperazine scaffold derivatives were 
analyzed for inhibition of p53/MDM2 binding by a competitive ELISA assay at varying 
concentrations (0-100 μM) and the results are shown for compounds 2.6a-b, 2.6d-g, 
2.7a-f, 2.11a-i, 2.12c, 2.12e, 2.12i, and 2.13.  
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2.3 Conclusion 
It was reasoned that the low levels of bio-activity were due to the compounds 
lacking the one of the three key side chains (Figure 2.11, A).  A majority of the 
compounds tested were the in dimeric form (Figure 2.11, C), and the two trimers tested, 
2.13 and 2.14, contained a hydrogen in the R3 position (Figure 2.11, B) as a substitutent 
of the desired aromatic or aliphatic group.   
 
Figure 2.11: Piperazine-2,5-dione-piperazine scaffold derivatives (A) Standard 
piperazine-2,5-dione-piperazine hybrid scaffold (B) Trimeric scaffold 2.13 containing 
aromatic or aliphatic groups in the R1-2 positions and a hydrogen in the R3 position (C) 
Standard dimeric scaffold  
 
Initially, a hydrogen was placed the R3 position on the scaffold (Figure 2.11, A) 
to facilitate the synthesis and acquire preliminary biological data.  However, the weak 
potency of the compounds provide a sound rational for the synthesis of a new library of 
piperazine-2,5-dione-piperazine scaffold derivatives containing an aromatic or aliphatic 
group in the R3 position.   A positive result of the ELISA assay was displayed in the 
persistent linearity of the graph through the 100 uM concentration (Figure 2.10), 
displaying the desired drug-like solubility properties of the first generation of piperazine-
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2,5-dione-piperazine scaffold derivatives.  The addition of side chains to the R3 position 
should increase the biological activity with the third binding side occupied. 
2.4  Experimental Section 
2.4.1  Materials and Methods 
Organic and inorganic reagents and solvents (ACS grade) were purchased from 
commercially available sources and used without modification unless otherwise noted.  
Thin layer chromatography (TLC) was performed on glass plates (EMD) precoated with 
0.25 mm thickness of silica gel (60 Å) with fluorescent indicator (EMD).  Column 
chromatography was performed using silica gel 60 Å (Silicycle).  All 
1
H, 
13
C, and DEPT 
NMR spectra were obtained using a Varian 400 MHz Mercury plus instrument at ambient 
temperatures in chloroform-d (CDCl3), unless otherwise specified.  Chemical shift values 
are reported in ppm (δ) relative to internal tetramethylsilane (TMS).  Multiplicity is 
expressed as: s = singlet, br s = broad singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet.  The corresponding coupling constants (J) are reported in Hertz (Hz).  
Automated flash chromatography was performed using a Biotage FlashMaster II system 
with Biotage silica cartridges.  Microwave synthesis was performed in a Biotage Initiator 
I reactor. High performance liquid chromatography (HPLC) was performed on a Jasco 
LC-NetII/ADC system. High resolution mass spectra were obtained on an Agilent 1100 
Series in the ESI-TOF mode.  Melting points (uncorrected) were obtained using a Melt-
Temp II
® 
Laboratory device.  Hydrogenation was performed in a H-Cube
TM
 continuous-
flow hydrogenation reactor (Thales Technology). 
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2.4.2  Experimental Procedures 
(S)-methyl 2-(2-bromoacetamido)-3-methylbutanoate (2.3a)  
 
To a suspension of 2.1a (5.97 mmol) in water (10 mL), cooled in an ice-salt bath, was 
added NaHCO3 (14.32 mmol) in one portion.  A solution of bromoacetyl bromide (5.97 
mmol) in benzene (6 mL) was slowly added via addition funnel to the chilled mixture.  
After completion of the addition, the reaction was brought to ambient temperature and 
stirred for an addition 24 h at rt.  The aqueous layer was extracted with benzene (3 x 40 
mL), the combined organic layers were washed with brine (1 x 100 mL), and dried 
(Na2SO4).  Removal of the solvent in vacuo afforded the pure product 2.3a (3.98 mmol, 
67%) as a white gel.  
1
H NMR (400 MHz, CDCl3) δ 7.02 (d, J = 8.1 Hz, 1H), 4.46 (dd, J 
= 8.8, 5.0 Hz, 1H), 3.86 (d, J = 1.4 Hz, 2H), 3.70 (s, 3H), 2.21 – 2.08 (m, 1H), 0.88 (dd, J 
= 10.2, 6.9 Hz, 6H).  
13
C NMR (101 MHz, CDCl3) δ 172.06 (1C), 165.97 (1C), 57.86 
(1C), 52.50 (1C), 31.45 (1C), 29.06 (1C), 19.06 (1C), 17.89 (1C).  HRMS (ESI) calc. for 
C8H14BrNO3 (M + H)
+
 251.0157, found 251.0229. 
(S)-methyl 2-(2-bromoacetamido)-3-(4-(tert-butoxy)phenyl)propanoate (2.3e) 
 
The product was obtained from 2.1e (3.47 mmol) in a similar manner as described for 
preparation of 2.3a affording the pure compound 4.31c (2.42 mmol, 90%) as a colorless 
oil.  
1
H NMR (400 MHz, CDCl3) δ 7.03 – 6.98 (m, 2H), 6.94 – 6.90 (m, 2H), 6.81 (d, J = 
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7.5 Hz, 1H), 4.80 (dt, J = 7.9, 5.9 Hz, 1H), 3.88 – 3.78 (m, 2H), 3.72 (s, 3H), 3.15 – 3.05 
(m, 2H), 1.32 (s, 9H).  
13
C NMR (101 MHz, CDCl3) δ 171.55 (1C), 165.28 (1C), 154.81 
(1C), 130.28 (1C), 129.94 (2C), 124.58 (2C), 78.75 (1C), 53.95 (1C), 52.70 (1C), 37.27 
(1C), 29.05 (3C). HRMS (ESI) calc. for C16H22BrNO4 (M + H)
+
 371.0732, found 
371.0808. 
(S)-tert-butyl 2- ((2-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) 
amino)-3-methylbutanoate (2.4a)   
 
A solution of 2.2a (0.802 mmol), in methanol (5 mL), was slowly added via an addition 
funnel to a solution of compound 2.3c (0.67 mmol) and TEA (2.01 mmol) in methanol 
(10 mL) and refluxed for 36 h.  The resulting light yellow solution was cooled to rt, and 
concentrated under reduced pressure.  The crude residue was dissolved in ethyl acetate 
(100 mL), washed with saturated citric acid (1 x 35 mL), saturated aqueous sodium 
bicarbonate (2 x 30 mL), brine (2 x 50 mL), and dried over Na2SO4.  Removal of the 
organic solvent in vacuo afforded the pure compound 2.4a (1.02 mmol, 60%) as a light 
yellow oil. 
1
H NMR (400 MHz, CD3OD) δ 7.32 – 7.14 (m, 5H), 4.76 (t, J = 6.3 Hz, 1H), 
δ 3.14 (dd, J = 165.9, 17.0 Hz, 2H) , 3.11 (d, J = 6.9 Hz, 2H), 2.79 (d, J = 5.8 Hz, 1H), 
1.85 (dq, J = 13.6, 6.8 Hz, 1H), 1.47 (s, 9H), 0.87 (dd, J = 6.8, 4.3 Hz, 6H).  
13
C NMR 
(101 MHz, CD3OD) δ 170.14 (1C), 168.11 (1C), 167.61 (1C), 132.15 (1C), 125.48 (2C), 
124.90 (2C), 123.43 (1C), 77.81 (1C), 64.04 (1C), 48.77 (1C), 48.51 (1C), 47.36 (1C), 
34.25 (1C), 27.69 (1C), 24.40 (3C), 15.63 (1C), 14.18 (1C).  HRMS (ESI) calc. for 
C21H32N2O5 (M + H)
+
 392.2311, found 392.2144. 
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(S)-methyl 2-(2-(((S)-1-(tert-butoxy)-3-methyl-1-oxobutan-2-yl)amino)acetamido)-4-
methylpentanoate (2.4b)  
 
The product was obtained from 2.3b (1.43 mmol) and 2.2a (1.43 mmol) in a similar 
manner as described for preparation of 2.4a affording compound 2.4b (0.89 mmol, 63%) 
as a clear yellow oil.  
1
H NMR (400 MHz, CD3OD) δ 4.53-4.46 (m, 1H), 3.72 (d, J = 2.6 
Hz, 3H), 3.38 (d, J = 16.8 Hz, 1H), 3.05 (d, J = 16.8 Hz, 1H), 2.92 (d, J = 5.8 Hz, 1H), 
1.96 (dp, J = 13.5, 6.8 Hz, 1H), 1.72 – 1.58 (m, 4H), 1.48 (s, 9H), 1.02 – 0.88 (m, 12H).  
13
C NMR (101 MHz, CD3OD) δ 173.89 (1C), 173.21 (1C), 172.98 (1C), 81.38 (1C), 
67.83 (1C), 51.59 (1C), 50.61 (1C), 50.34 (1C), 40.76 (1C), 31.43 (1C), 27.22 (3C), 
24.83 (1C), 22.04 (1C), 20.85 (1C), 18.48 (1C), 17.69 (1C).  HRMS (ESI) calc. for 
C18H34N2O5 (M + H)
+
 358.2468, found 358.2430. 
(S)-tert-butyl 2-((2-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)amino)-3-phenylpropanoate (2.4c) 
 
The product was obtained from 2.3c (6.90 mmol) and 2.2c (8.03 mmol) in a similar 
manner as described for preparation of 2.4a affording compound 2.4c (4.32 mmol, 64%) 
as a clear yellow oil.  
1
H NMR (400 MHz, CDCl3) δ 7.35 – 7.20 (m, 6H), 7.15 (m, 2H), 
7.09 – 7.03 (m, 2H), 4.73 (m, 1H), 3.71 (s, 3H), 3.34 (m, 2H), 3.05 (dd, J = 13.9, 5.5 Hz, 
1H), 2.99 (d, J = 17.4 Hz, 1H), 2.92 – 2.72 (m, 3H), 2.34 (bs, 1H), 1.39 (s, 9H).  13C 
NMR (101 MHz, CDCl3) δ 173.61 (1C), 172.01 (1C), 171.47 (1C), 137.39 (1C), 136.40 
(1C), 129.75 (2C), 129.31 (2C), 128.78 (2C), 128.59 (2C) 127.27 (2C), 126.96 (1C), 
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82.07 (1C), 63.20 (1C), 52.84 (1C), 52.49 (1C), 50.79 (1C), 40.00 (1C), 37.68 (1C), 
28.22 (3C).  HRMS (ESI) calc. for C25H32N2O5 (M + H)
+
 440.2311, found 440.2231. 
(S)-methyl 2-(2-(((S)-1-(tert-butoxy)-1-oxo-3-phenylpropan-2-yl)amino)acetamido)-
4-methylpentanoate (2.4d)  
 
The product was obtained from 2.3b (21.55 mmol) and 2.2c (25.81 mmol) in a similar 
manner as described for preparation of 2.4a affording compound 2.4d (13.90 mmol, 
64%) as a clear oil.  
1
H NMR (400 MHz, CDCl3) δ 7.31 – 7.19 (m, 5H), 7.05 (d, J = 8.6 
Hz, 1H), 4.45 (m, 1H), 3.69 (s, 3H), 3.43 – 3.37 (m, 2H), 3.02 (m, 2H), 2.76 (dd, J = 
13.7, 8.9 Hz, 1H), 1.54 – 1.43 (m, 3H), 1.41 (s, 9H), 0.86 (dd, J = 10.4, 6.2 Hz, 6H).  13C 
NMR (101 MHz, CDCl3) δ 173.79 (1C), 173.29 (1C), 171.59 (1C), 137.61 (1C), 129.78 
(2C), 128.60 (2C), 126.99 (1C), 82.17 (1C), 63.37 (1C), 52.38 (1C), 50.72 (1C), 50.17 
(1C), 40.62 (1C), 40.02 (1C), 28.23 (3C), 24.98 (1C), 23.10 (1C), 21.72 (1C).  HRMS 
(ESI) calc. for C22H34N2O5 (M + H)
+
 406.2468, found 406.2456. 
(S)-tert-butyl 2-((2-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)amino)-4-methylpentanoate (2.4e)  
 
The product was obtained from 2.3c (3.34 mmol) and 2.2b (4.53 mmol) in a similar 
manner as described for preparation of 2.4a affording compound 2.4e (1.93 mmol, 64%) 
as a clear yellow oil.  
1
H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 8.5 Hz, 1H), 7.31 – 7.19 
(m, 3H), 7.13 – 7.07 (m, 2H), 4.89-4.83 (m, 1H), 3.69 (s, 3H), 3.38 (d, J = 17.3 Hz, 1H), 
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3.11 (t, J = 6.0 Hz, 2H), 3.03 (dd, J = 8.2, 6.3 Hz, 1H), 2.95 (d, J = 17.3 Hz, 1H), 1.66 – 
1.54 (m, 1H), 1.42 (s, 9H), 1.36 – 1.21 (m, 2H), 0.82 (dd, J = 21.8, 6.6 Hz, 6H).  13C 
NMR (101 MHz, CDCl3) δ 174.95 (1C), 171.94 (1C), 171.48 (s), 136.07 (1C), 129.42 
(2C), 128.82 (2C), 127.36 (1C), 81.67 (1C), 60.89 (1C), 52.71 (1C), 52.44 (1C), 50.94 
(1C), 42.96 (1C), 38.09 (1C), 28.27 (3C), 25.01 (1C), 22.99 (1C), 22.27 (1C).  HRMS 
(ESI) calc. for C22H34N2O5 (M + H)
+
 406.2467, found 406.2509. 
(S)-tert-butyl 2-((2-(((S)-1-methoxy-3-methyl-1-oxobutan-2-yl)amino)-2-oxoethyl) 
amino)-4-methylpentanoate (2.4f)  
 
The product was obtained from 2.3a (3.98 mmol) and 2.2b (4.78 mmol) in a similar 
manner as described for preparation of 2.4a affording compound 2.4f (1.95 mmol, 50%) 
as a white oil.  
1
H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 8.5 Hz, 1H), 4.49 (td, J = 8.8, 
4.8 Hz, 1H), 3.72 (s, 3H), 3.45 (d, J = 17.2 Hz, 1H), 3.07 (d, J = 5.7 Hz, 1H), 2.99 (d, J = 
17.2 Hz, 1H), 2.00 (dt, J = 19.5, 6.5 Hz, 1H), 1.70 – 1.57 (m, 3H), 1.45 (s, 8H), 1.02 (d, J 
= 6.8 Hz, 3H), 0.98 – 0.91 (m, 9H).  13C NMR (101 MHz, CDCl3) δ 175.31 (1C), 172.10 
(1C), 171.15 (1C), 81.87 (1C), 67.40 (1C), 52.01 (1C), 51.42 (1C), 51.13 (1C), 42.04 
(1C), 31.73 (1C), 28.23 (3C), 25.23 (1C), 23.05 (1C), 22.35 (1C), 19.73 (1C), 18.41 (1C).  
HRMS (ESI) calc. for C18H34N2O5 (M + H)
+
 358.3261, found 358.2543. 
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(2S,3R)-tert-butyl 2-((2-(((S)-1-methoxy-3-methyl-1-oxobutan-2-yl)amino)-2-
oxoethyl)amino)-3-methylpentanoate (2.4g)   
 
The product was obtained from 2.3a (9.96 mmol) and 2.2d (10.96 mmol) in a similar 
manner as described for preparation of 2.4a affording compound 2.4g (6.24 mmol, 63%) 
as a clear yellow oil.  
1
H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 9.3 Hz, 1H), 4.56-4.51 
(m, 1H), 3.71 (s, 3H), 3.52-3.44 (m, 1H), 2.99-2.95 (m, 2H), 2.25 – 2.12 (m, 1H), 1.91 
(bs, 1H), 1.77 – 1.66 (m, 1H), 1.59 – 1.47 (m, 1H), 1.47 – 1.41 (m, 7H), 1.30 – 1.13 (m, 
1H), 0.99 – 0.85 (m, 12H).  13C NMR (101 MHz, CDCl3) δ 173.92 (1C), 172.42 (1C), 
171.80 (1C), 81.77 (1C), 67.07 (1C), 56.76 (1C), 52.24 (1C), 51.38 (1C), 38.59 (1C), 
31.27 (1C), 28.34 (3C), 25.48 (1C), 19.27 (1C), 17.92 (1C), 16.08 (1C), 11.93 (1C).  
HRMS (ESI) calc. for C18H34N2O5 (M + H)
+
 358.2468, found 358.2443. 
(S)-2-(2-(((S)-1-(tert-butoxy)-3-methyl-1-oxobutan-2-yl)amino)acetamido)-3-
phenylpropanoic acid (2.5a)  
 
To a solution of 2.4a (0.33 mmol) in methanol (2 mL) was added 3M aq. NaOH (3mL), 
and the reaction was stirred at ambient temperatures for 18 h.  Solvent was removed in 
vacuo, the resulting crude oil was redissolved in water (25 mL), and acidified to a pH of 
4 with 1N HCl.  The resulting acidified solution was extracted with EtOAc (3 x 30 mL), 
the combined organic layers were washed with brine (2 x 25 mL), dried over Na2SO4, 
and the residual solvent was removed in vacuo to afford the pure compound 2.5a (0.29 
mmol, 90%) as a light yellow oil.  
1
H NMR (400 MHz, CDCl3) δ 7.32 – 7.15 (m, 5H), 
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7.08 (s, 1H), 4.70 (d, J = 10.0 Hz, 1H), 4.32 (bs, 1H), 3.77 (dd, J = 263.2, 17.5 Hz, 2H), 
3.32 (s, 1H), 3.23 (dd, J = 13.9, 4.0 Hz, 1H), 3.06 (dd, J = 13.9, 7.3 Hz, 1H), 2.01 (m, 
1H), 1.44 (s, 9H).  HRMS (ESI) calc. for C18H34N2O5 (M + H)
+
 358.2468, found 
358.2443. 
(S)-2-(2-(((S)-1-(tert-butoxy)-3-methyl-1-oxobutan-2-yl)amino)acetamido)-4-
methylpentanoic acid (2.5b)  
 
The product was obtained from 2.4b (0.89 mmol) in a similar manner as described for 
preparation of 2.5a affording compound 2.5b (0.70 mmol, 78%) as a white solid.  
1
H 
NMR (400 MHz, CDCl3) δ 7.71 (d, J = 8.0 Hz, 1H), 4.59-4.53 (m, 1H), 4.09 (dd, J = 
123.9, 17.4 Hz, 2H), 3.26 (dd, J = 187.4, 17.4 Hz, 2H), 2.91 (d, J = 5.5 Hz, 1H), 2.04 – 
1.92 (m, 1H), 1.82 – 1.57 (m, 3H), 1.47 (s, 9H), 1.04 – 0.93 (m, 12H).  13C NMR (101 
MHz, CDCl3) δ 175.41 (1C), 173.87 (1C), 172.67 (1C), 81.98 (1C), 68.05 (1C), 51.15 
(1C), 50.91 (1C), 42.48 (1C), 41.02 (1C), 31.64 (1C), 28.34 (3C), 25.14 (1C), 23.07 (1C), 
22.10 (1C), 19.70 (1C), 18.26 (1C). 
 
(S)-2-(2-((S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-ylamino)acetamido)-3-
phenylpropanoic acid (2.5c)  
 
The product was obtained from 2.4c (4.32 mmol) in a similar manner as described for 
preparation of 2.5a affording compound 2.5c (1.80 mmol, 42%) as a light yellow oil.  
1
H 
NMR (400 MHz, CDCl3) δ 7.28 – 7.07 (m, 8H), 6.99 (m, 2H), 5.24 (dd, J = 10.9, 5.9 Hz, 
1H), 4.04 (m, 1H), 3.64 (dd, J = 111.4, 17.1 Hz, 2H), 3.27 (dd, J = 14.8, 5.9 Hz, 1H), 3.01 
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(dd, J = 13.9, 3.7 Hz, 1H), 2.84 (dd, J = 14.8, 10.9 Hz, 1H), 2.35 (dd, J = 13.8, 9.5 Hz, 
1H), 1.38 (s, 9H).  
13
C NMR (101 MHz, CDCl3) δ 168.92 (1C), 166.26 (1C), 165.97 
(1C), 136.35 (1C), 135.46 (1C), 129.62 (2C), 129.23 (2C), 128.94 (2C), 127.68 (1C), 
127.36 (1C), 83.03 (1C), 57.47 (1C), 56.75 (1C), 47.10 (1C), 40.16 (1C), 34.66 (1C), 
28.21 (3C).  HRMS (ESI) calc. for C24H30N2O5 (M + H)
+
 426.2155, found 426.2120. 
(S)-2-(2-((S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-ylamino)acetamido)-4-
methylpentanoic acid (2.5d)  
 
The product was obtained from 2.4d (13.90 mmol) in a similar manner as described for 
preparation of 2.5a affording compound 2.5d (6.19 mmol, 40%) as a light yellow gel.  
1
H 
NMR (400 MHz, CD3OD) δ 7.29 – 7.17 (m, 5H), 5.14 (dd, J = 12.1, 5.0 Hz, 1H), 3.80 
(dd, J = 82.1, 17.0 Hz, 2H), 3.38 (dd, J = 14.7, 5.0 Hz, 1H), 3.01 (dd, J = 14.7, 12.1 Hz, 
1H), 1.47 (s, 9H), 1.13 (t, J = 7.2 Hz, 2H), 0.94 – 0.85 (m, 1H), 0.80 (dd, J = 10.1, 6.6 
Hz, 6H).  
13
C NMR (101 MHz, CD3OD) δ 169.09 (1C), 168.43 (1C), 166.83 (1C), 136.56 
(1C), 128.73 (2C), 128.65 (2C) 127.01 (1C), 82.77 (1C), 58.08 (1C), 53.87 (1C), 42.74 
(1C), 34.25 (1C), 27.37 (3C), 24.00 (1C), 22.27 (1C), 20.99 (2C).  HRMS (ESI) calc. for 
C21H32N2O5 (M + H)
+
 392.2311, found 392.2234. 
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(S)-2-(2-(((S)-1-(tert-butoxy)-4-methyl-1-oxopentan-2-yl)amino)acetamido)-3-
phenylpropanoic acid (2.5e)  
 
The product was obtained from 2.4e (1.55 mmol) in a similar manner as described for 
preparation of 2.5a affording compound 2.5e (1.27 mmol, 82%) as a white solid.  
1
H 
NMR (400 MHz, CD3OD) δ 7.30 – 7.16 (m, 5H), 4.68 – 4.62 (m, 1H), 3.42 (d, J = 16.7 
Hz, 1H), 3.26 – 3.10 (m, 3H), 3.06-3.01 (1H), 1.73-1.60 (3H), 1.47 (s, 9H), 0.89 (dd, J = 
14.9, 6.7 Hz, 6H).  
13
C NMR (101 MHz, CD3OD) δ 173.31 (1C), 170.69 (1C), 137.27 
(1C), 129.26 (2C), 128.27 (2C), 126.60 (1C), 81.95 (1C), 59.99 (1C), 49.09 (1C), 41.61 
(1C), 37.54 (1C), 27.10 (3C), 24.83 (1C), 21.67 (2C).  HRMS (ESI) calc. for C21H32N2O5 
(M + H)
+
 392.2311, found 392.2301. 
(S)-2-(2-(((S)-1-(tert-butoxy)-4-methyl-1-oxopentan-2-yl)amino)acetamido)-3-
methylbutanoic acid (2.5f)  
 
The product was obtained from 2.4b (1.55 mmol) in a similar manner as described for 
preparation of 2.5a affording compound 2.5b (1.27 mmol, 82%) as a white solid.  
1
H 
NMR (400 MHz, CD3OD) δ 4.35 (d, J = 4.8 Hz, 1H), 3.49 (d, J = 16.7 Hz, 1H), 3.34 (d, 
J = 7.2 Hz, 1H), 3.24 (d, J = 16.7 Hz, 1H), 2.27 – 2.17 (m, 1H), 1.79 (dp, J = 13.3, 6.7 
Hz, 1H), 1.55 (ddd, J = 16.0, 9.9, 6.9 Hz, 2H), 1.48 (s, 9H), 0.96 (td, J = 7.1, 1.2 Hz, 
12H).  
13
C NMR (101 MHz, CD3OD) δ 174.00 (1C), 173.57 (1C), 171.42 (1C), 81.93 
(1C), 60.28 (1C), 57.82 (1C), 49.17 (1C), 41.78 (1C), 30.86 (1C), 27.10 (3C), 25.01 (1C), 
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21.79 (1C), 21.64 (1C), 18.49 (1C), 16.74 (1C).  HRMS (ESI) calc. for C17H32N2O5 (M + 
H)
+
 344.2311, found 344.2237. 
(S)-2-(2-(((2S,3R)-1-(tert-butoxy)-3-methyl-1-oxopentan-2-yl)amino)acetamido)-3-
methylbutanoic acid (2.5g)   
 
The product was obtained from 2.4g (6.14 mmol) in a similar manner as described for 
preparation of 2.5a affording compound 2.5g (3.65 mmol, 60%) as a yellow solid.  
1
H 
NMR (400 MHz, CDCl3) δ 7.84 (d, J = 9.0 Hz, 1H), 6.64 (bs, 1H), 4.47 (dd, J = 9.0, 4.7 
Hz, 1H), 3.51 (d, J = 17.2 Hz, 1H), 3.06 (dd, J = 11.3, 5.9 Hz, 2H), 2.29 – 2.19 (m, 1H), 
1.78 – 1.68 (m, 1H), 1.56 – 1.49 (m, 1H), 1.45 (s, 9H), 1.25 – 1.15 (m, 1H), 0.99 – 0.87 
(m, 12H).  
13
C NMR (101 MHz, CDCl3) δ 175.52 (1C), 173.48 (1C), 172.04 (1C), 81.98 
(1C), 66.87 (1C), 57.38 (1C), 51.06 (1C), 38.40 (1C), 31.00 (1C), 28.33 (3C), 25.67 (1C), 
19.39 (1C), 17.83 (1C), 15.89 (1C), 11.90 (1C).  HRMS (ESI) calc. for C17H23N2O5 (M + 
H)
+
 344.2311, found 344.2384. 
(S)-tert-butyl 2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-3-methylbutanoate 2.6a 
 
To a stirring solution of 2.5a (1.78 mmol) in anhydrous CHCl3 (8 mL), under argon, was 
added DIEA (1.95 mmol), and pivalic anhydride (1.78 mmol).  The solution was heated 
to a gentle reflux for 24 h.  After cooling to ambient temperatures, the reaction was 
diluted with DI H2O (50 mL) and the aqueous portion was extracted with CHCl3 (3 x 40 
58 
 
mL).  The combined organic layers were washed with 10% aq. citric acid (1 x 40 mL), 
sat. aq. NaHCO3 (1 x 40 mL), brine (1 x 50 mL), and dried (Na2SO4).  The residual 
solvent was removed in vacuo to afford the crude oil which was subsequently purified 
using flash chromatography on silica gel (30:70 EtOAc/hexanes) affording compound 
2.6a (0.64 mmol, 36%) as a light yellow solid.  
1
H NMR (400 MHz, CDCl3) δ 7.36 – 
7.27 (m, 3H), 7.24 – 7.19 (m, 2H), 4.72 (d, J = 10.0 Hz, 1H), 4.30 – 4.25 (m, 1H), 3.88 
(dd, J = 207.6, 17.4 Hz, 2H), 3.34 (dd, J = 13.9, 3.8 Hz, 1H), 2.95 (dd, J = 13.9, 8.8 Hz, 
1H), 2.14 – 2.03 (m, 1H), 1.45 (s, 9H), 1.01 (d, J = 6.6 Hz, 3H), 0.79 (d, J = 6.7 Hz, 3H).  
13
C NMR (101 MHz, CDCl3) δ 169.43 (1C), 166.56 (1C), 166.19 (1C), 135.49 (1C), 
129.78 (2C), 129.35 (2C), 127.83 (1C), 82.60 (1C), 62.17 (1C), 56.83 (1C), 46.59 (s, 
3H), 40.01 (s, 3H), 28.24 (3C), 27.57 (1C), 19.83 (1C), 19.69 (1C).  HRMS (ESI) calc. 
for C20H28N2O4 (M + H)
+
 360.2049, found 360.2022. 
(S)-tert-butyl 2-((S)-3-isobutyl-2,5-dioxopiperazin-1-yl)-3-methylbutanoate (2.6b)  
 
The product was obtained from 2.5b (0.70 mmol) in a similar manner as described for 
preparation of 2.6a. The crude oil was purified using flash chromatography on silica gel 
(30:70 EtOAc/hexanes) to afford 2.6b (1.63 mmol, 57%) as a white solid.  
1
H NMR (400 
MHz, CDCl3) δ 7.79 (s, 1H), 4.66 (d, J = 10.1 Hz, 1H), 4.16 (d, J = 17.2 Hz, 1H), 3.96 
(dd, J = 13.1, 4.0 Hz, 1H), 3.87 (d, J = 17.2 Hz, 1H), 2.20 – 2.08 (m, 1H), 1.80 – 1.65 (m, 
2H), 1.61 – 1.51 (m, 1H), 1.41 (s, 9H), 0.99 (d, J = 6.6 Hz, 3H), 0.92 (dd, J = 10.7, 6.3 
Hz, 6H), 0.85 (d, J = 6.7 Hz, 3H).  
13
C NMR (101 MHz, CDCl3) δ 169.42 (1C), 167.96 
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(1C), 167.52 (1C), 82.44 (1C), 61.91 (1C), 54.17 (1C), 46.79 (1C), 42.60 (1C), 28.16 
(3C), 27.84 (1C), 24.50 (1C), 23.36 (1C), 21.47 (1C), 19.84 (1C), 19.35 (1C).  HRMS 
(ESI) calc. for C17H30N2O4 (M + H)
+
 326.2206, found 326.2186. 
(S)-tert-butyl2-((S)-3-isobutyl-2,5-dioxopiperazin-1-yl)-3-phenylpropanoate (2.6d)  
 
The product was obtained from 2.5d (2.56 mmol) in a similar manner as described for the 
preparation of 2.6a affording compound 2.6d (0.41 mmol, 59%) as a white solid.  
1
H 
NMR (400 MHz, CDCl3) δ 7.30 – 7.11 (m, 5H), 5.30 (dd, J = 12.0, 5.1 Hz, 1H), 3.87 – 
3.83 (m, 1H), 3.82 (d, J = 8.3 Hz, 2H), 3.42 (dd, J = 15.0, 5.1 Hz, 1H), 2.92 (dd, J = 14.9, 
12.1 Hz, 1H), 1.46 (s, 9H), 1.40 (d, J = 9.7 Hz, 2H), 1.04 (m, 1H), 0.80 (dd, J = 8.2, 6.7 
Hz, 6H).  
13
C NMR (101 MHz, , CDCl3) δ 169.06 (1C), 167.31 (1C), 166.61 (1C), 136.32 
(1C), 128.90 (2C), 128.83 (2C), 127.28 (1C), 82.95 (1C), 57.06 (1C), 54.03 (1C), 47.24 
(1C), 42.67 (1C), 34.76 (1C), 28.18 (3C), 24.23 (1C), 23.09 (1C), 21.46 (1C).  HRMS 
(ESI) calc. for C21H30N2O4 (M + H)
+
 374.2206, found 374.2219. 
(S)-tert-butyl 2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-4-methylpentanoate (2.6e)  
 
The product was obtained from 2.5e (1.27 mmol) in a similar manner as described for 
preparation of 2.6a affording compound 2.6e (0.57 mmol, 45%) as a light yellow solid.  
1
H NMR (400 MHz, CDCl3) δ 7.36 – 7.27 (m, 3H), 7.21 (dd, J = 7.5, 1.6 Hz, 2H), 6.23 
60 
 
(s, 1H), 5.10 (dd, J = 11.1, 5.0 Hz, 1H), 4.34-4.31 (m, 1H), 3.58 (dd, J = 210.4, 17.1 Hz, 
2H), 3.25 (dd, J = 13.9, 3.9 Hz, 1H), 3.05 (dd, J = 13.9, 7.5 Hz, 1H), 1.62 (ddd, J = 14.7, 
10.0, 5.0 Hz, 2H), 1.43 (s, 9H), 1.29 – 1.14 (m, 1H), 0.91 (dd, J = 8.7, 6.6 Hz, 6H).  13C 
NMR (101 MHz, CDCl3) δ 170.08 (1C), 166.32 (1C), 166.18 (1C), 135.35 (1C), 129.91 
(2C), 129.21 (2C), 127.74 (1C), 82.64 (1C), 56.80 (1C), 54.52 (1C), 46.04 (1C), 40.20 
(1C), 36.82 (1C), 28.20 (3C), 24.99 (1C), 23.31 (1C), 21.53 (1C).  HRMS (ESI) calc. for 
C21H30N2O4 (M + H)
+
 374.2205, found 374.2278. 
(S)-tert-butyl 2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)-4-methylpentanoate (2.6f)  
 
The product was obtained from 2.5f (1.24 mmol) in a similar manner as described for 
preparation of 2.6a. The crude oil which was purified using flash chromatography on 
silica gel (30:70 EtOAc/hexanes) to afford 2.6f (0.57 mmol, 45%) as a white solid.  
1
H 
NMR (400 MHz, CDCl3) δ 6.81 (s, 1H), 5.11 (dd, J = 11.0, 5.3 Hz, 1H), 4.05 – 3.80 (m, 
3H), 2.44 – 2.30 (m, 1H), 1.74 – 1.62 (m, 4H), 1.44 (s, 9H), 1.03 (d, J = 7.1 Hz, 3H), 0.98 
– 0.89 (m, 9H).  13C NMR (101 MHz, CDCl3) δ 170.08 (1C), 166.58 91C), 166.42 (1C), 
82.62 (1C), 61.09 (1C), 54.60 (1C), 46.37 (1C), 36.79 (1C), 32.66 (1C), 28.20 (3C), 
25.38 (1C), 23.53 (1C), 21.17 (1C), 19.07 (1C), 16.69 (1C).  HRMS (ESI) calc. for 
C17H30N2O4 (M + H)
+
 326.2206, found 326.2214. 
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(2S,3S)-tert-butyl 2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)-3-methylpentanoate 
(2.6g)  
 
The product was obtained from 2.5g (3.63 mmol) in a similar manner as described for 
preparation of 2.6a affording compound 2.6g (2.20 mmol, 61%) as a white powder.  
1
H 
NMR (400 MHz, CDCl3) δ 8.23 (bs, 1H), 4.71 (d, J = 9.9 Hz, 1H), 4.15 (d, J = 17.4 Hz, 
1H), 3.79 (d, J = 17.6 Hz, 2H), 2.23 (m, 1H), 1.81 (m, 1H), 1.34 (s, 9H), 0.94 (d, J = 7.0 
Hz, 3H), 0.88 (d, J = 6.6 Hz, 3H), 0.83 (d, J = 6.8 Hz, 3H), 0.78 (t, J = 7.4 Hz, 3H).  
13
C 
NMR (101 MHz, CDCl3) δ 169.53 (1C), 167.48 (1C), 166.64 (1C), 82.27 (1C), 61.08 
(1C), 60.53 (1C), 46.59 (1C), 33.49 (1C), 32.72 (1C), 28.10 (3C), 25.81 (1C), 19.03 (1C), 
17.01 (1C), 15.87 (1C), 10.86 (1C).  HRMS (ESI) calc. for C17H30N2O4 (M + H)
+
 
326.2205, found 326.2097. 
(S)-2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-4-methylpentanoic acid (2.7c)   
 
The product was obtained from 2.6e (1.34 mmol) in a similar manner as described for 
preparation of 2.10a affording compound 2.7c (0.87 mmol, 45%) as a white powder.  
1
H 
NMR (400 MHz, CD3OD) δ 7.33-7.26 (m,3H), 7.27-7.15 (m, 2H), 5.10 (dd, J = 11.1, 4.8 
Hz, 1H), 4.37 (t, J = 4.4 Hz, 1H), 3.75 – 3.56 (m, 1H), 3.12 (ddd, J = 80.4, 13.8, 4.5 Hz, 
2H), 2.92 (d, J = 17.2 Hz, 1H), 1.58 (ddd, J = 14.6, 9.8, 4.8 Hz, 1H), 1.49 – 1.39 (m, 1H), 
1.04 – 0.93 (m, 1H), 0.88 (dd, J = 21.9, 6.2 Hz, 6H).  13C NMR (101 MHz, CD3OD) δ 
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172.44 (1C), 167.09 (1C), 166.74 (1C), 135.31 (1C), 130.12 (2C), 128.53 (2C), 127.19 
(1C), 56.70 (1C), 53.62 (1C), 45.40 (1C), 39.54 (1C), 36.42 (1C), 26.44 (1C), 24.40 (1C), 
22.09 (1C), 20.46 (1C).  HRMS (ESI) calc. for C17H22N2O4 (M + H)
+
 318.1579, found 
318.1664. 
(S)-2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)-4-methylpentanoic acid (2.7d)  
 
The product was obtained from 2.6f (2.95 mmol) in a similar manner as described for 
preparation of 2.10a affording compound 2.7d (0.87 mmol, 95%) as a light yellow solid.  
1
H NMR (400 MHz, CD3OD) δ 5.10 (dd, J = 11.4, 4.7 Hz, 1H), 3.98 (dd, J = 54.7, 17.3 
Hz, 2H), 3.76 (d, J = 5.1 Hz, 1H), 2.25 – 2.15 (m, 1H), 1.88 – 1.71 (m, 2H), 1.52-1.45 
(m, 1H), 1.03 – 0.98 (m, 9H), 0.96 (t, J = 6.7 Hz, 9H).  13C NMR (101 MHz, CD3OD) δ 
172.49 (1C), 167.69 (1C), 167.24 (1C), 61.12 (1C), 54.37 (1C), 46.46 (1C), 36.62 (1C), 
33.20 (1C), 25.17 (1C), 22.36 (1C), 20.09 (1C), 17.99 (1C), 16.55 (1C).  HRMS (ESI) 
calc. for C13H22N2O4 (M + H)
+
 270.1579, found 270.1666. 
(2S,3S)-2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)-3-methylpentanoic acid (2.7e)  
 
The product was obtained from 2.6g (1.84 mmol) in a similar manner as described for 
preparation of 2.10a affording compound 2.7e (0.99 mmol, 54%) as a white solid.  The 
structural confirmation of 2.7e was obtained by single-crystal X-ray diffraction.  1H 
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NMR (400 MHz, CD3OD) δ 4.80 – 4.73 (m, 1H), 4.14 (dd, J = 58.8, 17.3 Hz, 2H), 3.78 – 
3.69 (m, 1H), 3.32 (d, J = 15.4 Hz, 1H), 2.26 – 2.15 (m, 1H), 2.09 – 1.97 (m, 1H), 1.20 – 
1.09 (m, 1H), 1.06 – 0.85 (m, 12H).  13C NMR (101 MHz, CD3OD) δ 171.82 (1C), 
167.73 (1C), 167.47 (1C), 61.20 (1C), 60.34 (1C), 46.75 (1C), 33.27 (1C), 32.93 (1C), 
25.47 (1C), 18.11 (1C), 16.76 (1C), 15.04 (1C), 9.62 (1C).  HRMS (ESI) calc. for 
C13H22N2O4 (M + H)
+
 270.1579, found 270.1666. 
(S)-2-((S)-3-isobutyl-2,5-dioxopiperazin-1-yl)-3-phenylpropanoic acid (2.7f)  
 
The product was obtained from 2.6d (1.38 mmol) in a similar manner as described for 
preparation of 2.10a affording compound 2.7f (1.17 mmol, 85%) as a white solid.  
1
H 
NMR (400 MHz, CD3OD) δ 7.32 – 7.18 (m, 5H), 5.49 (s, 1H), 5.33 (dd, J = 12.4, 4.7 Hz, 
1H), 4.00 – 3.74 (m, 3H), 3.44 (dd, J = 14.8, 4.7 Hz, 1H), 3.08 (dd, J = 14.8, 12.4 Hz, 
1H), 1.42 (dd, J = 13.9, 7.3 Hz, 1H), 1.11 (ddd, J = 7.9, 6.4, 1.6 Hz, 2H), 0.79 (dd, J = 
9.5, 6.6 Hz, 6H).  
13
C NMR (101 MHz, CD3OD) δ 171.55 (1C), 168.50 (1C), 166.96 
(1C), 136.83 (1C), 128.72 (2C), 128.53 (2C ), 126.72 (1C), 57.04 (1C), 53.84 (1C), 42.62 
(1C), 34.04 (1C), 23.93 (1C), 21.96 (1C), 20.90 (1C).  HRMS (ESI) calc. for C17H22N2O4 
(M + H)
+
 318.1579, found 318.1533. 
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(S)-tert-butyl 2-(2-bromoacetamido)-3-phenylpropanoate (2.8a)  
 
The product was obtained from 2.2c (7.76 mmol) in a similar manner as described for 
preparation of 2.3a affording compound 2.8a (6.45 mmol, 83%) as a clear yellow oil.  
1
H 
NMR (400 MHz, CDCl3) δ 7.36 – 7.08 (m, 5H), 6.92 (d, J = 7.2 Hz, 1H), 4.77 – 4.63 (m, 
1H), 3.89 – 3.81 (m, 1H), 3.11 (d, J = 5.9 Hz, 2H), 1.41 (s, 9H).  13C NMR (101 MHz, 
CDCl3) δ 170.10 (1C), 165.17 (1C), 135.87 (1C), 129.75 (2C), 128.69 (2C), 127.38 (1C), 
83.05 (1C), 54.15 (1C), 38.06 (1C), 29.05 (1C), 28.17 (3C).  HRMS (ESI) calc. for 
C15H20BrNO3 (M + H)
+
 341.0627, found 307.0563. 
(S)-tert-butyl 2-(2-bromoacetamido)-4-methylpentanoate (2.8b)  
 
The product was obtained from 2.2b (6.71 mmol) in a similar manner as described for 
preparation of 2.3a affording compound 2.8b (5.94 mmol, 88%) as a clear yellow oil.  
1
H 
NMR (400 MHz, CDCl3) δ 6.82 (d, J = 7.7 Hz, 1H), 4.49 (td, J = 8.4, 5.2 Hz, 1H), 3.89 
(s, 2H), 1.71 – 1.58 (m, 3H), 1.47 (s, 9H), 0.95 (d, J = 6.0 Hz, 6H).  13C NMR (101 MHz, 
CDCl3) δ 171.72 (1C), 165.26 (1C), 82.56 (1C), 52.22 (1C), 41.91 (1C), 29.21 (1C), 
28.21 (3C), 25.17 (1C), 23.04 (1C), 22.36 (1C).  HRMS (ESI) calc. for C12H22BrNO3 (M 
+ H)
+
 307.0783, found 307.0675. 
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(S)-tert-butyl 2-(2-bromoacetamido)-3-methylbutanoate (2.8c)  
 
The product was obtained from 2.2a (5.14 mmol) in a similar manner as described for 
preparation of 2.3a affording compound 2.8c (3.98 mmol, 93%) as a clear yellow oil.  
1
H 
NMR (400 MHz, CDCl3) δ 6.94 (d, J = 7.6 Hz, 1H), 4.42 (dd, J = 8.7, 4.4 Hz, 1H), 3.91 
(s, 2H), 2.26 – 2.13 (m, 1H), 1.48 (s, 9H), 0.94 (t, J = 7.1 Hz, 6H).  13C NMR (101 MHz, 
CDCl3) δ 170.58 (1C), 165.46 (1C), 82.65 (1C), 58.21 (1C), 31.71 (1C), 29.33 (1C), 
28.26 (3C), 19.02 (1C), 17.78 (1C).  HRMS (ESI) calc. for C11H20BrNO3 (M + H)
+
 
293.0627, found 293.0589. 
(S)-tert-butyl 2-(2-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)acetamido)-3-
methylbutanoate (2.9a)   
 
The product was obtained from 2.2a (0.341 mmol) and 2.1c (0.44 mmol), in the presence 
of tert-butanol (10 mL), in a similar manner as described for preparation of 2.4a affording 
compound 2.9a (0.20 mmol, 60%) as a clear yellow oil.  
1
H NMR (400 MHz, CDCl3) δ 
7.61 (d, J = 8.9 Hz, 1H), 7.31 – 7.01 (m, 4H), 4.43-4.33 (m, 1H), 3.63 (m, 3H), 3.51-3.45 
(m, 1H), 3.27 (dd, J = 46.0, 16.5 Hz, 1H), 3.06 (d, J = 6.7 Hz, 1H), 2.23 – 2.03 (m, 1H), 
1.44 (s, 9H), 0.95 – 0.79 (m, 6H).  13C NMR (101 MHz, CD3OD) δ 170.14 (1C), 168.11 
(1C), 167.61 (1C), 132.15 (1C), 125.48 (2C), 124.90 (2C), 123.43 (1C), 77.81 (1C), 
64.04 (1C), 48.77 (1C), 48.51 (1C), 47.36 (1C), 34.25 (1C), 27.69 (1C), 24.40 (3C), 
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15.63 (1C), 14.18 (1C).  HRMS (ESI) calc. for C21H32N2O5 (M + H)
+
 392.2311, found 
392.2296. 
(S)-methyl 2-((2-(((S)-1-(tert-butoxy)-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)amino)-4-methylpentanoate (2.9c)  
 
The product was obtained from 2.2c (3.81 mmol) and 2.1b (4.96 mmol) in a similar 
manner as described for preparation of 2.9a affording compound 2.9c (3.05 mmol, 80%) 
as a thick yellow gel.  
1
H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 8.2 Hz, 1H), 7.30 – 7.13 
(m, 6H), 4.75-4.70 (m, 1H), 3.68 (s, 3H), 3.43 (dd, J = 7.2, 3.3 Hz, 1H), 3.38 (d, J = 17.1 
Hz, 1H), 3.24 – 3.19 (m, 1H), 3.15 – 3.03 (m, 2H), 2.99 (d, J = 17.1 Hz, 1H), 2.06 (s, 
2H), 1.64 (dp, J = 13.3, 6.7 Hz, 1H), 1.38 (s, 9H), 0.85 (dd, J = 17.0, 6.6 Hz, 6H).  
13
C 
NMR (101 MHz, CDCl3) δ 174.95 (1C), 171.94 (1C), 171.48 (s), 136.07 (1C), 129.42 
(2C), 128.82 (2C), 127.36 (1C), 81.67 (1C), 60.89 (1C), 52.71 (1C), 52.44 (1C), 50.94 
(1C), 42.96 (1C), 38.09 (1C), 28.27 (3C), 25.01 (1C), 22.99 (1C), 22.27 (1C).  HRMS 
(ESI) calc. for C22H34N2O5 (M + H)
+
 406.2467, found 406.2540. 
(2S,3R)-methyl 2-((2-(((S)-1-(tert-butoxy)-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)amino)-3-methylpentanoate (2.9d)  
 
The product was obtained from 2.2c (2.19 mmol) and 2.1c (2.19 mmol) in a similar 
manner as described for preparation of 2.9a affording compound 2.9d (1.20 mmol, 55%) 
as a cloudy yellow oil.  
1
H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 8.5 Hz, 1H), 7.32 – 
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7.13 (m, 6H), 4.75 (dt, J = 8.5, 6.2 Hz, 1H), 3.70 (s, 3H), 3.41 (d, J = 17.1 Hz, 1H), 3.17 
– 3.01 (m, 3H), 2.95 (d, J = 17.1 Hz, 1H), 1.73 – 1.60 (m, 2H), 1.40 (s, 9H), 1.15 – 1.01 
(m, 1H), 0.88 – 0.83 (m, 6H).  13C NMR (101 MHz, CDCl3) δ 175.12 (1C), 171.10 (1C), 
170.59 (1C), 136.43 (1C), 129.67 (2C), 128.64 (2C), 127.18 (1C), 82.26 (1C), 66.49 
(1C), 53.21 (1C), 51.92 (1C), 51.55 (1C), 38.43 (1C), 38.35 (1C), 28.17 (3C), 25.30 (1C), 
15.95 (1C), 11.81 (1C).  HRMS (ESI) calc. for C22H34N2O5 (M + H)
+
 406.2467, found 
406.2555. 
(S)-tert-butyl 2-(2-(((S)-1-methoxy-3-methyl-1-oxobutan-2-yl)amino)acetamido)-4-
methylpentanoate (2.9e)  
 
The product was obtained from 2.2b (5.01 mmol) and 2.1a (6.52 mmol) in a similar 
manner as described for preparation of 2.9a affording compound 2.9e (3.50 mmol, 70%) 
as a yellow crystalline solid.  
1
H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 8.5 Hz, 1H), 
4.53 – 4.46 (m, 1H), 3.72 (s, 3H), 3.45 (d, J = 17.2 Hz, 1H), 3.07 (d, J = 5.7 Hz, 1H), 
2.99 (d, J = 17.2 Hz, 1H), 2.05 – 1.95 (m, 2H), 1.68 – 1.59 (m, 3H), 1.45 (s, 9H), 1.02 (d, 
J = 6.8 Hz, 3H), 0.99 – 0.92 (m, 9H).  13C NMR (101 MHz, CDCl3) δ 175.31 (1C), 
172.10 (1C), 171.15 (1C), 81.84 (1C), 67.40 (1C), 52.01 (1C), 51.42 (1C), 51.13 (1C), 
42.04 (1C), 31.73 (1C), 28.23 (3C), 25.23 (1C), 23.05 (1C), 22.35 (1C), 19.73 (1C), 
18.41 (1C).  HRMS (ESI) calc. for C18H34N2O5 (M + H)
+
 358.2468, found 358.2422. 
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(S)-tert-butyl 2-(2-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino) 
acetamido)-3-methylbutanoate (2.9g)  
 
The product was obtained from 2.2a (0.49 mmol) and 2.1f (0.59 mmol) in a similar 
manner as described for preparation of 2.4a affording compound 2.9g (1.93 mmol, 64%) 
as a clear yellow oil.  
1
H NMR (400 MHz, CDCl3) δ 8.86 (s, 1H), 7.79 (d, J = 9.2 Hz, 
1H), 7.61 (d, J = 7.8 Hz, 1H), 7.30 (d, J = 8.0 Hz, 1H), 7.18 – 7.03 (m, 2H), 6.96 (s, 1H), 
4.41 (dd, J = 9.2, 4.6 Hz, 1H), 3.61 (s, 3H), 3.39 (d, J = 17.2 Hz, 1H), 3.21 (t, J = 6.7 Hz, 
2H), 3.08 (d, J = 17.2 Hz, 1H), 2.17 – 2.00 (m, 1H), 1.47 (s, 9H), 0.89 (dd, J = 19.9, 6.9 
Hz, 6H).  
13
C NMR (101 MHz, CDCl3) δ 174.92 (1C), 171.63 (1C), 171.16 (1C), 136.52 
(1C), 127.79 (1C), 123.37 (1C), 122.10 (1C), 119.55 (1C), 118.85 (1C), 111.61 (1C), 
110.29 (1C), 81.99 (1C), 62.43 (1C), 57.35 (1C), 52.12 (1C), 51.26 (1C), 42.87 (1C), 
31.42 (1C), 29.51 (1C), 28.27 (3C), 19.27 (1C), 17.81 (1C).  HRMS (ESI) calc. for 
C23H33N3O5 (M + H)
+
 431.2420, found 431.2493. 
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(S)-tert-butyl 2-(2-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino) 
acetamido)-3-phenylpropanoate (2.9h)  
 
The product was obtained from 2.2c (1.57 mmol) and 2.1f (1.88 mmol) in a similar 
manner as described for preparation of 2.4a affording compound 2.9h (0.94 mmol, 60%) 
as a clear yellow oil.  
1
H NMR (400 MHz, CDCl3) δ 8.76 (s, 1H), 7.60 (dd, J = 17.5, 8.1 
Hz, 1H), 7.34 – 7.07 (m, 8H), 6.93 (d, J = 2.1 Hz, 1H), 4.74 – 4.66 (m, 1H), 3.61 (s, 3H), 
3.57 (t, J = 6.1 Hz, 1H), 3.34 (d, J = 17.3 Hz, 1H), 3.19 – 2.95 (m, 4H), 2.87 (dd, J = 
13.8, 6.6 Hz, 1H), 1.42 (s, 9H).  
13
C NMR (101 MHz, CDCl3) δ 174.95 (1C), 171.44 
(1C), 170.71 (1C), 136.61 (1C), 136.51 (1C), 129.63 (2C), 128.65 (2C), 127.77 (1C), 
127.16 (1C), 123.45 (1C), 122.19 (1C), 119.63 (1C), 118.95 (1C), 111.66 (1C), 110.49 
(1C), 82.29 (1C), 62.24 (1C), 54.12 (1C), 53.45 (1C), 52.16 (1C), 51.04 (1C), 42.71 (1C), 
38.08 (1C), 29.45 (s, 6H), 28.22 (3C).  HRMS (ESI) calc. for C27H33N3O5 (M + H)
+
 
479.2420, found 479.2493. 
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(S)-tert-butyl 2-(2-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino) 
acetamido)-4-methylpentanoate (2.9i)  
 
The product was obtained from 2.2b (2.21 mmol) and 2.1f (2.66 mmol) in a similar 
manner as described for preparation of 2.4a affording compound 2.91 (1.42 mmol, 64%) 
as a clear yellow oil.  
1
H NMR (400 MHz, CDCl3) δ 8.36 (s, 1H), 7.63 (d, J = 7.8 Hz, 
1H), 7.36 (dd, J = 16.9, 8.4 Hz, 2H), 7.22 – 7.02 (m, 3H), 4.41-4.38 (m, 1H), 3.66 (s, 
3H), 3.38 (d, J = 17.3 Hz, 1H), 3.27 – 3.10 (m, 2H), 3.08 (d, J = 17.3 Hz, 1H), 1.46 (s, 
9H), 1.27-1.19 (m, 2H), 0.96-0.94 (m, 1H), 0.88 (dd, J = 6.3, 2.8 Hz, 6H).  
13
C NMR 
(101 MHz, CDCl3) δ 175.09 (1C), 172.17 (1C), 171.30 (1C), 136.40 (1C), 127.78 (1C), 
123.24 (1C), 122.33 (1C), 119.77 (1C), 119.02 (1C), 111.53 (1C), 111.03 (1C), 81.76 
(1C), 62.49 (1C), 52.20 (1C), 51.14 (1C), 50.97 (1C), 41.44 (1C), 29.54 (1C), 28.25 (3C), 
25.13 (1C), 23.06 (1C), 22.15 (1C).  HRMS (ESI) calc. for C24H35N3O5 (M + H)
+
 
445.2577, found 445.2512. 
(S)-2-(2-((S)-1-methoxy-1-oxo-3-phenylpropan-2-ylamino)-2-oxoethylamino)-3-
methylbutanoic acid (2.10a)  
 
Compound 2.9a (0.92 mmol) was dissolved in 4N HCl/Dioxane (10 mL) and was stirred 
at ambient temperature for 18 hours.  The solvent was removed in vacuo, the resulting 
crude oil was re-dissolved in DCM, and evaporated in vacuo (3 x 30 mL).  This provided 
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the pure compound 2.10a (0.91 mmol, 99%) as a yellow solid.  
1
H NMR (400 MHz, 
CD3OD) δ 7.39 – 7.24 (m, 5H), 4.43 – 4.32 (m, 2H), 3.96 (s, 1H), 3.72 (s, 3H), 3.65 (s, 
1H), 3.37 (dd, J = 14.1, 6.0 Hz, 1H), 3.22 (dd, J = 14.0, 8.0 Hz, 1H), 2.27 – 2.12 (m, 1H), 
1.01 – 0.93 (m, 6H).  13C NMR (101 MHz, CD3OD) δ 173.07 (1C), 168.53 (1C), 165.13 
(1C), 133.80 (1C), 129.17 (2C), 128.93 (2C), 127.83 (1C), 66.92 (1C), 60.73 (1C), 57.98 
(1C), 52.42 (1C), 35.44 (1C), 30.39 (1C), 18.34 (1C), 16.97 (1C).  HRMS (ESI) calc. for 
C17H24N2O5 (M - H)
-
 336.1652, found 336.1610. 
(S)-2-(2-((S)-1-methoxy-4-methyl-1-oxopentan-2-ylamino)-2-oxoethylamino)-3-
phenylpropanoic acid (2.10c) 
 
The product was obtained from 2.9c (2.95 mmol) in a similar manner as described for 
preparation of 2.10a affording compound 2.10c (2.94 mmol, 99%) as a light yellow solid.  
1
H NMR (400 MHz, CD3OD) δ 7.33 – 7.18 (m, 5H), 4.74 (dd, J = 9.4, 4.7 Hz, 1H), 3.95 
– 3.86 (m, 1H), 3.84 (s, 3H), 3.42 (q, J = 7.3 Hz, 1H), 3.25 (d, J = 4.7 Hz, 1H), 2.94 (dd, 
J = 14.0, 9.5 Hz, 1H), 1.84 – 1.62 (m, 3H), 0.96 (dd, J = 6.0, 2.3 Hz, 6H).  13C NMR (101 
MHz, CD3OD) δ 172.85 (1C), 169.28 (1C), 164.65 (1C), 137.02 (1C), 129.14 (2C), 
128.36 (2C), 126.78 (1C), 66.95 (1C), 57.99 (1C), 52.62 (1C), 46.18 (1C), 38.48 (1C), 
37.32 (1C), 24.71 (1C), 21.81 (1C), 20.80 (1C).  HRMS (ESI) calc. for C18H26N2O5 (M + 
H)
+
 350.1841, found 350.1913. 
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(S)-2-((2-(((S)-1-methoxy-3-methyl-1-oxobutan-2-yl)amino)-2-oxoethyl)amino)-4-
methylpentanoic acid (2.10e)  
 
The product was obtained from 2.9e (3.46 mmol) in a similar manner as described for 
preparation of 2.10a affording compound 2.10e (3.43 mmol, 99%) as a light yellow solid.  
1
H NMR (400 MHz, CD3OD) δ 4.53 – 4.42 (m, 1H), 4.03 (d, J = 3.9 Hz, 1H), 3.92 (d, J 
= 6.1 Hz, 1H), 3.86 (s, 3H), 3.65 (s, 2H), 2.46 – 2.33 (m, 1H), 1.78 – 1.57 (m, 3H), 1.12 
(d, J = 7.0 Hz, 3H), 1.07 (d, J = 6.9 Hz, 3H), 0.95 (ddd, J = 12.4, 6.2, 3.9 Hz, 6H).  
13
C 
NMR (101 MHz, CD3OD) δ 174.30 (1C), 168.31 (1C), 164.96 (1C), 66.94 (1C), 65.44 
(1C), 52.45 (1C), 51.11 (1C), 40.34 (1C), 40.21 (1C), 29.49 (1C), 24.79 (1C), 22.07 (1C), 
20.58 (1C), 18.03 (1C), 16.38 (1C).   
(S)-2-(2-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino)acetamido)-3-
methylbutanoic acid (2.10f)  
 
The product was obtained from 2.9g (1.23 mmol) in a similar manner as described for 
preparation of 2.10a affording compound 2.10f (2.57 mmol, 90%) as a light brown solid.  
1
H NMR (400 MHz, CD3OD) δ 7.52 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.13 
(dd, J = 11.1, 4.0 Hz, 1H), 7.09 – 7.02 (m, 1H), 4.44 (t, J = 6.5 Hz, 1H), 4.37 (d, J = 5.2 
Hz, 1H), 4.01 – 3.90 (m, 2H), 3.70 (s, 3H), 3.50 (qd, J = 15.0, 7.7 Hz, 2H), 3.34 (s, 2H), 
2.24-2.17 (m, 1H), 0.96 (t, J = 7.0 Hz, 6H).  
13
C NMR (101 MHz, CD3OD) δ 173.10 
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(1C), 168.97 (1C), 165.22 (1C), 137.00 (1C), 126.96 (1C), 124.39 (1C), 121.78 (1C), 
119.16 (1C), 117.69 (1C), 111.50 (1C), 105.93 (1C), 60.27 (1C), 57.92 (1C), 52.58 (1C), 
46.71 (1C), 30.42 (1C), 25.68 (1C), 18.38 (1C), 16.89 (1C).  HRMS (ESI) calc. for 
C19H25N3O5 (M + H)
+
 375.1794, found 375.1855. 
(S)-2-(2-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino)acetamido)-3-
phenylpropanoic acid (2.10g)  
 
The product was obtained from 2.9h (1.04 mmol) in a similar manner as described for 
preparation of 2.10a affording compound 2.10g (0.94 mmol, 92%) as a light yellow solid.  
1
H NMR (400 MHz, CD3OD) δ 7.52 – 7.46 (m, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.29 – 7.11 
(m, 8H), 7.09 – 7.03 (m, 1H), 4.72 (dd, J = 9.2, 4.8 Hz, 1H), 4.23 (t, J = 6.5 Hz, 1H), 3.86 
(d, J = 15.9 Hz, 1H), 3.69 (s, 3H), 3.43 (dd, J = 9.9, 6.5 Hz, 2H), 3.34 (s, 3H), 3.24 (dd, J 
= 14.0, 4.9 Hz, 1H), 2.91 (dd, J = 14.0, 9.2 Hz, 1H).   
13
C NMR (101 MHz, CD3OD) δ 
172.88 (1C), 169.04 (1C), 164.87 (1C), 136.93 (1C), 129.06 (1C), 128.34 (1C), 126.75 
(1C), 124.28 (1C), 121.78 (1C), 119.16 (1C), 117.68 (1C), 111.46 (1C), 105.97 (1C), 
60.19 (1C), 53.94 (1C), 52.50 (1C), 46.68 (1C), 37.25 (1C), 25.76 (1C).  HRMS (ESI) 
calc. for C23H25N3O5 (M + H)
+
 423.1794, found 423.1733. 
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(S)-2-(2-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino)acetamido)-4-
methylpentanoic acid (2.10h)  
 
The product was obtained from 2.9i (1.41 mmol) in a similar manner as described for 
preparation of 2.10a affording compound 2.10h (1.39 mmol, 99%) as a light yellow solid.  
1
H NMR (400 MHz, CD3OD) δ 7.52 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.18 – 
7.10 (m, 1H), 7.10 – 7.03 (m, 1H), 4.44 (dd, J = 12.2, 5.6 Hz, 2H), 3.97 – 3.84 (m, 2H), 
3.71 (s, 3H), 3.57 – 3.43 (m, 2H), 1.73 – 1.53 (m, 3H), 0.94 (dd, J = 12.6, 6.0 Hz, 6H).  
13
C NMR (101 MHz, CD3OD) δ 174.31 (1C), 168.95 (1C), 164.97 (1C), 137.01 (1C), 
126.94 (1C), 124.36 (1C), 121.81 (1C), 119.18 (1C), 117.66 (1C), 111.49 (1C), 105.93 
(1C), 60.26 (1C), 52.57 (1C), 51.10 (1C), 46.65 (1C), 40.36 (1C), 25.66 (1C), 24.82 (1C), 
22.11 (1C), 20.57 (1C).  HRMS (ESI) calc. for C23H25N3O5 (M + H)
+
 423.1794, found 
423.1733. 
(S)-methyl 2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)-3-phenylpropanoate (2.11a) 
 
The product was obtained from 2.10a (0.85 mmol) in a similar manner as described for 
preparation of 2.6a affording compound 2.11a (0.31 mmol, 46%) as a white solid.  
1
H 
NMR (400 MHz, CD3OD) δ 7.31 – 7.19 (m, 5H), 5.14 (dd, J = 12.1, 4.7 Hz, 1H), 3.97 
(dd, J = 17.4, 0.7 Hz, 1H), 3.77 (s, 3H), 3.64 (d, J = 4.9 Hz, 1H), 3.59 (d, J = 17.4 Hz, 
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1H), 3.42 (dd, J = 14.7, 4.6 Hz, 1H), 3.13 (dd, J = 14.6, 12.2 Hz, 1H), 1.94-1.86 (m, 1H), 
0.74 (d, J = 6.9 Hz, 3H), 0.60 (d, J = 6.8 Hz, 3H).  
13
C NMR (101 MHz, CD3OD) δ 
170.33 (1C), 167.43 (1C), 166.79 (1C), 136.76 (1C), 128.73 (2C), 128.65 (2C), 126.98 
(1C), 60.83 (1C), 58.41 (1C), 51.83 (1C), 33.72 (1C), 33.31 (1C), 17.80 (1C), 15.90 (1C).  
HRMS (ESI) calc. for C17H22N2O4 (M + H)
+
 318.1580, found 318.1502. 
(S)-methyl 2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-3-phenylpropanoate (2.11b) 
 
The product was obtained from 2.10b (0.78 mmol) in a similar manner as described for 
preparation of 2.6a affording compound 2.11b (0.31 mmol, 40%) as a yellow gel.  
1
H 
NMR (400 MHz, CD3OD) δ 7.34 – 7.17 (m, 8H), 7.08 – 7.03 (m, 2H), 4.94-4.89 (m, 1H), 
4.18 (t, J = 5.4 Hz, 1H), 3.74 (s, 3H), 3.37 (d, J = 17.1 Hz, 1H), 3.27-3.20 (m, 2H), 3.01 
(dd, J = 14.4, 10.5 Hz, 1H), 2.88 (qd, J = 13.8, 5.4 Hz, 2H).  
13
C NMR (101 MHz, 
CD3OD) δ 170.24 (1C), 167.41 (1C), 166.72 (1C), 136.83 (1C), 135.31 (1C), 129.95 
(2C), 128.78 (2C), 128.62 (2C), 128.40 (2C), 127.03 (1C), 126.93 (1C), 59.02 (1C), 
56.65 (1C), 51.77 (1C), 39.48 (1C), 33.90 (1C).  HRMS (ESI) calc. for C21H22N2O4 (M + 
H)
+
 366.1580, found 366.1525. 
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(S)-methyl 2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-4-methylpentanoate (2.11c) 
 
The product was obtained from 2.10c (2.85 mmol) in a similar manner as described for 
preparation of 2.6a affording compound 2.11c (2.42 mmol, 85%) as a yellow powder.  
1
H 
NMR (400 MHz, CDCl3) δ 7.36 – 7.27 (m, 3H), 7.21 (m, 2H), 5.23 (dd, J = 11.1, 5.0 Hz, 
1H), 4.37 – 4.32 (m, 1H), 3.71 (s, 3H), 3.61 (dd, J = 198.7, 17.2 Hz, 2H), 3.26 (dd, J = 
13.9, 3.9 Hz, 1H), 3.05 (dd, J = 13.9, 7.6 Hz, 1H), 1.67 (m, 1H), 1.56 – 1.47 (m, 1H), 
1.26 – 1.14 (m, 1H), 0.91 (dd, J = 8.6, 6.6 Hz, 6H).  13C NMR (101 MHz, CDCl3) δ 
171.43 (1C), 166.33 (1C), 165.80 (1C), 135.25 (1C), 129.89 (2C), 129.25 (2C), 127.80 
(1C), 56.72 (1C), 53.78 (1C), 52.77 (1C), 46.00 (1C), 40.23 (1C), 36.68 (1C), 24.85 (1C), 
23.26 (1C), 21.49 (1C). HRMS (ESI) calc. for C18H24N2O4 (M + H)
+
 332.1736, found 
332.1816. 
(S)-methyl 2-((S)-3-isobutyl-2,5-dioxopiperazin-1-yl)-3-methylbutanoate (2.11d) 
 
The product was obtained from 2.10d (3.46 mmol) in a similar manner as described for 
preparation of 2.6a affording compound 2.11d (2.58 mmol, 75%) as a white powder.  
1
H 
NMR (400 MHz, CDCl3) δ 6.38 (bs, 1H), 4.83 (d, J = 10.6 Hz, 1H), 4.21 (d, J = 17.3 Hz, 
1H), 4.01 (d, J = 16.5 Hz, 1H), 3.94 (d, J = 17.3 Hz, 1H), 3.72 (s, 3H), 2.21 (m, 1H), 1.77 
(m, 2H), 1.02 (d, J = 6.6 Hz, 3H), 0.99 (d, J = 6.3 Hz, 3H), 0.95 (d, J = 6.3 Hz, 3H), 0.90 
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(d, J = 6.7 Hz, 3H).  
13
C NMR (101 MHz, CDCl3) δ 170.82 (1C), 167.74 (1C), 166.49 
(1C), 61.13 (1C), 54.08 (1C), 52.42 (1C), 46.54 (1C), 42.58 (1C), 27.60 (1C), 24.61 (1C), 
23.37 (1C), 21.43 (1C), 19.79 (1C), 19.16 (1C).  HRMS (ESI) calc. for C14H24N2O4 (M + 
H)
+
 284.1736, found 284.1828. 
(S)-methyl 3-(1H-indol-3-yl)-2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)propanoate 
(2.11e)  
 
The product was obtained from 2.10f (0.83 mmol) in a similar manner as described for 
preparation of 2.6a affording compound 2.11e (0.52 mmol, 63%) as a yellow crystalline 
solid.  
1
H NMR (400 MHz, CDCl3) δ 8.62 (s, 1H), 7.61 – 7.52 (m, 2H), 7.28 (t, J = 8.9 
Hz, 1H), 7.19 – 7.04 (m, 3H), 7.00 (d, J = 1.9 Hz, 1H), 5.20 (dd, J = 11.6, 4.7 Hz, 1H), 
3.90 (d, J = 17.1 Hz, 1H), 3.76 (s, 3H), 3.69 (d, J = 17.2 Hz, 1H), 3.48 (d, J = 4.6 Hz, 
1H), 3.35 – 3.25 (m, 1H), 0.97 – 0.87 (m, 1H), 0.75 (d, J = 7.0 Hz, 3H), 0.48 (d, J = 6.8 
Hz, 3H).  
13
C NMR (101 MHz, CDCl3) δ 170.70 (1C), 166.75 (1C), 166.49 (1C), 136.53 
(1C), 127.07 (1C), 122.81 (1C), 122.48 (1C), 119.87 (1C), 118.39 (1C), 111.67 (1C), 
110.20 (1C), 60.97 (1C), 57.60 (1C), 52.82 (1C), 47.98 (1C), 33.09 (1C), 24.38 (1C), 
18.77 (1C), 16.03 (1C).  HRMS (ESI) calc. for C19H23N3O4 (M + H)
+
 357.1688, found 
357.1751. 
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(S)-methyl 2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-3-(1H-indol-3-yl)propanoate 
(2.11f)  
 
The product was obtained from 2.10g (1.42 mmol) in a similar manner as described for 
preparation of 2.6a affording compound 2.11f (0.71 mmol, 50%) as a yellow crystalline 
solid.  
1
H NMR (400 MHz, CD3OD) δ 7.54 (d, J = 7.9 Hz, 1H), 7.35 (d, J = 8.1 Hz, 1H), 
7.17 – 7.02 (m, 6H), 6.96 – 6.91 (m, 2H), 5.11 (dd, J = 10.5, 5.5 Hz, 1H), 4.15 (t, J = 5.2 
Hz, 1H), 3.73 (s, 3H), 3.46 (d, J = 17.2 Hz, 1H), 3.37 – 3.32 (m, 1H), 3.23 – 3.13 (m, 
2H), 2.83 (ddd, J = 40.0, 13.8, 5.3 Hz, 2H).  
13
C NMR (101 MHz, CD3OD) δ 170.72 
(1C), 167.29 (1C), 166.79 (1C), 136.97 (1C), 135.17 (1C), 129.87 (2C), 128.30 (2C), 
127.22 (1C), 126.96 (1C), 123.09 (1C), 121.52 (1C), 118.85 (1C), 117.82 (1C), 111.35 
(1C), 109.27 (1C), 57.90 (1C), 56.64 (1C), 51.75 (1C), 39.48 (1C), 23.97 (1C).  HRMS 
(ESI) calc. for C23H23N3O4 (M + H)
+
 405.1689, found 405.1588. 
(S)-methyl 3-(1H-indol-3-yl)-2-((S)-3-isobutyl-2,5-dioxopiperazin-1-yl)propanoate 
(2.11g)  
 
The product was obtained from 2.10h (1.54 mmol) in a similar manner as described for 
preparation of 2.6a affording compound 2.11g (0.80 mmol, 52%) as yellow crystals.  The 
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structural confirmation of 2.11g was obtained by single-crystal X-ray diffraction.  
1
H 
NMR (400 MHz, CDCl3) δ 8.17 (s, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.34 (d, J = 8.1 Hz, 
1H), 7.16 (dtd, J = 15.9, 7.1, 1.1 Hz, 2H), 7.04 (d, J = 2.3 Hz, 1H), 6.60 (d, J = 2.2 Hz, 
1H), 5.37 (dd, J = 11.6, 5.0 Hz, 1H), 3.89 – 3.82 (m, 2H), 3.79 (s, 3H), 3.51 (ddd, J = 
15.5, 4.9, 1.0 Hz, 1H), 3.29 (dd, J = 15.6, 11.6 Hz, 1H), 1.45 (ddd, J = 12.1, 9.2, 6.5 Hz, 
1H), 1.13 – 1.03 (m, 1H), 0.78 (d, J = 6.6 Hz, 6H). 
(2S,3S)-methyl 2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-3-methylpentanoate (2.11i)  
 
The product was obtained from 2.10d (1.19 mmol) in a similar manner as described for 
preparation of 2.6a affording compound 2.11i (0.48 mmol, 40%) as a white gel.  
1
H NMR 
(400 MHz, CDCl3) δ 7.68 (s, 1H), 7.30-7.20 (m, 5H), 4.87 (d, J = 10.4 Hz, 1H), 4.35 (s, 
1H), 4.07 (d, J = 17.4 Hz, 1H), 3.67 (s, 3H), 3.27 (d, J = 17.4 Hz, 1H), 3.15 (d, J = 4.7 
Hz, 2H), 1.80 – 1.64 (m, 1H), 0.82 (dd, J = 27.1, 5.7 Hz, 6H).  13C NMR (101 MHz, 
CDCl3) δ 171.02 (1C), 166.73 (1C), 166.23 (1C), 135.32 (1C), 130.21 (2C), 129.00 (2C), 
127.62 (1C), 59.64 (1C), 56.80 (1C), 52.32 (1C), 45.93 (1C), 39.99 (1C), 33.17 (1C), 
25.39 (1C), 15.79 (1C), 10.89 (1C).  HRMS (ESI) calc. for C18H24N2O4 (M + H)
+
 
332.1736, found 332.1802. 
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(S)-2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)-3-phenylpropanoic acid (2.12a)  
 
The product was obtained from 2.11a (0.31 mmol) in a similar manner as described for 
preparation of 2.12b affording compound 2.12a (0.09 mmol, 30%) as a yellow solid.  
1
H 
NMR (400 MHz, CD3OD) δ 7.31-7.28 (m, 3H), 7.26 – 7.14 (m, 2H), 5.26 (dd, J = 12.4, 
4.3 Hz, 1H), 3.90 (dd, J = 40.4, 17.3 Hz, 1H), 3.74 (dd, J = 17.3, 8.7 Hz, 1H), 3.63 (d, J = 
4.9 Hz, 1H), 3.48-3.40 (m, 1H), 3.24 (dd, J = 21.0, 4.5 Hz, 1H), 3.10 (dd, J = 14.8, 12.5 
Hz, 1H), 1.92 – 1.81 (m, 1H), 0.98 – 0.85 (m, 1H), 0.83 (d, J = 7.3 Hz, 1H), 0.77 (dd, J = 
6.7, 3.4 Hz, 2H), 0.71 (d, J = 7.0 Hz, 2H), 0.62 (d, J = 6.6 Hz, 1H), 0.54 (d, J = 6.8 Hz, 
2H).  HRMS (ESI) calc. for C16H20N2O4 (M + H)
+
 304.1423, found 304.1509. 
(S)-2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-3-phenylpropanoic acid (2.12b)  
 
To a stirring solution of 2.11b (0.10 mmol) in CH3CN (3 mL) was added aqueous LiOH 
(0.05 mmol/1 mL H2O).  The solution was stirred at ambient temperature for 18 h.  The 
solution was chilled to 0 
o
C and acidified with 1N HCl (to a pH of 4-5).  The aqueous 
portion was extracted with EtOAc (3 x 35 mL), the combined organic layers were washed 
with brine (2 x 40 mL), and dried over Na2SO4.  The remaining solvent was removed 
under reduced pressure to afford the pure compound 2.12b (0.049 mmol, 49%) as a white 
crystalline solid.  
1
H NMR (400 MHz, CD3OD) δ 7.34 – 7.17 (m, 8H), 7.08 – 7.03 (m, 
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2H), 4.94-4.89 (m, 1H), 4.18 (t, J = 5.4 Hz, 1H), 3.37 (d, J = 17.1 Hz, 1H), 3.27-3.20 (m, 
2H), 3.01 (dd, J = 14.4, 10.5 Hz, 1H), 2.88 (qd, J = 13.8, 5.4 Hz, 2H).  
13
C NMR (101 
MHz, CD3OD) δ 170.24 (1C), 167.41 (1C), 166.72 (1C), 136.83 (1C), 135.31 (1C), 
129.95 (2C), 128.78 (2C), 128.62 (2C), 128.40 (2C), 127.03 (1C), 126.93 (1C), 59.02 
(1C), 56.65 (1C), 39.48 (1C), 33.90 (1C).  HRMS (ESI) calc. for C20H20N2O4 (M + H)
+
 
352.1423, found 352.1495. 
(S)-3-(1H-indol-3-yl)-2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)propanoic acid 
(2.12c)  
 
The product was obtained from 2.11f (0.45 mmol) in a similar manner as described for 
preparation of 2.12b affording compound 2.12c (0.27 mmol, 59%) as an orange solid.  
1
H 
NMR (400 MHz, CD3OD) δ 7.21 (d, J = 7.9 Hz, 1H), 6.96 (d, J = 8.0 Hz, 1H), 6.78 – 
6.61 (m, 3H), 4.97 (dd, J = 12.0, 4.0 Hz, 1H), 3.51 (dd, J = 99.6, 17.4 Hz, 2H), 3.23 (d, J 
= 4.8 Hz, 1H), 3.13 (dd, J = 15.3, 4.5 Hz, 2H), 2.99 (s, 2H), 1.48 – 1.35 (m, 1H), 0.25 (d, 
J = 7.0 Hz, 3H), 0.10 (d, J = 6.8 Hz, 3H).  
13
C NMR (101 MHz, CD3OD) δ 172.02 (1C), 
167.24 (1C), 167.13 (1C), 136.98 (1C), 127.10 (1C), 123.06 (1C), 121.47 (1C), 118.83 
(1C), 117.90 (1C), 111.29 (1C), 109.55 (1C), 60.88 (1C), 33.24 (1C), 24.03 (1C), 17.68 
(1C), 15.78 (1C).  HRMS (ESI) calc. for C18H21N3O4 (M + H)
+
 343.1532, found 
343.1588. 
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(S)-2-((S)-3-isobutyl-2,5-dioxopiperazin-1-yl)-3-methylbutanoic acid (2.12f) 
 
The product was obtained from 2.11g (2.35 mmol) in a similar manner as described for 
preparation of 2.12b affording compound 2.12f (1.45 mmol, 40%) as a yellow solid.  
1
H 
NMR (400 MHz, CD3OD) δ 4.70 – 4.08 (m, 2H), 4.03 – 3.77 (m, 1H), 2.30 – 2.12 (m, 
1H), 1.89 – 1.56 (m, 4H), 1.00 – 0.89 (m, 12H).  13C NMR (101 MHz, CD3OD) δ 171.68 
(1C), 168.98 (1C), 167.65 (1C), 67.13 (1C), 61.69 (1C), 54.08 (1C), 42.53 (1C), 27.59 
(1C), 24.29 (1C), 22.15 (1C), 20.70 (1C), 18.95 (1C), 18.31 (1C).  HRMS (ESI) calc. for 
C13H22N2O4 (M + H)
+
 270.1579, found 270.1666. 
(S)-1-((S)-3-(1H-indol-3-yl)-1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl)-3-
isopropylpiperazine-2,5-dione (2.14) 
 
To a stirring solution of 2.12c (0.29 mmol) in DCM (5 mL), under argon, was added 
phenyl piperazine (0.35 mmol), EDC (0.35 mmol), and stirred at ambient temperatures 
for 18 h.  The solution concentrated under reduced pressure and the resulting crude 
residue was dissolved in ethyl acetate (100 mL), washed with aq. 5% KHSO4 (1 x 35 
mL), saturated aqueous sodium bicarbonate (2 x 30 mL), brine (2 x 50 mL), and dried 
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over Na2SO4.  The residual solvent was removed in vacuo to afford the crude oil which 
was subsequently purified using flash chromatography on silica gel (60:40 
EtOAc/hexanes) affording compound 2.14 (0.09 mmol, 30%) as a clear oil.  
1
H NMR 
(400 MHz, CDCl3) δ 8.10 (s, 1H), 7.69 – 7.64 (m, 1H), 7.35 – 7.30 (m, 1H), 7.25 – 7.13 
(m, 4H), 7.09 (d, J = 2.3 Hz, 1H), 6.91-6.85 (m, 1H), 6.79 (dd, J = 8.7, 0.9 Hz, 2H), 6.45 
(s, 1H), 5.98 (t, J = 8.0 Hz, 1H), 4.51 – 4.05 (m, 2H), 3.80 (t, J = 3.2 Hz, 1H), 3.74 – 3.61 
(m, 3H), 3.59 – 3.49 (m, 1H), 3.44 – 3.33 (m, 1H), 3.21 (dd, J = 14.5, 7.6 Hz, 1H), 3.12 – 
3.02 (m, 1H), 2.91 – 2.82 (m, 2H), 2.60 – 2.51 (m, 1H), 2.25 – 2.14 (m, 1H), 0.88 (d, J = 
7.0 Hz, 3H), 0.67 (d, J = 6.8 Hz, 3H).  
13
C NMR (101 MHz, CDCl3) δ 168.36 (1C), 
166.20 (1C), 165.96 (1C), 150.93 (1C), 136.39 (1C), 129.39 (2C), 123.12 (1C), 122.65 
(1C), 120.73 (1C), 120.17 (1C), 118.72 (1C), 116.78 (2C), 111.49 (1C), 110.16 (1C), 
61.03 (1C), 51.21 (1C), 49.69 (1C), 45.88 (1C), 45.71 (1C), 42.32 (1C), 41.24 (1C), 
32.83 (1C), 25.43 (1C), 18.90 (1C), 16.31 (1C).  HRMS (ESI) calc. for C28H33N5O3 (M + 
H)
+
 487.2583, found 487.2158. 
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Chapter Three: 
 
Design and Synthesis of the Hybrid 2,5-Piperazine-Dione-Pyrimidine Based Scaffold 
3.1 Introduction 
3.1.1 Pyrimidines 
Pyrimidines are six-membered rings that display a similar structure to benzene but 
differing in there containing nitrogen atoms in the 1 and 3 positions of the ring (Figure 
3.1). 
 
Figure 3.1: Structures of (A) Benzene (B) Pyrimidine 
 
Pyrimidines are an important class of heterocyclic aromatic compounds in the realm of 
life sciences due to their unique chemical properties.(Parks et al., 2008)  They have 
electron-deficient aromatic systems (Haridas, 2009; Parks et al., 2008)  and the 
pyrimidine structure displays a greater tortional flexibility when compared to similar 
compounds with a benzyl core, contributing to their high binding affinity.(Haridas, 2009) 
Pyrimidine analogs are apt to functionalization and synthesis most commonly involves 
cyclocondensation reactions with amidine, guanidine or thiourea derivatives.  (Parks et 
al., 2008; Samb et al., 2009)  There has been documented synthesis of functionalized 
pyrimidines by conventional heating solution phase, microwave heating, and solid phase 
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synthesis.(Kumar et al., 2002; Luo et al., 2002; Samb et al., 2009) Pyrimidine core 
scaffolds, bearing multiple functionalities, and substituted amino pyrimidines are 
prevalent in medicinal chemistry and commonly found within marketed drugs, as shown 
in Figure 3.2.  
 
Figure 3.2: Marketed drugs with pyrimidine sub-units highlighted in blue 
 
Scaffolds, based on a combination of functionalized piperazines and pyrimidines, 
have show drug like applications (Figure 3.3) as potent FLT3 tyrosine kinase inhibitors 
(Figure 3.3, C) (Gaul et al., 2007), potential antagonists of protein/protein interactions 
(Figure 3.3, A) (Volonterio et al., 2007), and potent dopamine D3-receptor antagonists 
(Figure 3.3, B) (Geneste et al., 2006). 
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Figure 3.3: Scaffolds containing piperazine and pyrimidine units circled in blue (A) 
Rebek’s pyridazine-based scaffold as antagonists of protein/protein interactions  (B) 
Wernets’s 1H-pyrimidin-2-one scaffold as dopamine D3-receptor antagonists  (C) 
Baumann’s 4-amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes as FLT3 
tyrosine kinase inhibitors 
 
 
3.1.2 Hybrid Scaffold Design 
For this project, we focused on the design, synthesis and biological evaluation of 
novel α-helix mimetics based on a hybrid scaffold comprised of functionalized piperazine 
or 2,5-DKP, and pyrimidine units, as depicted in Figure 3.4.  
 
Figure 3.4: Hybrid piperazine/pyrimidne scaffold 
 
 
This scaffold was designed to mimic the MDM2 binding domain of the p53 
peptide, utilizing the same Hamilton design methodology, as previously described in 
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Chapter 1.5.  Our scaffold design replaces the hydrophobic phenyl rings, used in the 
traditional Hamilton scaffold, with functionalized piperazine and 2,5-pyrimidine units. 
This novel design was thought to increase desired drug like properties of the parent 
terphenyl scaffold with the addition of polar functional groups while still maintaining the 
desired spacial arrangement of side chains in the ith, ith+4,and ith+7 positions, as shown 
in Figure 3.5.(Cummings and Hamilton, 2010)  
Figure 3.5: Schematic representations (A) a natural α-helix with the i-1, i, i + 4, i + 7, and i 
+ 11 residues, (B) 2D hybrid piperazine/pyrimidne scaffold, (C) 3D hybrid 
piperazine/pyrimidne scaffold. 
 
There are many documented facile syntheses of substituted pyrimidines.(Agarwal 
et al., 2005; Cherng, 2002; Kumar et al., 2002; Luo et al., 2002)  The addition of the 
facile pyrimidine chemistry coupled with the previously studied synthetic chemistry of 
substituted piperazines and DKPs (Chapter 2) was hoped to improve the overall ease of 
synthesis of the scaffold. 
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3.1.3 Molecular Modeling Studies 
In efforts to validate potential novel inhibitors of p53/MDM2 binding interactions 
in a virtual screening mode, we conducted computational simulations with Shrodeinger 
software of variations of the proposed target hybrid scaffold (Figure 3.4) docked into the 
hydrophobic pocket in the NH2 terminal domain of the MDM2 protein derived from the 
X-ray crystal structure of p53 bound to the hydrophobic pocket of MDM2 (PDB 
1YCQ).(Kussie et al., 1996)  Computational analysis of the proposed structures were 
ranked based on the docking GLIDE score and the top scoring structures were then 
synthesized.  Molecular modeling of the top GLIDE scoring structure of hybrid scaffold 
3.38 (shown in Figure 3.6) suggested that the hybrid scaffold targeted the same surface 
area of MDM2 where p53 binds, inserting the side chains into the desired F19, W23, and 
L26 binding pockets, as shown in Figure 3.7. 
 
Figure 3.6: Top scoring hybrid piperazine/pyrimidne scaffold 3.38 
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Figure 3.7: Molecular docking of the hybrid piperazine/pyrimidine scaffold.  Displayed 
are the three aromatic side chains in the key F19, W23, and L26 pockets in the MDM2 
hydrophobic grove (image by Courtney DuBoulay) 
 
  
Further analysis of the hybrid scaffold 3.38 overlayed with the p53 protein 
(Figure 3.8) displayed numerous hydrophobic interactions with the MDM2 protein, as 
shown in Figure 3.7. The benzyl group in the R1 place positions the ith group for 
hydrophobic interactions with Y100, and the benzyl group in the R2, ith+4, position 
displayed hydrophobic interactions with V93, L54, and V93. The third position benzyl 
group in the R3, ith+7, position displayed hydrophobic interactions with M62 and V93.  
The molecule displayed overall hydrophobic interactions with L54, L57, F55, G58, M62, 
F91,V93, I99, and I61 which are all reported to be located within the p53 binding 
pocket.(Kussie et al., 1996)   
93 
 
 
Figure 3.8: Hydrophobic interactions of the top scoring hybrid scaffold 3.38 
 
 
 
Figure 3.9: Overlay of the p53 protein (transparent light blue) with the proposed hybrid 
piperazine/pyrimidine scaffold docked to the MDM2 hydrophobic pocket (image by 
Courtney DuBoulay) 
 
 
The observed hydrophobic interactions at these positions were also observed in 
the binding of the p53 peptide and MDM2 (Kussie et al., 1996) demonstrating that hybrid 
scaffold 3.38 recognizes the target MDM2 protein surface and adopts a similar 
confirmation to the p53 peptide for its side chains. 
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3.2 Results and Discussion 
3.2.1 Hybrid Piperazine/Pyrimidine Scaffold, Approach 1 
The key component of this approach, depicted in Scheme 3.1, was the coupling of 
monomer A1 (Chapter 2) and monomer A2 (Scheme 3.2) by sulfur displacement to afford 
the target hybrid scaffold A1-A2.   
 
Scheme 3.1: Retrosynthesis of the Hybrid 2,5-DKP-Pyrimidine Scaffold, Approach 1 
 
The synthesis 2,5-DKP unit A1, depicted in Scheme 3.1, is  described in detail in 
Chapter 4, Scheme 4.10 and 4.12.  The synthesis of the A2 pyrimidine unit (Scheme 3.1) 
began with the use of α,β-unsaturated α-cyanoketones 3.1a-c, which were synthesized in 
house by other lab members.(Zhou et al.) Compounds 3.1a-c underwent microwave 
assisted condensation with commercially available 2-methyl-2-thiopseudourea 
hemisulfate salt in the presence of sodium ethoxide (NaOEt) and methanol to afford 
pyrimidines 3.2a-c as the pure products in high yields.(Thomas et al., 2004)  Conversely, 
no reaction was observed when the reaction was carried out in DMF and yields were 
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comparable when carried out in ethanol (data not shown). Compounds 3.2a-c were 
subsequently oxidized with meta-chloroperoxybenzoic acid (mCPBA), yielding the target 
A2 unit, compounds 3.3a-b.(Thomas et al., 2004) 
 
Scheme 3.2: Synthesis of pyrimidine unit A2, compounds 3.3a-b 
 
Coupling of piperazine dione 4.28b with pyrimidine 3.3a, depicted in Scheme 3.3, 
was attempted initially with sodium hydride (NaH) in THF or DMF, at various 
temperatures. The attempt in the aprotic solvent THF resulted in no reaction occurring 
while attempts using DMF resulted in the formation of undesired elimination product 3.5.  
Additional reactions were performed utilizing alternate bases, solvents, and temperatures 
in hopes of obtaining the desired substitution product 3.4 (Scheme 3.3). Unfortunately 
these modifications were not successful and all attempts resulted in no reaction occurring 
with all starting material still present as shown by TLC and NMR.   
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Entry Reagents Conditions Results 
1 NaH THF, 12 h at rt, 18 h at 40 °C No rxn 
2 NaH DMF, 100 °C, 6 h 3.5, 8% 
3 NaH DMF, 100 °C, 24 h 3.5, 10% 
4 TEA THF, reflux, 24 h No rxn 
5 TEA THF, MW, 120 °C, 30 min No rxn 
6 DIEA DMF, MW, 70 °C, 30 min No rxn 
7 DIEA 1-propanol, 105 °C, 2 h No rxn 
8 DIEA THF, MW, 115 °C, 20 min No rxn 
Scheme 3.3: Attempted formation of compound 3.4 
 
It was reasoned that the amide nitrogen of compound 4.28b was unable to act as 
an effective nucleophile.  Being a better nucleophile than 4.28b, compound 4.29b was 
used in the attempted coupling to compound 3.3a, as shown in Scheme 3.4.  Again, all 
attempts were unsuccessful at forming compound 3.6 and resulted in no reaction (Scheme 
3.4). 
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Entry Reagents Conditions 
1 TEA THF, reflux, 24 h 
2 TEA THF, MW, 120 °C, 30 min 
3 DIEA DMF, MW, 70 °C, 30 min 
4 DIEA 1-propanol, 105 °C, 2 h 
Scheme 3.4: Attempted formation of compound 3.6 
 
Model reactions were performed to assess whether the nucleophilcity of the amide 
nitrogen, the poor reactivity of the pyrimidine monomer toward nucleophilic aromatic 
substitution, or a combination of both, were preventing reaction success.  As shown in 
Scheme 3.5, the indole nitrogen of compound 3.7 was unable to displace the sulfone 
functional group in pyrimidine 3.3a, or the notably more reactive chlorine substituted 
pyrimidine 3.9, as shown in Scheme 3.6.(Cherng, 2002; Gudmundsson, 2006; Zhang et 
al., 2006)  Further attempts at chlorine displacement with more nucleophilic piperazine 
4.29b were also unsuccessful, as shown in Scheme 3.7.(Cushing et al., 1999; Luo et al., 
2002)   
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Entry Reagents Conditions 
1 NaH THF, 0 °C for 2 h, reflux for 18 h  
2 NaH THF, 0 °C for 10 min, reflux for 48 
h  
3 DIEA DMF, MW, 80 °C, 10 min  
4 TEA THF, MW, 130 °C, 10 min 
5 DIEA DMF, MW, 150 °C,  40 min  
Scheme 3.5: Attempted indole mediated sulfone displacement 
 
 
Entry Reagents Conditions 
1 DIEA DMF, MW, 150 °C,  40 min 
2 BINAP, Pd(OAc)2, Cs2CO3 1,4-dioxane, 120 °C, 20 min  
3 DIEA NMP, MW, 120 °C, 30 min  
4 DIEA 2-propanol, MW, 150 °C, 3 h 
5 DIEA toluene, MW, 100 °C,  30 min  
Scheme 3.6: Attempted indole mediated chlorine displacement 
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Entry Reagents Conditions 
1 TEA toluene, reflux,  18 h 
2 DIEA toluene, reflux, 48 h  
3 TEA 1,4-dioxane, 80 °C, 24 h   
Scheme 3.7: Attempted chlorine displacement 
 
These sets of data verified that neither increasing the nucleophilicity of the 
reacting amine or the reactivity of the leaving group was able to optimize the coupling 
reaction.  The synthetic approach followed for the scaffold formation by coupling two 
different distinct monomers was discontinued and alternate synthetic methodologies were 
explored for the hybrid piperazine/pyrimidine scaffold formation.  
3.2.2 Hybrid Piperazine/Pyrimidine Scaffold, Approach 2 
The next approach at synthesis of the piperazine/pyrimide hybrid scaffold 
involved the formation of a functionalized amino pyrimidine a, followed by bromine 
displacement c, and intramolecular cyclization to afford the target molecule A1-A2, as 
shown in Scheme 3.8. 
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Scheme 3.8: Retrosynthesis hybrid 2,5-DKP-pyrimidine scaffold, Approach 2 
 
This synthesis began with the formation of an α,β-unsaturanted α-nitro ketone, a, 
that would be used to form the functionalized pyrimidine c upon condensation with an 
appropriate guanidine b (Scheme 3.8). 
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Scheme 3.9: General synthetic method for nitro-containing pyrimidines 
 
 
For the formation of the α,β-unsaturanted α-nitro ketone (Scheme 3.9, a), it was 
initially thought that coupling commercially available ester 3.13 with nitromethane 
(CH3NO2) in the presence of either potassium tert-butoxide (KOBt) or potassium tert-
amyloxide (KOt-amyl) could yield the β-ketonitro compound 3.14 (Scheme 3.10).  This 
reaction scheme did not yield the desired product 3.15 and all starting material remained 
unreacted.(Zhang et al., 2004) 
 
Entry Reagents Conditions Results 
1 KOBt, CH3NO2 DMSO, 0 
o
C - 10 min, rt - 24h No rxn 
2 CH3CHC(CH3)2OK, CH3NO2 THF,  0 
o
C - 10 min, rt - 3h No rxn 
Scheme 3.10: Proposed synthesis of 3.15, Attempt 1 
 
It was anticipated that the subsequent coupling to phenyl ester 3.17 would afford 
improved results when compared with methyl ester 3.13, taking into consideration that a 
phenoxy moiety is a better leaving group than the OMe moiety.(Zhang et al., 2004)  The 
next attempt at the formation of compound 3.15 began with esterification of phenyl acetic 
acid (compound 17, Scheme 3.11).  As shown in Scheme 3.12, the reaction was initially 
performed in the presence of phenol, N,N′-dicyclohexylcarbodiimide (DCC),  4-
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(dimethylamino) pyridine (DMAP), and DCM, yielding the target ester 3.17, although 
yields were not optimal and the purification was lengthy and difficult.(Yamazaki et al., 
2001)  Subsequent treatment with N,N′-diisopropylcarbodiimide (DIC) did not improve 
the reaction conditions. Further treatment with ethyl-(N’,N’-dimethylamino) 
propylcarbodiimide-hydrochloride (EDC) and 1-hydroxybenzotriazole (HOBt) or DMAP 
did improve conditions and optimal conditions were obtained with microwave assisted 
coupling in the presence of EDC, DMAP, and DIEA, providing compound 3.17 in good 
yield, 80%.   
 
Scheme 3.11: Proposed synthesis 3.15, Attempt 2 
 
 
 
Entry Reagents Conditions Results 
1 Phenol, DCC, DMAP DCM, rt, 18h 36% 
2 Phenol, DIC, DMAP DCM, rt, 18h 30% 
3 Phenol, EDC, HOBt, DIEA DCM, rt, 22h 74% 
4 Phenol, EDC, DMAP, DIEA DCM, rt, 22h 70% 
5 Phenol, EDC, DMAP, DIEA DCM, MW, 60 
o
C, 20 min 80% 
Scheme 3.12: Formation of ester 3.17 
 
 
Subsequent attempts at the coupling of compound 3.17 with nitromethane to yield 
compound 3.14 were inefficient, low yielding (17-18%), and difficult to purify, as shown 
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in Scheme 3.13.(Zhang et al., 2004)  These results were not optimal for the synthesis of 
starting materials, therefore an additional route for the formation of compound 3.15 was 
explored.  
 
Entry Reagents Conditions Results 
1 KOBt, CH3NO2 DMSO, rt, 18h 17% 
2 KOBt, CH3NO2 DMSO, rt, 48h 18% 
3 KOBt, CH3NO2, K2CO3 DMSO, rt, 24h Traces 
4 KOBt, CH3NO2, K2CO3 DMSO, rt, 48h Traces 
Scheme 3.13: Synthesis of 3.14 
 
The final attempt at the formation of the α,β-unsaturanted α-nitroketone building 
blocks is depicted in Scheme 3.14. Aldehydes 3.18a-c underwent microwave assisted 
nitroaldol reactions in the presence of nitromethane and TEA, to afford the pure adducts 
3.19a-c, quickly and with modest yields.(Gan et al., 2006; Ma and You, 2007) The 
alcohols were oxidized to the corresponding ketones 3.20a-b and 3.15 by means of 
pyridinium chlorochromate (PCC) and subsequent microwave assisted treatment with 
N,N-dimethylformamide dimethyl acetal (DMF-DMA) afforded the target α,β-
unsaturanted α-nitroketone compounds 3.21a-b with modest yields.(Bartlett et al., 1990)    
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Scheme 3.14: Synthesis of 3.21a-b 
 
Pyrimidine formation began with microwave-assisted condensation of 3.21a-b 
with guanidine hydrochloride in the presences of potassium carbonate and ethanol 
afforded pyrimidines 3.22a-b as the pure product with high yields (Scheme 
3.15).(Radwan and El-Sherbiny, 2007)  Compound 3.21a was also reacted with 
benzylamine hydrochloride under the same microwave-assisted conditions affording 
pyrimidine 3.23.  Pyrimidine 3.23 underwent 5% Pd/C catalyzed nitro reduction yielding 
compound 3.24 in high yields as the pure product.  Compound 3.24 subsequently 
underwent Cu(I) catalyzed bromine insertion, yielding pyrimidine 3.25.(Ueno et al., 
2008) 
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Scheme 3.15: Synthesis of nitro-based pyrimidines 
 
X-ray crystal structures were obtained for compounds 3.20a, 3.21a, 3.23, 3.24, and 3.25 
 from Dr. Frank Fronczek at Lousiana State University.(Figure 3.10) 
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Figure 3.10: Crystal structures for compounds 3.20a, 3.21a, 3.22a, 3.24, and 3.25 
 
 
From previous experience with the piperazine 2,5-diones, it was envisioned that 
compounds 2.3c could be coupled to the 5-amino substituent of pyrimidine 3.24, as 
shown in Scheme 3.16.  Numerous reagents and reaction conditions were explored for the 
synthesis although none were successful.  It was reasoned that the 5-amino substituent of 
pyrimidine 3.24 was not able to react as an efficient nucleophile due to the electron 
withdrawing effects of the pyrimidine ring.  
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Entry Reagents Conditions 
1 DIEA DMF, 110 °C, 24 h 
2 DIEA DMF, MW, 150 °C, 30 min 
3 DIEA Methanol, reflux, 24 h 
4 TEA Methanol, reflux, 24 h 
5 DIEA Methanol, MW, 100 °C, 75 min 
Scheme 3.16: Attempted formation of compound 3.26 
 
Model reactions were performed to determine whether an alternate synthetic 
strategy relying on the nucleophilic aromatic substitution of functionalized pyrimidines, 
for the formation of the hybrid piperazine/pyrimidine scaffold, could be optimized.  
Bromine displacement of pyrimidine 3.35 with phenyl piperazine 3.27 in the presence of 
DIEA and 2-ethoxy ethanol failed to provide the desired product compound 3.28, as 
depicted in Scheme 3.17. Cu(I) catalyzed bromine insertion of pyrimidine 3.29 was 
unsuccessful (Scheme 3.18), and the coupling of pyrimidine 3.31 to N-Boc phenylalanine 
3.32 using a variety of reagents and conditions, as shown in Scheme 3.19, also failed.  
Unfortunately, these attempts were not successful in generating the desired product.  This 
concluded the use of pyrimidine-based bromine displacement as inefficient for the 
formation of the hybrid piperazine/pyrimidine scaffold and alternative synthetic routes 
were explored. 
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Scheme 3.17: Attempted formation of 3.28 by bromine displacement 
 
 
         
Scheme 3.18: Attempted formation of 3.30 by bromine insertion  
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Entry Reagents Conditions 
1 HOBt, DIC DCM, rt, 24 h 
2 DIEA, Isobutyl chloroformate Toluene, 0 °C to rt for 1 h, rt, 24 h 
3 HOBt, EDC DCM, rt, 4 h, 30 °C, 18 h 
Scheme 3.19: Attempted amine coupling to compound 3.31 
 
3.2.3 Hybrid Piperazine/Pyrimidine Scaffold, Approach 3 
Our next approach towards the formation of the hybrd piperazine/pyrimidine 
scaffold, began with the synthesis of a functionalized piperazine a, followed by 
guanidinylation b, and subsequent condensation to afford the target scaffold A1-A2, as 
shown in Scheme 3.20 
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Scheme 3.20: Retrosynthesis hybrid piperazine/pyrimidine scaffold, Approach 3 
 
This synthetic route, as shown in Schemes 3.21-22, began by reacting previously 
synthesized piperazine monomeric unit, 2.32b,with silver triflate in the presence of an 
N,N-diboc-pseudo guanidinylating agent 3.35 (synthesis shown in Scheme 3.21) to afford 
compound 3.36.(Delle Monache et al., 1993; DeMong and Williams, 2003)  Reactions 
for this step were also carried out using barium chloride, mercury chloride, and THF as 
the solvent.(Agarwal et al., 2005; Andrews et al., 1949; Powell et al., 2003)  While the 
desired product, compound 3.35, was synthesied, the isolation was difficult and the yields 
were low (20-30%, data not shown).  N-Boc deprotection of 3.36 was achieved using 
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standard TFA/DCM conditions, producing compound 3.37. Compound 3.37 underwent 
condensation with compound 3.1b, to afford the target scaffold 3.38.  
 
Scheme 3.21: Synthesis of N,N-diboc-pseudo guanidinylating agent 3.35 
 
 
 
Scheme 3.22: Successful synthesis of hybrid scaffold 3.38 
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3.2.4 Fluorescence Polarization Assays 
Scaffold 3.38 underwent biological testing by means of fluorescence polarization 
assays to determine if the compound did disrupt p53/MDM2 or BclxL/Bax binding 
interactions.  An IC50 > 100 µM was obtained for both assays which was not a desirable 
value for a potential drug candidate. 
3.3 Conclusion 
Although successful, the synthesis of hybrid scaffold 3.38 was lengthy, low 
yielding, and hard to reproduce.  The difficult synthesis coupled with poor biological data 
encouraged us to put this scaffold synthesis on hold and explore alternative options.  
3.4 Experimental Procedures 
4-tert-Butyl-2-methylsulfanyl-pyrimidine-5-carbonitrile (3.2a)   
 
A mixture of 3.1a (1.11 mmol), sodium ethoxide (1.11 mmol), and 2-methyl-2-
thiopseudourea (2.22 mmol) in anhydrous methanol (3 mL) was heated in a Biotage 
microwave at 70 ºC for 15 minutes.  After cooling to ambient temperature, the solution 
was diluted with 100 mL DI H2O, 50 mL of saturated KHSO4, and extracted with EtOAc 
(3 x 30 mL).  The combined organic layers were washed with brine (2 x 30 mL), dried 
(Na2SO4), and evaporated under reduced pressure.  The crude product was purified by 
flash chromatography on silica gel (1:10 EtOAc/hexanes) to afford 3.2a as a light yellow 
oil (0.68 mmol, 65%).  
1
H NMR (400 MHz, CDCl3 8.61 (s, 1H), 2.586 (s, 3H), 1.487 
(s, 9H).  
13
C NMR (100 MHz, CDCl3)  178.84 (1C),175.78 (1C), 161.66 (1C), 117.12 
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(1C), 101.10 (1C), 40.08 (1C), 28.63 (3C), 14.58 (1C).  HRMS (ESI) calc. for C10H13N3S 
(M + H)
+
 207.0839, found 207.0722. 
 4-Benzyl-2-methylsulfanyl-pyrimidine-5-carbonitrile (3.2b)   
 
This was obtained from 3.1b (0.93 mmol) in a similar manner as described for the 
preparation of 3.2a.  The crude product was purified by flash chromatography on silica 
gel (1:10 EtOAc/hexanes) to afford 3.2b as a light yellow solid (0.84 mmol, 84%).  
1
H 
NMR (400 MHz, CDCl3)  8.60 (s, 1H), 7.42-7.23 (m, 5H), 4.22 (s, 2H), 2.57 (s, 3H).  
13
C NMR (100 MHz, CDCl3) 176.98 (1C), 171.27 (1C), 159.98 (1C), 135.77 (1C), 
129.50 (2C), 129.05 (2C), 127.63 (1C), 115.60 (1C), 102.96 (1C), 29.91 (1C), 14.66 
(1C).  HRMS (ESI) calc. for C13H11N3S (M + H)
+
 241.0673, found 241.0747. 
2-Methylsulfanyl-4-naphthalen-1-ylmethyl-pyrimidine-5-carbonitrile (3.2c) 
 
This was obtained from 3.1c (0.378 mmol) in a similar manner as described for the 
preparation of 3.2a.  The crude product was purified by flash chromatography on silica 
gel (1:10 EtOAc/hexanes) to afford 3.2c as a light yellow oil (0.21 mmol, 56%).  
1
H 
NMR (400 MHz, CDCl3 8.62 (s, 1H), 8.26 (d, J = 8.13 Hz, 1H), 7.89-7.78 (m, 2H), 
7.55-7.42 (m, 3H), 4.69 (s, 2H), 2.40 (s, 3H).  
13
C NMR (100 MHz, CDCl3 176.83 
(1C), 171.12 (1C), 160.09 (1C), 134.16 (1C), 132.18 (1C), 132.04 (1C), 128.99 (1C), 
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128.64 (1C), 126.49 (1C), 126.09 (1C), 125.72 (2C), 124.67 (1C), 115.74 (1C), 103.16 
(1C), 29.93 (1C), 14.53 (1C).  HRMS (ESI) calc. for C17H13N3S (M + H)
+
 291.0630, 
found 291.0902. 
4-tert-Butyl-2-methanesulfonyl-pyrimidine-5-carbonitrile (3.3a)    
 
To a stirred and cooled (0 ºC) solution of compound 3.2a (1.78 mmol) in anhydrous 
DCM (25 mL) was added m-CPBA (7.18 mmol) and the mixture was stirred at 0 ºC for 4 
hours.  The mixture was brought to ambient temperatures, treated with 10% Na2SO3 (6 
mL), and subsequently filtered.  The filtrate was washed with 10% aqueous NaHCO3 (2 x 
30 mL), brine (2 x 35 mL), dried (Na2SO4), and evaporated under reduced pressure.  The 
crude product was purified by chromatography on silica gel using the Flash Master 3 
purification station (3:7 EtOAc/hexanes), affording 3.3a as a white solid (1.21 mmol, 
68%).  
1
H NMR (400 MHz, CDCl3  9.07 (s, 1H), 3.39 (s, 3H), 1.576 (s, 9H).  
13
C 
NMR (100 MHz, CDCl3 182.67 (1C), 166.15 (1C), 163.61 (1C), 114.84 (1C), 109.63 
(1C), 40.60 (1C), 39.17 (1C), 28.63 (3C).  HRMS (ESI) calc. for C10H13N3O2S (M + H)
+
 
239.0728, found 239.0629. 
4-Benzyl-2-methanesulfonyl-pyrimidine-5-carbonitrile (3.3b) 
 
This was obtained from 3.2b (0.306 mmol) in a similar manner as described for the 
preparation of 3.3a.   The crude product was purified by chromatography on silica gel 
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using the Flash Master 3 purification station (3:7 EtOAc/hexanes), to afford 3.3b as a 
light yellow solid (0.307 mmol, 42%).  
1
H NMR (400 MHz, CDCl3 8.98 (s, 1H), 7.34-
7.18 (m, 5H), 4.37 (s, 2H), 3.30 (s, 3H).  
13
C NMR (100 MHz, CDCl3 174.77 (1C), 
167.09 (1C), 161.99 (1C), 134.44 (1C), 129.51 (2C), 129.45 (2C), 43.20 (1C), 39.22 
(1C).  MS (ESI) m/z 274.06 (M + H)
+
.  HRMS (ESI) calc. for C13H11N3O2S (M + H)
+
 
273.0572, found 273.0658. 
phenyl 2-phenylacetate (3.17)  
 
To phenyl acetic acid (3.67 mmol), in anhydrous DCM (8 mL), under argon, was added 
EDC (4.04 mmol) and HOBt (4.04 mmol).  The reaction was chilled to 0 
o
C and phenol 
(5.51 mmol) in DCM (2 mL) was added via a syringe.  The reaction was brought to 
ambient temperatures and stirred for an additional 22 hours.  The reaction mixture was 
washed with 1 N HCl (1 x 30 mL), brine (2 x 30 mL), dried over Na2SO4, and 
concentrated in vacuo to afford the crude oil.  The crude product was purified by 
chromatography on silica gel (1:10 EtOAc/hexanes), affording compound 3.17 as a clear 
oil (2.36 mmol, 78%).  1H NMR (400 MHz, CDCl3) δ 7.45 – 7.30 (m, 7H), 7.26 – 7.20 
(m, 1H), 7.11 – 7.04 (m, 2H), 3.88 (s, 2H).  13C NMR (101 MHz, CDCl3) δ 170.23 (1C), 
150.97 (1C),   133.71 (1C), 129.62 (2C), 129.55 (2C), 128.96 (2C), 127.58 (1C), 126.09 
(1C), 121.68 (2C), 41.68 (1C).  MS (ESI) m/z 213.1 (M + H)
+
.   
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2-nitro-1-phenylethanol (3.19a)   
 
A mixture of 3.18a (30 mmol), TEA (45 mmol) in nitromethane (8 mL) was heated in a 
Biotage microwave at 80 ºC for 4 minutes.  After cooling to ambient temperature, the 
solution was diluted with DI H2O (125 mL), saturated KHSO4 (20 mL) and subsequently 
extracted with EtOAc (3 x 35 mL).  The combined organic layers were washed with brine 
(2 x 50 mL), dried (Na2SO4), and evaporated under reduced pressure.  The crude product 
was purified by chromatography on silica gel using the Flash Master 3 purification 
station (15:85 EtOAc/hexanes) to afford 3.19a (22.1 mmol, 56%) as a clear oil.  
1
H NMR 
(400 MHz, CDCl3) δ 7.52 – 7.24 (m, 5H), 5.36 (dd, J = 9.6, 2.9 Hz, 1H), 4.46 (ddd, J = 
16.4, 13.3, 6.3 Hz, 2H), 2.93 (bs, 1H).  
13
C NMR (101 MHz, CDCl3) δ 138.38 (1H), 
132.41 (1C), 129.25 (2C), 129.15 (2C), 126.18 (1C), 81.45 (1C), 71.23 (1C).  MS (ESI) 
m/z 166.1 (M - H)
-
.   
1-nitro-3-phenylpropan-2-ol (3.19b)  
 
The product was obtained from 3.18b (8.56 mmol) in a similar manner as described for 
the preparation of 3.19a.  The crude product was purified by chromatography on silica 
gel using the Flash Master 3 purification station (1:1 EtOAc/hexanes) to afford 3.19b 
(5.30 mmol, 62%) as a clear oil. 
1
H NMR (400 MHz, CDCl3) δ 7.38 – 7.26 (m, 3H), 7.25 
– 7.20 (m, 2H), 4.60 – 4.49 (m, 1H), 4.44 – 4.34 (m, 2H), 2.84 (ddd, J = 28.2, 13.6, 6.1 
Hz, 3H).  MS (ESI) m/z 180.1 (M - H)
-
.   
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4-methyl-1-nitropentan-2-ol (3.19c)   
 
The product was obtained from 3.18c (5.81 mmol) in a similar manner as described for 
the preparation of 3.19a.  The crude product was purified by chromatography on silica 
gel using the Flash Master 3 purification station (1:4 EtOAc/hexanes) to afford 3.19c 
(4.99 mmol, 86%) as a clear oil. 1H NMR (400 MHz, CDCl3) δ 4.40-4.30 (m, 3H), 2.87 
(bs, 1H), 1.86 – 1.74 (m, 1H), 1.52 – 1.42 (m, 1H), 1.25 – 1.16 (m, 1H), 0.94-0.91 (m, 
6H).  MS (ESI) m/z 146.1 (M - H)
-
.     
2-nitro-1-phenylethanone (3.20a)  
 
To a stirring mixture of 3.19a (6.05 mmol) in DCM (200 mL), was added PCC (15.11 
mmol) in one portion, and stirred at ambient temperature for 36 hours. The resulting dark 
brown solution was filtered over silica and washed with additional DCM (800 mL).  The 
combined organic solutions were concentrated in vacuo, triturated with chilled hexanes, 
and the precipitate was filtered yielding a crude yellow solid.  The resulting yellow 
crystalline solid was recrystalized in DCM/hexanes (10:1) yielding compound 3.20a 
(5.39 mmol, 90%) as pale yellow crystals.  The structural confirmation of 3.20a was 
obtained by single-crystal X-ray diffraction.  1H NMR (400 MHz, CDCl3) δ 7.88 (dd, J = 
8.4, 1.2 Hz, 2H), 7.72 – 7.66 (m, 1H), 7.64 – 7.48 (m, 2H), 5.91 (s, 2H).  13C NMR (101 
MHz, CDCl3) δ 185.93 (1C), 135.33 (1C), 129.55 (2C), 128.47 (2C), 127.10 (1C), 81.55 
(1C).  MS (ESI) m/z 166.2 (M + H)
+
.   
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4-methyl-1-nitropentan-2-one (3.20b)   
 
The product was obtained from 3.19c (5 mmol) in a similar manner as described for the 
preparation of 3.20a yielding 3.20b (3.70 mmol, 74%) as a pale yellow oil.  
1
H NMR 
(400 MHz, CDCl3) δ 5.26 (s, 2H), 2.41 (d, J = 6.9 Hz, 2H), 2.25 – 2.04 (m, 1H), 0.95 (dd, 
J = 6.6, 0.7 Hz, 6H). 
13
C NMR (101 MHz, CDCl3) δ 196.11 (1C), 83.83 (s, 4H), 49.30 
(1C), 24.63 (1C), 22.49 (2C).  MS (ESI) m/z 146.2 (M + H)
+
.   
1-nitro-3-phenylpropan-2-one (3.15)  
 
The product was obtained from 3.19b (8.56 mmol) in a similar manner as described for 
the preparation of 3.20a yielding 3.15 (4.28 mmol, 50%) as a dark yellow oil.  13C NMR 
(101 MHz, CD3OD) δ 203.90 (1C), 132.65 (1C), 129.60 (2C), 128.65 (2C), 127.30 (1C), 
83.39 (1C), 41.58 (1C).  MS (ESI) m/z 180.1 (M + H)
+
.   
(Z)-3-(dimethylamino)-2-nitro-1-phenylprop-2-en-1-one (3.21a)  
 
To a mixture of 3.20a (5.41 mmol) in anhydrous toluene (5 mL), was added N,N-
dimethylformamide dimethylacetal (1.58 mmol) and heated in a Biotage microwave at 70 
ºC for 10 minutes.  The excess solvent was removed in vacuo and was co-evaporated 
with MeOH (2 x 30 mL).  The resulting orange oil was purified by chromatography on 
silica gel using the Flash Master 3 purification station (1:1 EtOAc/Hexanes) to afford 
3.21a (47%, 2.52 mmol) as a pale yellow crystals.  The structural confirmation of 3.21a 
was obtained by single-crystal X-ray diffraction.  1H NMR (400 MHz, CDCl3) δ 8.36 (s, 
1H), 7.83 (dd, J = 5.2, 3.3 Hz, 2H), 7.58 – 7.50 (m, 1H), 7.45 (t, J = 7.5 Hz, 2H), 3.37 (s, 
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3H), 2.78 (s, 3H).  
13
C NMR (101 MHz, CDCl3) δ 188.27 (1C), 153.75 (1C), 138.62 
(1C), 133.12 (1C), 128.86 (4C), 48.36 (1C), 42.40 (1C).  MS (ESI) m/z 221.2 (M + H)
+
.   
5-nitro-4-phenylpyrimidin-2-amine (3.22a)  
 
To 0.5-2.0 mL microwave vial was added 3.21a (1.4 mmol), guanidine hydrochloride 
(2.1 mmol), K2CO3 (2.52 mmol), EtOH (1 mL), and heated in a Biotage microwave at 
135 ºC for 30 minutes. The solution was cooled to room temperature, decanted out of the 
microwave vial, diluted with DCM (5 mL), and the remaining solution was removed in 
vacuo.  The resulting yellow solid was recrystallized in boiling EtOH affording 
compound 3.22a (71%, 0.99 mmol).  The structural confirmation of 3.22a was obtained 
by single-crystal X-ray diffraction.  
1
H NMR (400 MHz, CDCl3) δ 8.98 (s, 1H), 7.58 – 
7.42 (m, 5H), 5.85 (s, 2H).  
13
C NMR (101 MHz, CDCl3) δ 164.01 (1C), 162.92 (1C), 
157.04 (1C), 135.59 (1C), 130.90 (1C), 128.77 (2C), 128.18 (2C).  HRMS (ESI) calc. for 
C10H8N4O2 (M + H)
+
 216.0647, found 216.0845. 
5-nitro-2,4-diphenylpyrimidine (3.23)  
 
This was obtained from benzamindine hydrochloride hydrate (1.74 mmol) and compound 
3.21a (1.16 mmol) in a similar manner as described for preparation of 3.22a. The crude 
product was recrystallized in boiling EtOH to afford 3.23 as clear yellow crystals (0.92 
mmol, 80%).  The structural confirmation of 3.23 was obtained by single-crystal X-ray 
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diffraction.  1H NMR (400 MHz, CDCl3) δ 9.22 (s, 1H), 8.60 – 8.56 (m, 2H), 7.77 – 7.72 
(m, 2H), 7.62 – 7.51 (m, 6H).  13C NMR (101 MHz, CDCl3) δ 166.01 (1C), 160.18 (1C), 
153.85 (1C), 135.92 (1C), 134.55 (1C), 132.66 (2C), 131.61 (2C), 129.62 (2C), 129.09 
(2C), 128.86 (2C).  MS (ESI) m/z 278.09 (M + H)
+
.  HRMS (ESI) calc. for C16H11N3O2 
(M + H)
+
 277.0851, found 277.0911. 
2,4-diphenylpyrimidin-5-amine (3.24)  
 
A solution of  3.23 (0.11 mmol) in CH3CN (3 mL) underwent hydrogenation in a 
ThalesNano H-Cube Tutor Hydrogenation Reactor, in the presence of a 5% Pd/C 
cartridge, at ambient temperatures, 30 bar pressure, and a flow rate of 1 mL/min.  This 
yielded the pure compound 3.24 (0.093 mmol, 85%) as clear crystals.  The structural 
confirmation of 3.24 was obtained by single-crystal X-ray diffraction.   1H NMR (400 
MHz, CD3OD ) δ 8.34 (s, 1H), 8.27 – 8.23 (m, 2H), 7.88 – 7.83 (m, 2H), 7.57 – 7.34 (m, 
6H).  
13
C NMR (101 MHz, CD3OD) δ 154.55 (1C), 149.70 (1C), 144.30 (1C), 138.16 
(1C), 138.02 (1C), 137.09 (1C), 129.24 (1C), 128.86 (1C), 128.68 (2C), 128.23 (2C), 
128.19 (2C), 126.84 (2C).  HRMS (ESI) calc. for C16H13N3 (M + H)
+
 247.1109, found 
247.1173. 
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5-bromo-2,4-diphenylpyrimidine (3.25)  
 
To an ice bath chilled solution of compound 3.24 (1.14 mmol) in acetic acid (2 mL) was 
slowly added NaNO2 (2.27 mmol) dissolved in conc. H2SO4 (0.5 mL) via an addition 
funnel.  The reaction was stirred at 0 
o
C for 30 min, warmed to ambient temperature, 
followed by the addition of Cu(I)Br (2.27 mmol) in 47% aq. HBr (2.3 mL).  The solution 
was subsequently heated to 80 
o
C for 14 hours, brought to ambient temperature, then 
chilled to 0 
o
C.  Following cooling, the reaction mixture was diluted with EtOAc (45 
mL), neutralized with solid NaHCO3 (300 mg) and saturated aqueous NaHCO3 (10 mL).  
The aqueous phase was extracted with EtOAc (3 x 35 mL), the combined organic layers 
were washed with sat. aq. NaHCO3 (2 x 25 mL), brine (2 x 50 mL), dried over Na2SO4, 
and the residual solvent was removed in vacuo. The resulting yellow/orange solid was 
recrystallized in DCM/Hexanes (10:1) yielding compound 3.25 (1.1 mmol, 60%) as clear 
yellow crystals.  The structural confirmation of 3.25 was obtained by single-crystal X-ray 
diffraction.  1H NMR (400 MHz, CDCl3) δ 8.86 (s, 1H), 8.45 – 8.37 (m, 2H), 7.89 – 7.81 
(m, 2H), 7.50 – 7.36 (m, 6H).  13C NMR (101 MHz, CDCl3) δ 164.14 (1C), 163.22 (1C), 
160.59 (1C), 137.53 (1C), 136.84 (1C), 131.28 (1C), 130.39 (1C), 129.72 (2C), 128.84 
(2C), 128.52 (2C), 128.40 (2C), 116.81 (1C).  HRMS (ESI) calc. for C16H11BrN2 (M + 
H)
+
 310.0106, found 310.0209. 
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N,N'-Bis(tert-butoxycarbonyl)-S-methylisothiourea (3.35) 
 
To a stirring mixture of 2-methyl-2-thiopseudourea hemisulfate salt (7.19 mmol) in DCM 
(14 mL) and saturated aq. NaHCO3 (12 mL), was added Boc anhydride (14.39 mmol) and 
stirred at ambient temperatures for 18 hours.  The aqueous layer was extracted with DCM 
(3 x 40 mL) and the combined organic layers were washed with brine (2 x 50 mL), dried 
(Na2SO4), and concentrated in vacuo to afford the crude oil.  The resulting oil was 
purified by chromatography on silica gel using the Flash Master 3 purification station 
(5:95 EtOAc/Hexanes) to afford 3.35 (4.27 mmol, 60%) as a white gel.  1H NMR (400 
MHz, CDCl3) δ 2.40 (s, 3H), 1.52 (s, 9H), 1.50 (s, 9H).  
13
C NMR (101 MHz, CDCl3) δ 
171.65 (1C), 160.98 (1C), 151.00 (1C), 83.46 (1C), 81.19 (1C), 28.25 (6C), 14.63 (1C). 
HRMS (ESI) calc. for C12H22N2O4S (M + H)
+
 290.1300, found 290.1382. 
(S)-tert-butyl (((tert-butoxycarbonyl)amino)(2,4-dibenzylpiperazin-1-
yl)methylene)carbamate (3.36) 
 
To a solution of 4.33b (0.751 mmol) and 3.35 (0.976 mmol) in anhydrous DMF (4 mL), 
under argon, was added TEA (2.25 mmol), and stirred at ambient temperatures for 10 
minutes.  Following this was the addition of silver triflate (1.05 mmol) and the reaction 
was stirred for an additional 6 hours at ambient temperatures.  The solution was diluted 
with EtOAc (15 mL) and filtered over a short pad of diatomaceous earth.  The filtrate of 
organic solution was washed with brine (2 x 50 mL), dried (Na2SO4), and reduced in 
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vacuo to provide the crude oil which underwent purification by chromatography on silica 
gel using the Flash Master 3 purification station (20:80 EtOAc/hexanes) to afford 3.36 
(0.56 mmol, 78%) as a light yellow oil.  1H NMR (400 MHz, CDCl3) δ 7.40 – 7.24 (m, 
5H), 7.14 (d, J = 6.1 Hz, 3H), 7.07 (s, 2H),3.74 (s, 2H), 3.39 (m, 3H), 2.92 – 2.82 (m, 
2H), 2.65 (d, J = 11.6 Hz, 1H), 2.18 (m, 2H), 2.04 (s, 1H), 1.48 (s, 18H).  
13
C NMR (101 
MHz, CDCl3) δ 171.35 (1C), 155.04 (2C), 138.92 (1C), 138.39 (1C), 129.75 (2C), 129.48 
(2C), 128.50 (2C), 128.48 (2C), 127.43 (1C), 126.43 (1C), 79.69 (1C), 63.17 (1C), 62.91 
(1C), 60.60 (1C), 53.19 (1C), 53.00 (1C), 36.45 (1C), 31.81 (1C), 28.39 (6C).  MS (ESI) 
m/z 509.31 (M + H)
+
.  MS (ESI) m/z 509.3 (M + H)
+
.   
(S)-4-benzyl-2-(2,4-dibenzylpiperazin-1-yl)pyrimidine-5-carbonitrile (3.38) 
 
To a stirring mixture of 3.37 (0.38 mmol) in EtOH (4 mL) was added 3.1b (0.38 mmol) 
and TEA (0.77 mmol).  The solution was heated to a gentle reflux for 18 hours.  After 
cooling to ambient temperatures, the solution was reduced in vacuo and purified by 
chromatography on silica gel using the Flash Master 3 purification station (20:80 
EtOAc/Hexanes) to afford 3.38 (0.033 mmol, 8%) as a white gel.  
1
H NMR (400 MHz, 
CDCl3) δ 8.33 (s, 1H), 7.36 – 7.15 (m, 12H), 7.05-6.99 (m, 3H), 4.86-4.78 (m, 1H), 4.59 
(dd, J = 29.5, 13.1 Hz, 1H), 4.08-3.95 (m, 2H), 3.49 (d, J = 12.9 Hz, 1H), 3.36-3.23 (m, 
2H), 3.19 – 3.07 (m, 1H), 2.91 (d, J = 11.2 Hz, 1H), 2.73-2.59 (m, 2H), 2.06 (td, J = 12.0, 
3.5 Hz, 1H), 1.96-1.89 (m, 1H).  
13
C NMR (101 MHz, CDCl3) δ 172.25 (1C), 161.62 
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(1C), 160.59 (1C), 138.99 (1C), 138.26 (1C), 136.71 (1C), 129.66 (2C), 129.60 (2C), 
129.53 (2C), 128.84 (2C), 128.54 (2C), 128.47 (2C) 127.50 (1C), 127.23 (1C), 126.36 
(1C), 117.63 (1C), 101.57 (1C), 63.12 (1C), 60.63 (1C), 53.30 (1C), 43.22 (1C), 40.32 
(1C), 35.69 (1C), 29.86 (1C).  HRMS (ESI) calc. for C30H29N5 (M + H)
+
 459.2423, found 
459.2426. 
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Chapter Four: 
 
Design and Synthesis of Functionalized 2,5 and 2,6-Diketopiperazines 
 
4.1 Introduction 
 
4.1.1 Piperazine Diones 
 
The heterocyclic family of the diketopiperazines (DKP) including 2,6 and 2,5-
DKPs has been widely studied and synthesized. (Figure 4.1).(Fytas et al., 2008; Maity 
and Koenig, 2008; Martins and Carvalho, 2007; Oguz et al., 2002; Perrotta et al., 2001; 
Teixido et al., 2007)  They have been shown to have important biological activity and a 
wide spectrum of pharmaceutical applications despite being the smallest cyclic peptide 
known.(Niida et al., 2005) 
 
Figure 4.1: Structures of DKPs (A) 2,6-DKP (B) 2,5-DKP 
 
 
They are known to display a variety of antitumor (Kanoh et al., 1999; Kanzaki et al., 
2000; Nicholson et al., 2006), antifungal (Asano, 2003; Houston et al., 2004), antiviral 
(Sinha et al., 2004), and antibacterial properties (Abraham, 2005; Sugie et al., 2001),to 
name a few. (Martins and Carvalho, 2007)  Di-substituted DKP’s have been used to 
transports drugs across the blood brain barrier  (Teixido et al., 2007) and several DKPs 
have significant biological activity in their affinity for the neurokinin-2-receptors.(Nefzi 
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et al., 1997) Successful synthesis of the 2,5 and 2,6-DKPs, by both solution and solid 
phase chemistry, has been amply reported in the literature.(Fytas et al., 2008; Maity and 
Koenig, 2008; Perrotta et al., 2001; Sinha et al., 2004; Teixido et al., 2007) 
4.1.2 Design of 3-R-Piperazine-2,5 and 2,6-Dione Scaffold 
Our group initially targeted the use of hydrazine linked functionalized 2,5 and 
2,6-DKP units for the formation of α-helix mimetic scaffolds, as shown in Figure 4.2. 
These scaffolds, based on Hamilton’s terphenyl scaffold, were designed to mimic the 
MDM2 binding domain of the p53 peptide, specifically the hydrophobic face of two turns 
of a p53 α-helix, with key aromatic and hydrophobic residues in the ith, ith+3, and ith+7 
positions.  This novel design was envisioned to increase desired drug like properties of 
the parent terphenyl scaffold with the addition of polar functional groups.  The R and R’ 
positions of the scaffold can be broadly diversified by altering the functional group 
and/or stereochemistry of the position by using the desired natural or unnatural amino 
acid or amino ester as the starting material.  Different starting materials can be used for 
each of the hydrazine-linked monomers to achieve numerous possible combinations. 
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Figure 4.2: 2,5 and 2,6 DKP based scaffold 
 
 
4.2 Results and Discussion for the 3-R-Piperazine-2,6-Dione Scaffold 
4.2.1 Retrosynthesis of 3-R-Piperazine-2,6-Dione Scaffold 
3-R-piperazine-2,6-diones can be prepared by solution or solid phase synthesis.  
A general retrosynthetic route for the hydrazine bound monomeric unit, A1, is shown in 
Scheme 4.1.  The amino acid methyl-esters a underwent N-alkylation b and hydrazine 
formation c, followed by formation of the cyclic anhydride d.  Coupling of cyclic 
anhydride d produced a β-alanine linker derivative f, and subsequent intramolecular 
cyclization afforded the desired hydrazine bound A1 unit.  Following N-Boc deprotection, 
coupling of the A1 unit with an additional cyclic anhydride d can form the dimeric unit 
A1-A2, which can serve as a building block for the synthesis of the target trimeric scaffold 
A1-A2-A3 via iteration of these steps. 
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Scheme 4.1: Retrosynthesis of the 3-R-piperazine-2,6-dione scaffold 
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4.2.2  Synthesis of Key Di-acid Derivatives 4.5a-c 
The formation of di-acids 4.5a-c was performed in a 3-4 step optimized synthesis 
as depicted in Scheme 2.2. The free amino acids 4.1a-c were reacted with thionyl 
chloride in the presence of methanol yielding methyl ester derivatives 4.2a-c as the HCl 
salts, in high yields. The methyl esters of standard and non-standard amino acids were 
subsequently N-alkylated with ethyl bromoacetate in the presence of 
diisopropylethylamine (DIEA), forming 4.3a-d, in moderate to high yields, 52-88%.   
The key step of this synthetic process was the insertion of the N-Boc protected 
hydrazine moiety.  This type of reaction had been successfully performed in our lab by 
means of nitrosation, selective reductions, and subsequent N-Boc protection.(Oguz et al., 
2002)  However, due to the inefficiency of the protocol and the toxicity of the 
nitrosamine intermediates, an alternative method using electrophilic amination by means 
of tert-butyl 3-(trichloromethyl)-1,2-oxazirdine-2-carboxylate (N-Boc oxaiziridine, 
Scheme 2.2) for hydrazine formation was established in our laboratories. The N-Boc 
oxaiziridine was prepared in our laboratory (Avancha, 2006) according to previously 
reported literature procedures.(Hannachi et al., 2004; Vidal et al., 1993; Vidal et al., 
1998)  Use of the N-Boc oxaiziridine proved optimal due to its ability to cleanly transfer 
the N-Boc group to the desired secondary amine position in one step and it was less toxic 
than previously used agents. 
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Scheme 4.2: Synthesis of di-acids 4.5a-c 
 
As shown in Scheme 4.2, compounds 4.3a-c underwent electrophilic amination, using N-
boc oxaiziridine, resulting in the formation of the corresponding N-Boc protected 
hydrazines 4.4a-c. Basic hydrolysis of compounds 4.4a-c yielded the desired N-Boc 
protected hydrazine di-acids 4.5a-c in high yields (75-85%) as the pure products. 
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4.2.3 Solid Phase Synthesis  
Dr. Umut Oguz pursued the coupling and cyclization of di-acid dervatives 4.5a-c 
by solid phase synthesis (Scheme 2.3), ultimately yielding the trimeric 2,6-DKP scaffold 
4.12 which exhibited an IC50 of 4.7 uM inhibition for Bcl-xL/Bax interactions, according 
to fluorescence polarization assay analysis. The key step of this synthetic route was the 
formation of the cyclic anhydride 4.6.  The synthetic details will not be discussed but 
analogs prepared utilizing her novel protocols will be.  
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Scheme 4.3: Solid phase synthesis of the 3-R-piperazine-2,6-dione scaffold 
 
4.2.4 Solution Phase Synthesis of 2,6-DKP Monomers 
My focus was the solution phase synthesis of the 2,6-DKP (Scheme 4.4).  
Hydrazine di-acids 4.5a-b were treated with DIC in the presence of DCM to generate the 
cyclic anhydrides 4.6a-b in situ.  Coupling of β-alanine benzylester hydrochloride with 
4.6a afforded 4.13a.(Brockunier et al., 2004)  The purification of 4.13a was lengthy and 
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tedious and the yield was poor.  Compound 4.13a underwent cyclization via activation of 
the carboxylic acid with acetic anhydride in the presence of sodium acetate, yielding the 
target 2,6-DKP, 4.14a.  
Scheme 4.4: Solution phase synthesis of the 2,6-DKPs 
 
 
The conditions followed for the synthesis of 4.14a were not optimal, as yields for 
the coupling and cyclization steps were low, purification was difficult, and acylation of 
the amide nitrogen resulted in significant formation of undesired sideproduct compound 
4.15b (and determined by Dr. Oguz).  Attempts in the lab to improve this synthesis by 
using orthogonally protected di-esters to generate a mono-acid aiming at facilitating the 
regioselective coupling and improving yields were unsuccessful.(Anderson, 2009) 
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4.2.5 Attempts at Isolation of Cyclic Anhydride 4.6 
In order to optimize the conditions for the solution phase synthesis of the 2,6 DKP 
monomers, various reaction conditions were explored in the attempt to isolate and purify 
the cyclic anhydride 4.6a-b (Scheme 4.5) prior to subsequent coupling.(Brockunier et al., 
2004; Humphrey and Chamberlin, 1997; Paul and Anderson, 1960)  In all cases, the 
formation of the cyclic anhydrides were observed by TLC, however, the isolation of 4.6a-
b was not accomplished due to the instability of the compounds. 
 
Entry Reagents Conditions 
4.5b DIC DCM, MW 90 °C, 25 min 
4.5b DCC THF, MW 110 °C, 30 min 
4.5b DCC DCM, 0 °C to rt, 24 h 
4.5b EDC DCM, 0 °C to rt, 24 h 
4.5b Pivalic Anhydride DCM, rt, 28 h 
4.5b Ac2O rt to reflux, 12 h 
4.5b HATU, DIEA DCM, rt, 24 h 
*
4.5c EDC, HOBt DCM, 60 °C, 24 h 
*
4.5c DCC MeCN, rt, 24 h 
*
4.5c CDI THF, rt, 24 h 
*
4.5c Ac2O, pyridine DCM, rt, 18 h 
*
4.5c Ac2O MW 130 °C, 20 min 
             *by L. Anderson 
Scheme 4.5: Attempted cyclic anhydride 4.6 isolation 
 
The cyclization step remained the bottle neck of the synthetic protocol.  The low yields 
and difficult synthesis of the 2,6-DKP based scaffolds were deemed impractical and 
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inefficient for the generation of focused libraries.  Taking all the information into 
consideration, the work on the 2,6-DKP based scaffold was concluded and the design of  
alternative DKP based scaffolds were explored. 
4.3 Results and Discussion for the 3-R-Piperazine-2,5-Diones 
4.3.1 Retrosynthesis of 3-R-Piperazine-2,5-Dione, Unit A1: Approach 1 
The next synthetic strategy involved the use of the DKP-2,5-dione units as 
depicted in Scheme 4.6.  It was expected that the cyclization of the 2,5-DKP units would 
be more accessible due to the increased nucleophilicity of the reacting amino group. For 
this approach (Scheme 4.6), we concentrated on synthesizing the monomeric 2,5-DKP 
unit that did not contain a hydrazine moiety in hopes that the presence of the free amine 
would facilitate the synthetic process.  This approach began by reacting commercially 
available amino acids a with succinimidyl diazoacetate (synthesized in house, Scheme 
4.7) to form the diazoacetamide derivative b, followed by coupling c, and  ring closure 
via metal catalyzed N-H insertion yielding the target A1 unit.   
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Scheme 4.6: Retrosynthesis of 3-R-piperazine-2,5-dione, A1: Approach 1 
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4.3.2 Synthesis of Compound 4.19 
Compound 4.19 (Scheme 4.7) was synthesized following literature procedures 
(Blankley et al., 1969a; Ouihia et al., 1993) and was chosen as a key intermediate 
because of its reported high stability and easier handling when compared with the 
moisture-sensitive acid chloride analogs.(Blankley et al., 1969b)  
 
Scheme 4.7: Synthesis of succinimidyl diazoacetate 
 
 
4.3.3 Attempted Synthesis of the 2,5-DKP Monomer 4.22 
 
Depicted in Route 1 of Scheme 4.8, commercially available amino acid methyl 
esters 4.3a-b were treated with 4.19 (Scheme 4.7), under basic conditions followed by 
hydrolysis, yielding the diazoacetamide dervatives 4.20a-b.  Compound 4.20a was further 
coupled to commercially available β-alanine methyl ester hydrochloride yielding 
compound 4.21 (Scheme 4.8, Route 1).  Attempts at ring closure via metal catalyzed N-H 
insertion (compounds 4.22 and 4.25) by treatment with Cu(I) catalysis(Ma et al., 2005) 
failed to provide compound 4.22 (Scheme 4.8, Route 2).  Further, relavent synthetic 
efforts carried out by our laboratories all proved unsuccessful.(Anderson, 2009).  
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Scheme 4.8: Attempted synthesis of 2,5-DKP monomer 4.22 and 4.25 
 
 
The synthesis of 2,5-DKP monomers via approach 1 was not successful.  The initial 
treatment with compound 4.19 and further coupling to commercially available β-alanine 
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methyl ester hydrochloride were low yielding and difficult to purify.  Further attempts at 
copper catalyzed ring closure were also unsuccessful on my part as well as additional 
group members.   
4.3.4 Retrosynthesis of 3-R-Piperazine-2,5-Dione, Unit A1: Approach 2  
In the next approach, it was intended to first synthesize the 2,5-DKP monomeric 
unit, then insert the hydrazine moiety as a branching point to extend the scaffold (Scheme 
4.9). It was hoped that the chemically simplified monomer unit A1 would facilitate the 
synthetic process.  It was also advantageous to implore this synthetic method as there 
were documented syntheses of this nature beginning with commercially available amino 
acid esters.(Maity and Koenig, 2008)  This approach involved the coupling or N-
acylation of commercially available amino acid methyl esters a, hydrolysis b, and 
intramolecular cyclization c followed by hydrazine formation to afford the desired 
hydrazine linked 2,5-DKP unit, A1 (Scheme 4.9). 
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Scheme 4.9: Retrosynthesis of 3-R-piperazine-2,5-dione, A1: Approach 2 
 
4.3.5 Synthesis of 2,5-DKP Monomer, Route 1 
Two different routes were investigated to determine an efficient synthesis of the 
desired 2,5-DKP monomer.  Route 1 (Scheme 4.10) began with commercially available 
esters 4.3a-b. These esters underwent microwave assisted coupling reactions with N-
phenyl glycine in the presence of HBTU and DIEA yielding esters 4.26a-b.  
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Scheme 4.10: Route 1 used to synthesize the 2,5-DKP monomers 
 
Synthesis of the methylesters 4.26a-b was attempted by activation of the carboxylic acid 
utilizing various reagents (Scheme 4.11).  Standard coupling using EDC under basic 
conditions (Entry 1&2, Scheme 4.11) yielded a complicated product mixture.  The 
addition of heat to the EDC couplings did not minimize the formation of the undesired 
side products.  Next, the use of an aminium-based coupling reagent, 1H-Benzotriazolium 
1-[bis(dimethylamino)methylene]-5chloro-,hexafluorophosphate (1-),3-oxide (HCTU) 
was investigated (Entry 3, Scheme 4.11) for its reported effects in reducing the rates of 
racimization in a reaction and high level of stability. Unfortunately HCTU was not a 
successful reagent in the clean formation of 4.26a as it too resulted in the formation of 
numerous side products.  Lastly, an alternate aminium based coupling reagent O-
(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) was 
used for its reported ability to minimize reaction racimization and higher reactivity when 
compared with HCTU. As shown in Entry 4 of Scheme 4.11, the use of HBTU did 
144 
 
provide the desired 4.26a compound without the formation of numerous side products 
although only in trace amounts.  Successful synthesis of 4.26a-b was determined to be 
carried out in a Biotage Microwave Reactor at 85 
o
C for 30 minutes in the presence of 
HBTU, DIEA, and DMF.(Fara et al., 2006)  These reaction conditions showed both good 
yields (86% of compound 4.26a) and minimal formation of side products. 
 
Entry Entry Conditions Results 
1 4.3b EDC, HOBt, DIEA, CH3CN, rt, 4h Multiple side products 
2 4.3b EDC, DIEA, CH3CN, reflux, 24h Multiple side products 
3 4.3b HCTU, DIEA, DMF, 80 
o
C, 24h Multiple side products 
4 4.3b HBTU, DIEA, DMF, 80 
o
C, 24h Traces 
5 4.3b HBTU, DIEA, DMF, MW, 85 
o
C, 30 min 86% 
Scheme 4.11: Attempts to synthesize 4.26a 
 
Esters 4.26a-b underwent basic saponification to provide acids 4.27a-b in good 
yields. Synthesis of the diketopiperazines 4.28a-b was carried out in the presence of 
HBTU in a Biotage Reactor.   Finally, reduction of 4.28a-b with lithium aluminum 
hydride afforded the desired piperazine target monomers 4.29a-b.   
Although successful and high yielding, the synthesis of diketopiperazines 4.27a-b 
involved tedious and lengthy purification.  Further attempts to employ N-aryl and N-alkyl 
glycine as an alternative to N-phenyl glycine failed to provide the desired product (data 
not shown).  Efficient examples were limited to the starting materials reported in Scheme 
4.10.  
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X-ray crystals structures of compounds 4.27a-b (Figure 4.3) were obtain at 
Lousiana State University, by Dr. Frank Froncezk, and the crystal structures did verify 
the s stereochemistry of the compounds.  
 
Figure 4.3: X-ray crystal structures of compounds 4.27a and 4.27b 
 
4.3.6 Synthesis of 2,5-DKP Monomer, Route 2 
Route 2, depicted in Scheme 4.12, was investigated as an alternative synthetic 
strategy to improve conditions, efficiency, and applicability to a wider range of amino 
acids.  Route 2 began with reactions of esters 4.3b-c, 4.30 with bromoacetyl bromide in a 
biphasic system of aqueous saturated sodium bicarbonate in benzene, to yield compounds 
4.30a-c as the pure product in good yields.(Maity and Koenig, 2008) Esters 4.31a-c were 
subsequently reacted with benzyl amine in methanol to yield the diketopiperazines 4.32a-
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c as the pure product, which were reduced to the corresponding piperazines 4.33a-b in 
the presence of 1M borane/tetrahydrofuran.(Le Bourdonnec et al., 2006)  
 
Scheme 4.12: Route 2 used to synthesize the 2,5-DKP monomer 
 
 
Although both Routes 1 and 2 did lead to the desired 2,5-DKP monomer, Route 2 
was chosen as the preferred synthetic protocol based on the higher efficiency, 
reproducibility, and dexterity of starting material when compared to Route 1. 
4.3.7 Hydrazine Insertion 
A few different options were explored to achieve hydrazine formation of 4.35 
(Scheme 4.13).  The first was by performing N-nitrosation of the amide.  This was to be 
achieved by generating NOCL gas in situ using tert-butylnitrite and TMS-Cl in the 
presence of pyridine and DCM.(Francom and Robins, 2003) Also nitrosonium 
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tetrafluoroborate (NOBF4) in the presence of pyridine in acetonitrile was also attempted 
for N-nitrosation.  These conditions unfortunately did result in the desired product 4.35 
formation.   Our efforts at hydrazine insertion to the 2,5-DKP monomer were halted due 
to the inefficiency of the synthetic route and the high toxicity of the reagents. 
 
Entry Reagents Conditions 
1  TMS-Cl, tert-butyl nitrite, pyridine  DCM, 0 °C to rt, 24 h  
2  TMS-Cl, tert-butyl nitrite, pyridine  DCM, 0 °C to 40 °C, 6 h  
3  TMS-Cl, tert-butyl nitrite, pyridine  DCM, rt to 40 °C, 6 h  
4  NOBF4, pyridine  CH3CN, -10 °C to 0 °C, 2 h  
5  NOBF4, pyridine  CH3CN, 0 °C, 2 h  
Scheme 4.13: Attempts at hydrazine formation 
 
4.4  Conclusion 
 Our efforts in the synthesis of repetitively linked hydrazine bound functionalized 
2,5 and 2,6-DKP units linked for the formation of α-helix mimetic scaffolds were 
successful in the synthesis of a library of amino di-acid derivatives and a variety of 
functionalized 2,5 and 2,6-DKPs.  Numerous approached described were unsuccessful at 
the desired di- and trimeric scaffold formation.  The primary difficulty with the described 
approaches was the low yielding cyclization step or the inability for cyclization to occur.  
The use of the 2,5-DKP monomeric units did offer promising data with their ease of 
synthesis and high yields although the insertion of the hydrazine moiety remains a 
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challenge.  Further evaluation of the functionalized 2,5-DKP units as building block for 
the construction of α-helix mimetics, provides promising synthetic potential. 
4.5  Experimental Procedures 
Methyl 1-aminocyclohexanecarboxylate hydrochloride (4.2a)  
 
To an ice water bath chilled solution of 4.1a (1.41 mmol) in MeOH (10 mL) was slowly 
added thionyl chloride (4.28 mmol) and brought to ambient temperatures.  The solution 
was stirred for an additional 6 hours at a gentle reflux.  The solution was cooled to 
ambient temperatures, the residual solvent was removed in vacuo to afford the pure 
product 4.2a (1.38 mmol, 95%) as a white solid. 
1
H NMR (400 MHz, CD3OD) δ 3.84 (s, 
3H), 2.17 – 2.05 (m, 2H), 1.88 – 1.46 (m, 8H).  13C NMR (101 MHz, CD3OD) δ 171.19 
(1C), 59.59 (1C), 52.71 (1C), 31.62 (2C), 24.06 (1C), 20.62 (2C).  MS (ESI) m/z 158.56 
(M + H)
+
.   
(S)-methyl 2-((2-ethoxy-2-oxoethyl)amino)-3-methylbutanoate (4.3a)  
 
To a solution L-valine methyl ester hydrochloride (5.96 mmol) in anhydrous CH3CN (20 
mL) acetonitrile, under argon, was slowly added diisopropyl ethyl amine (11.93 mmol) 
and ethyl bromoacetate (11.93 mmol).  The reaction mixture was kept under argon at 
ambient temperatures and stirred for 24 hours.  To the mixture was added, DI H2O (50 
mL) and 10% citric acid (10 mL), followed by extraction with ethyl acetate ( 3 x 50 mL). 
The combined organic layers were washed with brine (2 x 50 mL), dried over Na2SO4, 
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and the residual solvent was removed in vacuo to afford the crude product 4.3a as a light 
yellow oil. Purification by flash column chromatography on silica gel (ethyl 
acetate/hexane, 1:10) afforded compound 4.3a as a clear oil (3.58 mmol, 62%).  
1
H NMR 
(400 MHz, CDCl3) δ 6.93 (d, J = 7.5 Hz, 1H), 4.52 (dd, J = 8.8, 4.8 Hz, 1H), 3.91 (s, 
2H), 3.76 (s, 3H), 2.27 – 2.15 (m, 1H), 0.94 (dd, J = 9.9, 6.9 Hz, 6H).  13C NMR (101 
MHz, CDCl3) δ 172.06 (1C), 165.73 (1C), 57.91 (2C), 52.55 (1C), 31.53 (1C), 29.15 
(1C), 19.09 (2C), 17.91 (1C).  MS (ESI) m/z 218.1 (M + H)
+
. 
(S)-methyl 2-((2-ethoxy-2-oxoethyl)amino)-4-methylpentanoate (4.3b) 
 
This was obtained from L-leucine methyl ester hydrochloride (0.66 mmol) in a similar 
manner as described for preparation of 4.3a. Purification by flash column 
chromatography on silica gel (ethyl acetate/hexane, 1:10) afforded compound 4.3b as a 
yellow oil (0.46 mmol, 70%).  
1
H NMR (400 MHz, CDCl3) δ 4.17 (q, J = 7.1 Hz, 2H), 
3.71 (s, 3H), 3.44 – 3.29 (m, 4H), 2.13 (bs, 1H), 1.74 (dp, J = 13.4, 6.7 Hz, 1H), 1.51 (td, 
J = 7.1, 2.4 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H), 0.91 (dd, J = 6.6, 1.8 Hz, 6H).  
13
C NMR 
(101 MHz, CDCl3) δ 175.67 (1C), 171.91 (1C), 61.06 (1C), 59.46 (1C), 51.99 (1C), 
49.40 (1C), 42.69 (1C), 25.04 (1C), 22.93 (1C), 22.43 (1C), 14.40 (1C).  MS (ESI) m/z 
345.2 (M - H)
-
. 
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methyl 1-((2-ethoxy-2-oxoethyl)amino)cyclohexanecarboxylate (4.3d) 
 
This was obtained from 4.2a (0.84 mmol) in a similar manner as described for 
preparation of 4.3a. Purification by flash column chromatography on silica gel (ethyl 
acetate/hexane, 5:95) afforded compound 4.3d as a yellow oil (0.42 mmol, 52%).  
1
H 
NMR (400 MHz, CDCl3 ) δ 4.17 (q, J = 7.1 Hz, 2H), 3.68 (s, 2H), 3.30 (s, 2H), 2.50 (bs, 
1H), 1.95-1.89 (m, 2H), 1.68-1.62 (m, 2H), 1.54-1.48 (m, 2H), 1.44 – 1.35 (m, 4H), 1.26 
(t, J = 7.1 Hz, 3H).  
13
C NMR (101 MHz, CDCl3) δ 176.03 (1C), 172.28 (1C), 61.51 
(1C), 61.11 (1C), 51.99 (1C), 45.34 (1C), 33.41 (2C), 25.72 (1C), 22.07 (2C), 14.40 (1C).  
MS (ESI) m/z 242.2 (M - H)
-
. 
(S)-tert-butyl 2-(2-ethoxy-2-oxoethyl)-2-(1-methoxy-3-methyl-1-oxobutan-2-
yl)hydrazinecarboxylate (4.4a)  
 
A solution 4.3a (3.69 mmol) in anhydrous MeOH (10 mL), under argon, was chilled to -
78˚C in a dry ice/ acetone bath.  To the chilled solution, was added oxaiziridine (4.06 
mmol), warmed to ambient temperatures, and stirred for an additional 18 h.  The solvent 
was removed in vacuo and the residual white residue was diluted with DI H2O (50 mL). 
The aqueous solution was extracted with EtOAc (3 x 35 mL), washed with brine (2 x 50 
mL), dried (Na2SO4), and evaporated under reduced pressure.  The crude product was 
purified using flash chromatography on silica gel (30:70 EtOAc/hexanes) to afford 4.4a 
as a clear oil (2.95 mmol, 80%).  
1
H NMR (400 MHz, CDCl3) δ 4.14 (q, J = 7.1 Hz, 2H), 
3.71 (s, 3H), 3.07 (d, J = 9.7 Hz, 1H), 1.99 (ddt, J = 13.3, 9.9, 6.7 Hz, 1H), 1.44 (s, 9H), 
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1.26 (t, J = 7.1 Hz, 3H), 1.12 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 6.7 Hz, 3H).  MS (ESI) m/z 
281.1 (M + H)
+
. 
(S)-2-(2-(tert-butoxycarbonyl)-1-(carboxymethyl)hydrazinyl)-3-methylbutanoic acid 
(4.5a)  
 
To a solution of 4.4a (1.51 mmol) in anhydrous MeOH (10 mL), was added 1M NaOH 
(30 mL) and vigorously stirred for 24 hours.  The solvent was removed in vacuo, and to 
the residue was added DI H2O (15 mL), acidified with 15% citric acid (20 mL), and 
extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine 
(2 x 30 mL), dried over Na2SO4, and evaporated under reduced pressure to afford the 
pure compound 4.5a (1.13 mmol, 75%) as a white solid. m.p. = 130-134 
o
C.  
1
H NMR 
(400 MHz, CD3OD ) δ 3.72-3.60 (m, 2H), 3.30 (dt, J = 3.2, 1.6 Hz, 1H), 3.22 (d, J = 8.1 
Hz, 1H), 2.0-1.91 (m, 1H), 1.51 – 1.41 (m, 9H), 1.10 (d, J = 6.6 Hz, 3H), 0.97 (d, J = 6.8 
Hz, 3H).  
13
C NMR (101 MHz, CD3OD) δ 174.01 (1C), 172.27 (1C), 157.13 (1C), 90.39 
(1C), 80.84 (1C), 73.53 (1C), 28.75 (1C), 27.42 (3C), 19.39 (1C), 18.36 (1C).  MS (ESI) 
m/z 289.1 (M - H)
-
. 
(S)-2-(2-(tert-butoxycarbonyl)-1-(carboxymethyl)hydrazinyl)-4-methylpentanoic 
acid (4.5b) 
 
This was obtained from 4.4b (1.69 mmol) in a similar manner as described for 
preparation of 4.5a yielding the pure compound 4.5b (1.27 mmol, 75%).  
1
H NMR (400 
MHz, CD3OD) δ 3.70-3.65 (m, 3H), 1.93 (s, 1H), 1.66 – 1.40 (m, 12H), 0.94 (t, J = 7.3 
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Hz, 6H).  
13
C NMR (101 MHz CD3OD) δ 174.86 (1C), 172.38 (1C) 80.81 (1C), 65.43 
(1C), 57.82 (1C), 39.05 (1C), 27.37 (1C), 24.54 (1C), 22.19 (1C), 20.98 (1C).  MS (ESI) 
m/z 303.1 (M - H)
-
. 
(S)-2-(2-(tert-butoxycarbonyl)-1-(carboxymethyl)hydrazinyl)-3-phenylpropanoic 
acid (4.5c) 
 
This was obtained from 4.4c (1.20 mmol) in a similar manner as described for 
preparation of 4.5a yielding the pure compound 4.5c (0.96 mmol, 80%).  
1
H NMR (400 
MHz, CD3OD) δ 7.29 – 7.16 (m, 5H), 3.90 (t, J = 7.3 Hz, 1H), 3.71 (d, J = 1.6 Hz, 2H), 
3.03 (d, J = 7.3 Hz, 2H), 1.46 (s, 9H).  
13
C NMR (101 MHz, CD3OD) δ 203.79 (1C), 
173.46 (1C), 137.54 (1C), 129.05 (2C), 128.21 (2C), 126.41 (2C), 69.31 (1C), 57.17 
(1C), 35.90 (1C), 27.50 (2C).  MS (ESI) m/z 337.1 (M - H)
-
. 
(S)-2-(8-isopropyl-13,13-dimethyl-3,7,11-trioxo-1-phenyl-2,12-dioxa-6,9,10-
triazatetradecan-9-yl)acetic acid (4.13a) 
 
To a solution of 4.5a  (0.69 mmol) in DCM (5 mL), was added DIC (0.69 mmol), and the 
solution stirred at ambient temperature for 3 hours (or until the disappearance of the 
starting material 4.5a was observed by TLC confirming the formation of 4.6a).  To the 
stirring solution of 4.6a in DCM was added β-alanine benzyl ester hydrochloride (0.69 
mmol), triethylamine (1.38 mmol), and stirred at ambient temperature for 18 hours.  The 
solvents were removed in vacuo, the resulting residue was diluted with DI H20 (20 mL), 
acidified with 1N HCl, and extracted with EtOAc (3 x 50 mL).  The combined organic 
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layers were washed with brine (2 x 50 mL), dried over Na2SO4, and the solvent was 
removed in vacuo to give the crude product. The crude product was purified using flash 
chromatography on silica gel (70:30 EtOAc/hexanes) to afford 4.13a as a light yellow oil 
(0.21 mmol, 30%).  
1
H NMR (400 MHz, CDCl3)  δ 7.35-7.41 (m, 5H), 5.17 (s, 2H),  3.3-
3.8 (m, 5H),  2.6 (t, 2H), 1.9 (m, 1H), 1.4 (s, 9H), 1.1 (d, 3H), 0.97 (d, 3H).  MS (ESI) 
m/z 452.2 (M + H)
+
. 
(S)-benzyl 3-(4-((tert-butoxycarbonyl)amino)-3-isopropyl-2,6-dioxopiperazin-1-
yl)propanoate (4.14a) 
 
To a solution of 4.13a (0.22 mmol) in acetic anhydride (10 mL) was added sodium 
acetate (1.33 mmol). The reaction mixture was refluxed at 75 °C for 18 hours then 
brought to ambient temperatures. To the reaction was added DI H20 (50 mL) and 
extracted with chloroform (3 x 30 mL).  The combined organic layers were washed with 
1.2 N NaOH (1 x 60 mL), brine (2 x 50 mL), and dried over Na2SO4.  The solvent was 
removed in vacuo to give the crude product which was purified by flash 
chromatographed on silica gel (30:70 EtOAc/Hexanes) to provide 4.14a (0.04 mmol,  
20%) as a clear oil. 
1
H NMR (400 MHz, CDCl3)  δ 7.31-7.4 (m, 5H), 5.09 (s, 2H),  4.03-
4.2 (m, 2H),  3.8-4.0 (dd, 2H), 3.37 (d, 1H), 2.6-2.7 (m, 2H), 1.9-2.0 (m, 1H), 1.4 (s, 9H), 
1.1 (d, 3H), 0.98 (d, 3H).   MS (ESI) m/z 451.2 (M + H)
+
. 
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(E)-2-(2-tosylhydrazono)acetic acid (4.17) 
 
A solution of glycolic acid monohydrate (0.22 m) in DI H2O (50 mL) was warmed to 60 
o
C. This warm solution was then subsequently treated with a warm (approximately 60 
°C) solution of 4.16 (0.22 m) in conc. HCl (10 mL) and heated for an additional 10 
minutes. The resulting mixture was brought to ambient temperatures and stirred for an 
additional 12 hours then placed in a refrigerator overnight.  The crude product was 
collected on a filter, washed with cold water, and allowed to dry at ambient temperatures 
for 2 days. The crude product was recrystallized with boiling benzene and chilled 
hexanes to afford compound 4.17 (0.19 m, 87%) as white crystals, m.p. 146–152 °C.  The 
structural confirmation of 4.17 was obtained by single-crystal X-ray diffraction.  
1
H 
NMR (400 MHz, DMSO) δ 12.29 (s, 1H), 7.69 (d, J = 8.3 Hz, 2H), 7.42 (d, J = 8.1 Hz, 
2H), 7.17 (s, 1H), 2.36 (s, 3H). 
13C NMR (101 MHz, DMSO) δ 164.26 (1C), 144.72 (1C), 
138.14 (1C), 136.37 (1C), 130.58 (2C), 127.78 (2C), 21.70 (1C).  MS (ESI) m/z 241.2 (M 
- H)
-
. 
(E)-2-(2-tosylhydrazono)acetyl chloride (4.18) 
 
To a suspension of 4.17 (0.18 m) in benzene (220 mL) was added thionyl chloride (0.36 
m) and heated to reflux for 18 hours. The reaction mixture was cooled to ambient 
temperatures, filtered through a diatomaceous earth mat on a sintered-glass funnel, and 
concentrated in vacuo to afford the crude solid. The residual solid was tritutrated with 
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warm benzene to afford acid chloride 4.18 (0.054 m, 30%) as pale yellow crystals, m.p. 
102–106 °C.  1H NMR (400 MHz, (D3C)2SO) δ 7.69 (d, J = 8.3 Hz, 2H), 7.42 (d, J = 8.1 
Hz, 2H), 7.10 (s, 1H), 2.36 (s, 3H).
  13
C NMR (101 MHz, (D3C)2SO) δ 164.25 (1C), 
138.15 (1C), 136.45 (1C), 130.43 (2C), 127.78 (2C), 21.61 (1C).  MS (ESI) m/z 261.6 (M 
+ H)
+
. 
2,5-dioxopyrrolidin-1-yl 2-diazoacetate (4.19)  
 
To a chilled mixture of Na2CO3 (1.41 mmol) and N-hydroxy succinimide (0.85 mmol) in 
anhydrous DCM (5 mL) was added 4.18 (0.70 mmol) in DCM (3 mL).  Reaction was 
maintained at 0 
0
C for 2 hours then stirred at ambient temperatures for an additional 3 
hours.  The reaction mixture was filtered through a diatomaceous earth mat on a sintered-
glass funnel, and concentrated in vacuo to afford the crude yellow solid.  The crude 
product was recrystallized with boiling DCM and chilled hexanes to afford compound 
4.19 (0.32 mmol, 45%) as yellow crystals.  The structural confirmation of 4.19 was 
obtained by single-crystal X-ray diffraction. 
(S)-methyl 4-methyl-2-(2-(phenylamino)acetamido)pentanoate (4.26a) 
 
A mixture of L-leucine methyl ester hydrochloride (3.96 mmol), N-phenyl glycine (7.94 
mmol), HBTU (4.76 mmol), and DIEA (7.94 mmol) in anhydrous DMF (12 mL) was 
heated in the Biotage microwave at 85 ºC for 30 minutes.  After cooling to ambient 
temperature, the solution was diluted with DI H2O (100 mL) and saturated KHSO4 (30 
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mL).  The aqueous solution was extracted with EtOAc (3 x 35 mL), washed with brine (2 
x 50 mL), dried (Na2SO4), and evaporated under reduced pressure.  The crude product 
was purified by chromatography on silica gel performed using the Flash Master 3 
purification station (30:70 EtOAC/hexanes) to afford 4.26a as a light yellow oil (3.40 
mmol, 86%).  1H NMR (400 MHz, CDCl3) δ 7.19 (m, 2H), 7.07 (m, 1H), 6.79 (m,1H), 
6.61 (m, 2H), 4.66 (m, 1H), 3.80 (d, J = 4.19 Hz, 2H), 3.67 (s, 3H), 1.65-1.43 (m, 3H), 
0.87 (dd, J = 15.07 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 173.39 (1C), 170.96 (1C), 
147.38 (1C), 129.55 (2C), 119.29 (1C), 113.57 (2C),52.45 (1C), 50.61 (1C), 49.02 (1C), 
41.38 (1C), 24.99 (1C), 23.03 (1C), 21.85 (1C).  HRMS (ESI) calc. for C15H22N2O3 (M + 
H)
+
 278.1630, found 278.1715. 
(S)-methyl 3-phenyl-2-(2-(phenylamino)acetamido)propanoate (4.26b) 
 
This was obtained from L-phenylalanine methyl ester hydrochloride (0.66 mmol) in a 
similar manner as described for preparation of 4.26a. The crude product was purified by 
chromatography on silica gel using a Flash Master 3 purification station (30:70 
EtOAc/hexanes) to afford 4.26b as a clear oil (0.95 mmol, 72%).  
1
H NMR (400 MHz, 
CDCl3) δ 7.27-7.09 (m, 5H), 6.93 (m, 2H), 6.82 (m, 2H), 6.56 (m, 1H), 4.95 (m, 1H), 
3.75 (d, J = 8.59 Hz, 2H), 3.70 (s, 3H), 3.06 (dd, J = 6.01 Hz, 2H). 
13
C NMR (100 MHz, 
CDCl3) δ 171.89 (1C), 170.49 (1C), 147.11 (1C), 135.71 (1C), 129.62 (2C), 129.36 (2C), 
128.78 (1C), 127.28 (2C), 119.40 (1C), 113.51 (2C), 52.75 (1C), 52.54 (1C), 48.86 (1C), 
38.13 (1C).  HRMS (ESI) calc. for C18H20N2O3 (M + H)
+
 312.1473, found 312.1603. 
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(S)-4-methyl-2-(2-(phenylamino)acetamido)pentanoic acid (4.27a) 
 
To a solution of 4.26a (0.77 mmol) in methanol (15 mL) was added 3M NaOH (1.92 
mmol) and stirred at ambient temperature for 24 hours.  The solution was acidified with 
6M HCl (4 mL), extracted with EtOAc (3 x 30 mL), washed with brine (2 x 40 mL), 
dried (Na2SO4), and evaporated under reduced pressure.  The crude product was 
recrystallized with boiling EtOAc to afford 4.27a (0.58 mmol, 76%) as yellow crystals.  
The structural confirmation of 4.27a was obtained by single-crystal X-ray diffraction.  
1
H 
NMR (400 MHz, CD3OD) δ 7.99 (d, J = 8.48 Hz, 1H), 7.16-7.08 (m, 2H), 6.71-6.56 (m, 
3H), 4.49-4.47 (m, 1H), 3.77 (q, J = 17.22 Hz, 2H), 3.34 (s, 1H), 1.63-1.47 (m, 3H), 0.86 
(d, J = 5.79 Hz, 6H).  
13
C NMR (100 MHz, CD3OD) δ 174.55 (1C), 172.87 (1C), 148.06 
(1C), 128.90 (2C), 117.94 (1C), 112.93 (2C), 50.61 (1C), 48.69 (1C), 40.46 (1C), 24.71 
(1C), 22.20 (1C), 20.54 (1C). HRMS (ESI) calc. for C14H20N2O3 (M - H)
-
 264.1473, 
found 264.1401. 
(S)-3-phenyl-2-(2-(phenylamino)acetamido)propanoic acid (4.27b) 
 
This was obtained from 4.26b (0.64 mmol) in a similar manner as described for 
preparation of 4.27a.  The crude product was recrystallized with boiling EtOAc to afford 
4.27b (0.50 mmol, 77%) as light yellow crystals.  The structural confirmation of 4.27b 
was obtained by single-crystal X-ray diffraction.   
1
H NMR (400 MHz, CD3OD) δ 7.87 
(s, 1H), 7.17-7.00 (m, 7H), 6.70 (m, 1H), 6.51 (m, 2H), 4.76-4.71 (m, 1H), 3.68 (q, J = 
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17.44 Hz, 2H), 3.07 (ddd, J = 21.65, 6.38 Hz, 2H). 
13
C NMR (101 MHz, CD3OD) δ 
173.04 (1C), 172.68 (1C), 148.05 (1C), 136.55 (1C), 129.13 (2C), 128.95 (2C), 128.28 
(1C), 126.61 (2C), 117.93 (1C), 112.88 (2C), 53.14 (1C), 48.44 (1C), 37.11 (1C).  HRMS 
(ESI) calc. for C17H18N2O3 (M - H)
-
 298.1317, found 298.1267. 
(S)-3-isobutyl-1-phenylpiperazine-2,5-dione (4.28a) 
 
A mixture of 4.27a (0.97 mmol), HBTU (1.16 mmol), and DIEA (1.07 mmol) in 
anhydrous DMF (2 mL) was heated in the Biotage microwave at 80 ºC for 25 minutes.  
After cooling to ambient temperature, the solution was diluted with DI H2O (60 mL), 
extracted with EtOAc (3 x 30 mL), washed with brine (2 x 30 mL), dried (Na2SO4), and 
evaporated under reduced pressure.  The crude product was purified by chromatography 
on silica gel using the Flash Master 3 purification station (40:60 EtOAc/hexanes), 
recrytallized with boiling EtOAc/chilled hexanes to afford 4.28a as a light yellow crystals 
(0.96 mmol, 99%).  The structural confirmation of 4.28a was obtained by single-crystal 
X-ray diffraction.  
1
H NMR (400 MHz, CDCl3) δ 7.43 (m2H), 7.34-7.27 (m, 2H), 7.06 (s, 
1H), 4.33 (dd, J = 52.81 Hz, 2H), 4.13 (m, 1H), 1.88-1.73 (m, 3H), 1.00 (dd, J = 14.60 
Hz, 6H).  
13
C NMR (100 MHz, CDCl3) δ 166.99 (1C), 166.61 (1C), 140.53 (1C), 129.64 
(2C), 127.72 (2C), 125.53 (1C), 54.53 (1C), 52.72 (1C), 42.71 (1C), 24.60 (1C), 23.34 
(1C), 21.59 (1C).  HRMS (ESI) calc. for C14H18N2O2 (M + H)
+
 246.1368, found 
246.1441. 
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(S)-3-benzyl-1-phenylpiperazine-2,5-dione (4.28b) 
 
This was obtained from 4.27b (0.16 mmol) in a similar manner as described for 
preparation of 4.28a.   The crude product was purified by chromatography on silica gel 
performed using the Flash Master 3 purification station (30:70 EtOAc/hexanes), 
affording 4.28b as a light yellow solid (0.13 mmol, 84%).  
1
H NMR (400 MHz, CDCl3) δ 
7.44-7.36 (m, 5H), 7.34-7.27 (m, 3H), 7.11 (d, J = 7.40 Hz, 2H), 6.06 - 6.02 (bs, 1H), 
4.46 (m, 1H), 3.85 (d, J = 17.24 Hz, 1H), 3.35 (d, J = 17.20 Hz, 1H), 3.31-3.26 (m, 1H), 
3.19 (dd, J = 13.84 Hz, 1H).  
13
C NMR (100 MHz, CDCl3) δ 166.47 (1C), 165.68 (1C), 
140.23 (2C), 135.08 (2C), 130.44 (2C), 129.65 (1C), 129.18 (1C), 128.06 (1C), 127.91 
(1C), 125.54 (2C), 57.23 (1C), 52.08 (1C), 41.01 (1C).  HRMS (ESI) calc. for 
C17H16N2O2 (M + H)
+
 280.1211, found 280.1316. 
 (S)-methyl 2-(2-bromoacetamido)-4-methylpentanoate (4.31a)  
 
To a suspension of 4.3a (27.52 mmol) in water (10 mL), cooled in an ice-salt bath, was 
added NaHCO3 (55.63 mmol) in one portion.  A solution of bromoacetyl bromide (23.18 
mmol) in benzene (8.5 mL) was slowly added via addition funnel to the chilled mixture.  
After completion of the addition, the reaction was brought to ambient temperature and 
stirred for an additional 24h at rt.  The aqueous layer was extracted with benzene (3 x 50 
mL) and the combined organic layers were washed with brine (1 x 100 mL) and dried 
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(Na2SO4).  Removal of the solvent in vacuo afforded the pure product 4.31a (14.37 
mmol, 62%) as a colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 6.87 (s, 1H), 4.62 – 4.55 
(m, 1H), 3.87 (d, J = 1.6 Hz, 2H), 3.73  (s, 3H), 1.71 – 1.54 (m, 3H), 0.92 (d, J = 6.2 Hz, 
6H).  
13
C NMR (101 MHz, CDCl3) δ 173.06 (1C), 165.62 (1C), 52.71 (1C), 51.56 (1C), 
41.55 (1C), 29.02 (1C s), 25.07 (1C), 23.01 (1C), 22.14 (1C). 
(S)-methyl 2-(2-bromoacetamido)-3-phenylpropanoate (4.31b)   
 
The product was obtained from L-phenylalanine methyl ester hydrochloride (23.18 
mmol) in a similar manner as described for preparation of 4.30a affording the pure 
compound 4.31b ( 14.02 mmol, 90%) as a colorless oil. 
1
H NMR (400 MHz, CDCl3) δ 
7.33 – 7.21 (m, 3H), 7.13 – 7.08 (m, 2H), 6.91 (d, J = 7.2 Hz, 1H), 4.84 (dt, J = 7.9, 5.8 
Hz, 1H), 3.83 (d, J = 2.9 Hz, 2H), 3.73 (s, 3H), 3.20 – 3.07 (m, 2H).  13C NMR (101 
MHz, CDCl3) δ 171.52 (1C), 165.60 (1C), 135.51 (1C), 129.49 (2C), 128.91 (2C), 127.57 
(1C), 53.96 (1C), 52.75 (1C), 37.91 (1C), 28.82 (1C).  MS (ESI) m/z 300.02 (M + H)
+
. 
(S)-methyl 2-(2-bromoacetamido)-3-(4-(tert-butoxy)phenyl)propanoate (4.31c) 
 
The product was obtained from 4.30 (3.47 mmol) in a similar manner as described for 
preparation of 4.31a affording the pure compound 4.31c (2.42 mmol, 90%) as a colorless 
oil.  
1
H NMR (400 MHz, CDCl3) δ 7.03 – 6.98 (m, 2H), 6.94 – 6.90 (m, 2H), 6.81 (d, J = 
7.5 Hz, 1H), 4.80 (dt, J = 7.9, 5.9 Hz, 1H), 3.88 – 3.78 (m, 2H), 3.72 (s, 3H), 3.15 – 3.05 
(m, 2H), 1.32 (s, 9H).  
13
C NMR (101 MHz, CDCl3) δ 171.55 (1C), 165.28 (1C), 154.81 
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(1C), 130.28 (1C), 129.94 (2C), 124.58 (2C), 78.75 (1C), 53.95 (1C), 52.70 (1C), 37.27 
(1C), 29.05 (3C). MS (ESI) m/z 372.08 (M + H)
+
. 
(S)-1-benzyl-3-isobutylpiperazine-2,5-dione (4.32a) 
 
A solution of benzylamine (5.56 mmol) in methanol (4.5 mL) was slowly added via an 
additional funnel to a solution of compound 4.30a (4.64 mmol) and TEA (11.59 mmol) in 
methanol (10 mL) and refluxed for 36 h.  The resulting light yellow solution was cooled 
to ambient temperatures, concentrated, and the resulting residue was dissolved in ethyl 
acetate (100 mL).  The organic phase was washed with saturated citric acid (1 x 35 mL), 
saturated aqueous sodium bicarbonate (2 x 30 mL), brine (2 x 50 mL), and dried 
(Na2SO4).  Filtration and removal of the organic solvent in vacuo gave a crude pale 
yellow solid, which was recrystallized from toluene to afford compound 4.32a (61%) as a 
white solid.  
1
H NMR (400 MHz, CDCl3) δ 7.38 – 7.22 (m, 5H), 6.24 (s, 1H), 4.59 (dd, J 
= 37.3, 14.5 Hz, 2H), 4.09 – 4.01 (m, 1H), 3.91 – 3.77 (m, 2H), 1.88 – 1.61 (m, 3H), 0.97 
(dd, J = 12.0, 6.4 Hz, 6H).  
13
C NMR (101 MHz, CDCl3) δ 166.67 (1C), 165.87 (1C), 
135.41 (1C), 129.20 (2C), 128.57 (2C), 128.39 (1C), 54.10 (1C), 49.98 (1C), 49.05 (1C), 
43.23 (1C), 24.53 (1C), 23.40 (1C), 21.44 (1C).  HRMS (ESI) calc. for C18H18N2O2 (M + 
H)
+
 294.1368, found 294.1441. 
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(S)-1,3-dibenzylpiperazine-2,5-dione (4.32b) 
 
The product was obtained from 4.31b (3.77 mmol) in a similar manner as described for 
preparation of 4.32a. Yield: 34%, white solid.  
1
H NMR (400 MHz, CDCl3) δ 7.38 – 7.12 
(m, 910H), 6.18 (bs, 1H), 4.55 – 4.42 (m, 2H), 4.38 – 4.29 (m, 1H), 3.54 (d, J = 17.6 Hz, 
1H), 3.17 (qd, J = 13.7, 5.3 Hz, 2H), 3.02 (dd, J = 17.6, 0.7 Hz, 1H).  MS (ESI) m/z 
295.14 (M + H)
+
. 
(S)-1-benzyl-3-isobutylpiperazine (4.33a)   
 
To a solution of 2.31a (1.64 mmol) in anhydrous tetrahydrofuran (10 mL) was added 1M 
boran-tetrahydrofuran solution (9.83 mmol), and the reaction was heated to reflux under 
argon for 36 h.  The mixture was brought to ambient temperature for 10 min then chilled 
to 0 
o
C.  To the chilled, stirring solution was added methanol (20 mL) and the solution 
was kept at 0 
o
C for 1 h.  A 4M anhydrous solution of hydrogen chloride in dioxane (5 
mL) was subsequently added to the reaction and heated to reflux for 1 h.  After cooling to 
ambient temperature, aqueous ammonium hydroxide solution (10 mL) was added to the 
mixture, subsequently stirred for 10 min at rt, and concentrated in vacuo.  The resulting 
residue was dissolved in methanol (20 mL) and again concentrated in vacuo.  This 
process was repeated 4 times, affording compound 4.32a (53%) as a yellow oil. 
1
H NMR 
(400 MHz, CDCl3) δ 7.31 – 7.24 (m, 2H), 6.94 (d, J = 7.9, 2H), 6.86 (t, J = 7.3, 1H), 3.53 
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(d, J = 10.4, 2H), 3.17 – 3.10 (m, 1H), 3.02 (td, J = 11.7, 3.0, 1H), 2.97 – 2.89 (m, 1H), 
2.73 (td, J = 11.6, 3.2, 1H), 2.43 – 2.31 (m, 2H), 1.75 (dt, J = 13.2, 6.6, 1H), 1.38 – 1.23 
(m, 2H), 0.95 (t, J = 6.4, 7H).  MS (ESI) m/z 233.20 (M + H)
+
. 
(S)-1,3-dibenzylpiperazine (4.33b) 
 
The product was obtained from 2.31b (1.64 mmol) in a similar manner as described for 
preparation of 2.32a. Yield: 62%, clear oil.  
1
H NMR (400 MHz, CD3OD) δ 7.37 – 7.15 
(m, 10H), 3.76 – 3.44 (m, 4H), 3.32 (dd, J = 17.7, 1H), 3.16 – 2.84 (m, 4H), 2.47 (t, J = 
10.8 Hz, 1H), 2.31 (dd, J = 12.7, 10.1 Hz, 1H).  MS (ESI) m/z 267.19 (M + H)
+
. 
4.4  References 
Abraham, W.-R. (2005). Controlling pathogenic Gram-negative bacteria by interfering 
with their biofilm formation. Drug Design Reviews--Online 2, 13-33. 
 
Anderson, L. (2009) Design and synthesis of substituted 1,4-hydrazine-linked piperazine-
2,5- and 2,6-diones and 2,5-terpyrimidinylenes as alpha-helical mimetics, University of 
South Florida, Tampa. 
 
Asano, N. (2003). Glycosidase inhibitors: update and perspectives on practical use. 
Glycobiology 13, 93R-104R. 
 
Avancha, K. K. V. R. (2006) Design and synthesis of core structural intermediates for 
novel HIV-1 protease inhibitors and synthesis, biological activity, and molecular 
modeling of novel 20S proteasome inhibitors. , University of South Florida, Tampa. 
 
Blankley, C. J., Sauter, F. J., and House, H. O. (1969a). Crotyl diazoacetate. Org Syn 49, 
22-27. 
 
Blankley, C. J., Sauter, F. J., and House, H. O. (1969b). Crotyl diazoacetate. Organic 
Syntheses 49. 
 
Brockunier, L. L., He, J., Colwell, L. F., Habulihaz, B., He, H., Leiting, B., Lyons, K. A., 
Marsilio, F., Patel, R. A., Teffera, Y., et al. (2004). Substituted piperazines as novel 
164 
 
dipeptidyl peptidase IV inhibitors. Bioorganic & Medicinal Chemistry Letters 14, 4763-
4766. 
 
Fara, M. A., Diaz-Mochon, J. J., and Bradley, M. (2006). Microwave-assisted coupling 
with DIC/HOBt for the synthesis of difficult peptoids and fluorescently labeled peptides-
a gentle heat goes a long way. Tetrahedron Letters 47, 1011-1014. 
 
Francom, P., and Robins, M. J. (2003). Nucleic Acid Related Compounds. 118. 
Nonaqueous Diazotization of Aminopurine Derivatives. Convenient Access to 6-Halo- 
and 2,6-Dihalopurine Nucleosides and 2'-Deoxynucleosides with Acyl or Silyl Halides. 
Journal of Organic Chemistry 68, 666-669. 
 
Fytas, C., Zoidis, G., and Fytas, G. (2008). A facile and effective synthesis of lipophilic 
2,6-diketopiperazine analogues. Tetrahedron 64, 6749-6754. 
 
Hannachi, J.-C., Vidal, J., Mulatier, J.-C., and Collet, A. (2004). Electrophilic Amination 
of Amino Acids with N-Boc-oxaziridines: Efficient Preparation of N-Orthogonally 
Diprotected Hydrazino Acids and Piperazic Acid Derivatives. Journal of Organic 
Chemistry 69, 2367-2373. 
 
Houston, D. R., Synstad, B., Eijsink, V. G. H., Stark, M. J. R., Eggleston, I. M., and van 
Aalten, D. M. F. (2004). Structure-Based Exploration of Cyclic Dipeptide Chitinase 
Inhibitors. Journal of Medicinal Chemistry 47, 5713-5720. 
 
Humphrey, J. M., and Chamberlin, A. R. (1997). Chemical Synthesis of Natural Product 
Peptides: Coupling Methods for the Incorporation of Noncoded Amino Acids into 
Peptides. Chemical Reviews (Washington, D C) 97, 2243-2266. 
 
Kanoh, K., Kohno, S., Katada, J., Takahashi, J., and Uno, I. (1999). (-)-Phenylahistin 
arrests cells in mitosis by inhibiting tubulin polymerization. Journal of Antibiotics 52, 
134-141. 
 
Kanzaki, H., Imura, D., Nitoda, T., and Kawazu, K. (2000). Enzymatic conversion of 
cyclic dipeptides to dehydro derivatives that inhibit cell division. Journal of Bioscience 
and Bioengineering 90, 86-89. 
 
Le Bourdonnec, B., Goodman, A. J., Graczyk, T. M., Belanger, S., Seida, P. R., 
DeHaven, R. N., and Dolle, R. E. (2006). Synthesis and Pharmacological Evaluation of 
Novel Octahydro-1H-pyrido[1,2-a]pyrazine as micro -Opioid Receptor Antagonists. 
Journal of Medicinal Chemistry 49, 7290-7306. 
 
Ma, M., Peng, L., Li, C., Zhang, X., and Wang, J. (2005). Highly Stereoselective [2,3]-
Sigmatropic Rearrangement of Sulfur Ylide Generated through Cu(I) Carbene and 
Sulfides. Journal of the American Chemical Society 127, 15016-15017. 
165 
 
Maity, P., and Koenig, B. (2008). Synthesis and structure of 1,4-dipiperazino benzenes: 
Chiral terphenyl-type peptide helix mimetics. Organic Letters 10, 1473-1476. 
Martins, M. B., and Carvalho, I. (2007). Diketopiperazines: biological activity and 
synthesis. Tetrahedron 63, 9923-9932. 
 
Nefzi, A., Ostresh, J. M., and Houghten, R. A. (1997). The Current Status of Heterocyclic 
Combinatorial Libraries. Chemical Reviews (Washington, D C) 97, 449-472. 
 
Nicholson, B., Lloyd, G. K., Miller Brian, R., Palladino Michael, A., Kiso, Y., Hayashi, 
Y., and Neuteboom Saskia, T. C. (2006). NPI-2358 is a tubulin-depolymerizing agent: in-
vitro evidence for activity as a tumor vascular-disrupting agent. Anti-cancer drugs 17, 25-
31. 
 
Niida, A., Oishi, S., Sasaki, Y., Mizumoto, M., Tamamura, H., Fujii, N., and Otaka, A. 
(2005). Facile access to (Z)-alkene-containing diketopiperazine mimetics utilizing 
organocopper-mediated anti-SN2' reactions. Tetrahedron Letters 46, 4183-4186. 
 
Oguz, U., Guilbeau, G. G., and McLaughlin, M. L. (2002). A facile stereospecific 
synthesis of alpha -hydrazino esters. Tetrahedron Letters 43, 2873-2875. 
 
Ouihia, A., Rene, L., Guilhem, J., Pascard, C., and Badet, B. (1993). A new 
diazoacylating reagent: preparation, structure, and use of succinimidyl diazoacetate. 
Journal of Organic Chemistry 58, 1641-1642. 
 
Paul, R., and Anderson, G. W. (1960). N,N'-Carbonyldiimidazole, a new peptide-forming 
reagent. Journal of the American Chemical Society 82, 4596-4600. 
 
Perrotta, E., Altamura, M., Barani, T., Bindi, S., Giannotti, D., Harmat, N. J. S., 
Nannicini, R., and Maggi, C. A. (2001). 2,6-Diketopiperazines from Amino Acids, from 
Solution-Phase to Solid-Phase Organic Synthesis. Journal of Combinatorial Chemistry 3, 
453-460. 
 
Sinha, S., Srivastava, R., De Clercq, E., and Singh, R. K. (2004). Synthesis and Antiviral 
Properties of Arabino and Ribonucleosides of 1,3-Dideazaadenine, 4-Nitro-1,3-
dideazaadenine and Diketopiperazine. Nucleosides, Nucleotides & Nucleic Acids 23, 
1815-1824. 
 
Sugie, Y., Hirai, H., Inagaki, T., Ishiguro, M., Kim, Y.-J., Kojima, Y., Sakakibara, T., 
Sakemi, S., Sugiura, A., Suzuki, Y., et al. (2001). A new antibiotic CJ-17,665 from 
Aspergillus ochraceus. Journal of Antibiotics 54, 911-916. 
 
Teixido, M., Zurita, E., Malakoutikhah, M., Tarrago, T., and Giralt, E. (2007). 
Diketopiperazines as a tool for the study of transport across the Blood-Brain Barrier 
166 
 
(BBB) and their potential use as BBB-shuttles. Journal of the American Chemical 
Society 129, 11802-11813. 
 
Vidal, J., Guy, L., Sterin, S., and Collet, A. (1993). Electrophilic amination: preparation 
and use of N-Boc-3-(4-cyanophenyl)oxaziridine, a new reagent that transfers a N-Boc 
group to N- and C-nucleophiles. Journal of Organic Chemistry 58, 4791-4793. 
 
Vidal, J., Hannachi, J.-C., Hourdin, G., Mulatier, J.-C., and Collet, A. (1998). N-Boc-3-
Trichloromethyloxaziridine: a new, powerful reagent for electrophilic amination. 
Tetrahedron Letters 39, 8845-8848. 
 
 
167 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Apendix A: Selected 1H and 13C NMR Spectra 
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(S)-methyl 2-(2-bromoacetamido)-3-methylbutanoate (2.3a) 
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(S)-tert-butyl 2-((2-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)amino)-3-methylbutanoate (2.4a)   
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170 
 
(S)-methyl 2-(2-(((S)-1-(tert-butoxy)-3-methyl-1-oxobutan-2-yl)amino)acetamido)-4-
methylpentanoate (2.4b)  
 
(S)-2-((S)-3-isobutyl-2,5-dioxopiperazin-1-yl)-3-phenylpropanoic acid (2.7f) G63 
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(S)-tert-butyl 2-((2-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)amino)-3-phenylpropanoate (2.4c)  
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(S)-methyl 2-(2-(((S)-1-(tert-butoxy)-1-oxo-3-phenylpropan-2-yl)amino)acetamido)-
4-methylpentanoate (2.4d)  
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173 
 
S)-tert-butyl 2-((2-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)amino)-4-methylpentanoate (2.4e)  
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174 
 
(S)-tert-butyl 2-((2-(((S)-1-methoxy-3-methyl-1-oxobutan-2-yl)amino)-2-oxoethyl) 
amino)-4-methylpentanoate (2.4f)  
 
 
175 
 
(2S,3R)-tert-butyl 2-((2-(((S)-1-methoxy-3-methyl-1-oxobutan-2-yl)amino)-2-
oxoethyl)amino)-3-methylpentanoate (2.4g)  
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(S)-2-(2-(((S)-1-(tert-butoxy)-3-methyl-1-oxobutan-2-yl)amino)acetamido)-3-
phenylpropanoic acid (2.5a)  
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177 
 
(S)-2-(2-(((S)-1-(tert-butoxy)-3-methyl-1-oxobutan-2-yl)amino)acetamido)-4-
methylpentanoic acid (2.5b)  
 
 
178 
 
(S)-2-(2-((S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-ylamino)acetamido)-3-
phenylpropanoic acid (2.5c)  
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179 
 
(S)-2-(2-((S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-ylamino)acetamido)-4-
methylpentanoic acid (2.5d)  
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180 
 
(S)-2-(2-(((S)-1-(tert-butoxy)-4-methyl-1-oxopentan-2-yl)amino)acetamido)-3-
phenylpropanoic acid (2.5e)  
 
 
 
181 
 
(S)-2-(2-(((S)-1-(tert-butoxy)-4-methyl-1-oxopentan-2-yl)amino)acetamido)-3-
methylbutanoic acid (2.5f) 
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182 
 
(S)-2-(2-(((2S,3R)-1-(tert-butoxy)-3-methyl-1-oxopentan-2-yl)amino)acetamido)-3-
methylbutanoic acid (2.5g)   
 
 
183 
 
(S)-tert-butyl 2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-3-methylbutanoate (2.6a)  
 
 
184 
 
(S)-tert-butyl 2-((S)-3-isobutyl-2,5-dioxopiperazin-1-yl)-3-methylbutanoate (2.6b)  
 
 
185 
 
(S)-tert-butyl2-((S)-3-isobutyl-2,5-dioxopiperazin-1-yl)-3-phenylpropanoate (2.6d)  
 
 
186 
 
(S)-tert-butyl 2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-4-methylpentanoate (2.6e)  
 
 
 
187 
 
(S)-tert-butyl 2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)-4-methylpentanoate (2.6f)  
 
 
188 
 
(2S,3S)-tert-butyl 2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)-3-methylpentanoate 
(2.6g)  
 
 
189 
 
 (S)-2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)-4-methylpentanoic acid (2.7d)  
 
 
190 
 
(2S,3S)-2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)-3-methylpentanoic acid (2.7e)
 
 
191 
 
(S)-tert-butyl 2-(2-bromoacetamido)-3-phenylpropanoate (2.8a)  
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192 
 
(S)-tert-butyl 2-(2-bromoacetamido)-4-methylpentanoate (2.8b)  
 
 
193 
 
(S)-tert-butyl 2-(2-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)acetamido)-3-
methylbutanoate (2.9a)  
 
 
194 
 
(S)-methyl 2-((2-(((S)-1-(tert-butoxy)-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)amino)-4-methylpentanoate (2.9c)  
 
 
195 
 
(2S,3R)-methyl 2-((2-(((S)-1-(tert-butoxy)-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)amino)-3-methylpentanoate (2.9d)  
 
 
196 
 
(S)-tert-butyl 2-(2-(((S)-1-methoxy-3-methyl-1-oxobutan-2-yl)amino)acetamido)-4-
methylpentanoate (2.9e)  
 
 
197 
 
(S)-tert-butyl 2-(2-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino) 
acetamido)-3-methylbutanoate (2.9g)  
 
 
198 
 
(S)-tert-butyl 2-(2-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino) 
acetamido)-3-phenylpropanoate (2.9h)  
 
 
199 
 
(S)-tert-butyl 2-(2-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino) 
acetamido)-4-methylpentanoate (2.9i)  
 
 
200 
 
(S)-2-(2-((S)-1-methoxy-1-oxo-3-phenylpropan-2-ylamino)-2-oxoethylamino)-3-
methylbutanoic acid (2.10a) 
 
 
201 
 
(S)-2-(2-((S)-1-methoxy-4-methyl-1-oxopentan-2-ylamino)-2-oxoethylamino)-3-
phenylpropanoic acid (2.10c)  
 
 
202 
 
(S)-2-((2-(((S)-1-methoxy-3-methyl-1-oxobutan-2-yl)amino)-2-oxoethyl)amino)-4-
methylpentanoic acid (2.10e)  
 
 
203 
 
(S)-2-(2-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino)acetamido)-3-
methylbutanoic acid (2.10f)  
 
 
 
204 
 
(S)-2-(2-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino)acetamido)-3-
phenylpropanoic acid (2.10g)  
 
 
205 
 
(S)-methyl 2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)-3-phenylpropanoate (2.11a)  
 
 
 
206 
 
(S)-methyl 2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-3-phenylpropanoate (2.11b)  
 
 
207 
 
(S)-methyl 2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-4-methylpentanoate (2.11c) 
 
 
208 
 
(S)-methyl 2-((S)-3-isobutyl-2,5-dioxopiperazin-1-yl)-3-methylbutanoate (2.11d)  
 
 
 
209 
 
(S)-methyl 3-(1H-indol-3-yl)-2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)propanoate 
(2.11e)  
 
 
210 
 
(S)-methyl 2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-3-(1H-indol-3-yl)propanoate 
(2.11f)  
 
 
211 
 
(S)-methyl 3-(1H-indol-3-yl)-2-((S)-3-isobutyl-2,5-dioxopiperazin-1-yl)propanoate 
(2.11g)  
 
(S)-2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)-3-phenylpropanoic acid (2.12a)  
 
212 
 
(2S,3S)-methyl 2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-3-methylpentanoate (2.11i)  
 
 
213 
 
(S)-3-(1H-indol-3-yl)-2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)propanoic acid 
(2.12c)  
 
 
214 
 
(S)-2-((S)-3-isobutyl-2,5-dioxopiperazin-1-yl)-3-methylbutanoic acid (2.12f) 
 
 
 
215 
 
(S)-1-((S)-3-(1H-indol-3-yl)-1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl)-3-
isopropylpiperazine-2,5-dione (2.14) 
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4-Benzyl-2-methylsulfanyl-pyrimidine-5-carbonitrile (3.2b) 
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4-tert-Butyl-2-methylsulfanyl-pyrimidine-5-carbonitrile (3.2a) 
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2-Methylsulfanyl-4-naphthalen-1-ylmethyl-pyrimidine-5-carbonitrile (3.2c) 
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4-tert-Butyl-2-methanesulfonyl-pyrimidine-5-carbonitrile (3.3a) 
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4-Benzyl-2-methanesulfonyl-pyrimidine-5-carbonitrile (3.3b) 
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phenyl 2-phenylacetate (3.17) 
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2-nitro-1-phenylethanol (3.19a) 
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1-nitro-3-phenylpropan-2-ol (3.19b) 
 
4-methyl-1-nitropentan-2-ol (3.19c)   
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2-nitro-1-phenylethanone (3.20a) 
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4-methyl-1-nitropentan-2-one (3.20b) 
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1-nitro-3-phenylpropan-2-one (3.21a) 
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5-nitro-4-phenylpyrimidin-2-amine (3.22a) 
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5-nitro-2,4-diphenylpyrimidine (3.23) 
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2,4-diphenylpyrimidin-5-amine (3.24) 
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5-bromo-2,4-diphenylpyrimidine (3.25) 
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N,N'-Bis(tert-butoxycarbonyl)-S-methylisothiourea (3.35) 
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232 
 
(S)-tert-butyl (((tert-butoxycarbonyl)amino)(2,4-dibenzylpiperazin-1-
yl)methylene)carbamate (3.36) 
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233 
 
(S)-4-benzyl-2-(2,4-dibenzylpiperazin-1-yl)pyrimidine-5-carbonitrile (3.38) 
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234 
 
Methyl 1-aminocyclohexanecarboxylate hydrochloride (4.2a)  
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(S)-methyl 2-((2-ethoxy-2-oxoethyl)amino)-3-methylbutanoate (4.3a) 
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(S)-methyl 2-((2-ethoxy-2-oxoethyl)amino)-4-methylpentanoate (4.3b) 
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methyl 1-((2-ethoxy-2-oxoethyl)amino)cyclohexanecarboxylate (4.3d) 
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(S)-tert-butyl 2-(2-ethoxy-2-oxoethyl)-2-(1-methoxy-3-methyl-1-oxobutan-2-
yl)hydrazinecarboxylate (4.4a)  
 
(E)-2-(2-tosylhydrazono)acetyl chloride (4.18) 
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(S)-2-(2-(tert-butoxycarbonyl)-1-(carboxymethyl)hydrazinyl)-3-methylbutanoic acid 
(4.5a) 
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240 
 
(S)-2-(2-(tert-butoxycarbonyl)-1-(carboxymethyl)hydrazinyl)-4-methylpentanoic 
acid (4.5b) 
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241 
 
(S)-2-(2-(tert-butoxycarbonyl)-1-(carboxymethyl)hydrazinyl)-3-phenylpropanoic 
acid (4.5c) 
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(E)-2-(2-tosylhydrazono)acetic acid (4.17) 
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(S)-methyl 4-methyl-2-(2-(phenylamino)acetamido)pentanoate (4.26a) 
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244 
 
(S)-methyl 3-phenyl-2-(2-(phenylamino)acetamido)propanoate (4.26b) 
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245 
 
(S)-4-methyl-2-(2-(phenylamino)acetamido)pentanoic acid (4.27a) 
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(S)-3-phenyl-2-(2-(phenylamino)acetamido)propanoic acid (4.27b) 
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(S)-3-isobutyl-1-phenylpiperazine-2,5-dione (4.28a) 
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(S)-3-benzyl-1-phenylpiperazine-2,5-dione (4.28b) 
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(S)-methyl 2-(2-bromoacetamido)-4-methylpentanoate (4.31a) 
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(S)-methyl 2-(2-bromoacetamido)-3-phenylpropanoate (4.31b)   
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(S)-methyl 2-(2-bromoacetamido)-3-(4-(tert-butoxy)phenyl)propanoate (4.31c) 
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(S)-1-benzyl-3-isobutylpiperazine-2,5-dione (4.32a) 
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(S)-1,3-dibenzylpiperazine-2,5-dione (4.32b) 
 
(S)-1-benzyl-3-isobutylpiperazine (4.33a)   
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(S)-1,3-dibenzylpiperazine (4.33b) 
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Appendix B: Selected Mass Spectra 
 
 
 
 
 
 
 
 
 
 
 
 
256 
 
 
(S)-methyl 2-(2-bromoacetamido)-3-methylbutanoate (2.3a) 
 
257 
 
(S)-methyl 2-(2-bromoacetamido)-3-(4-(tert-butoxy)phenyl)propanoate (2.3e) 
 
258 
 
(S)-tert-butyl 2-((2-(((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)amino)-4-methylpentanoate (2.4e)  
 
259 
 
(S)-tert-butyl 2-((2-(((S)-1-methoxy-3-methyl-1-oxobutan-2-yl)amino)-2-oxoethyl) 
amino)-4-methylpentanoate (2.4f)  
 
260 
 
(S)-2-(2-(((2S,3R)-1-(tert-butoxy)-3-methyl-1-oxopentan-2-yl)amino)acetamido)-3-
methylbutanoic acid (2.5g)  
 
261 
 
(S)-tert-butyl 2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-4-methylpentanoate (2.6e)  
 
262 
 
(2S,3S)-tert-butyl 2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)-3-methylpentanoate 
(2.6g)  
 
 
263 
 
(S)-2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-4-methylpentanoic acid (2.7c)   
 
 
 
264 
 
(S)-2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)-4-methylpentanoic acid (2.7d)  
 
 
265 
 
(2S,3S)-2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)-3-methylpentanoic acid (2.7e)  
 
 
266 
 
(S)-tert-butyl 2-(2-bromoacetamido)-3-phenylpropanoate (2.8a)  
 
 
 
267 
 
(S)-tert-butyl 2-(2-bromoacetamido)-4-methylpentanoate (2.8b)  
 
 
 
268 
 
(S)-methyl 2-((2-(((S)-1-(tert-butoxy)-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)amino)-4-methylpentanoate (2.9c)  
 
 
269 
 
(2S,3R)-methyl 2-((2-(((S)-1-(tert-butoxy)-1-oxo-3-phenylpropan-2-yl)amino)-2-
oxoethyl)amino)-3-methylpentanoate (2.9d)  
 
 
270 
 
(2S,3R)-methyl 2-((2-(((S)-1-(tert-butoxy)-3-methyl-1-oxobutan-2-yl)amino)-2-
oxoethyl)amino)-3-methylpentanoate (2.9f)  
 
 
271 
 
(S)-tert-butyl 2-(2-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino) 
acetamido)-3-methylbutanoate (2.9g)  
 
 
272 
 
(S)-tert-butyl 2-(2-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino) 
acetamido)-3-phenylpropanoate (2.9h)  
 
 
273 
 
(S)-2-(2-((S)-1-methoxy-1-oxo-3-phenylpropan-2-ylamino)-2-oxoethylamino)-3-
methylbutanoic acid (2.10a)  
 
 
 
274 
 
(S)-2-(2-((S)-1-methoxy-4-methyl-1-oxopentan-2-ylamino)-2-oxoethylamino)-3-
phenylpropanoic acid (2.10c)  
 
 
275 
 
(S)-2-(2-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino)acetamido)-3-
methylbutanoic acid (2.10f)  
 
 
276 
 
(S)-methyl 2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-4-methylpentanoate (2.11c)  
 
 
277 
 
(S)-methyl 2-((S)-3-isobutyl-2,5-dioxopiperazin-1-yl)-3-methylbutanoate (2.11d)  
 
 
 
 
278 
 
(S)-methyl 3-(1H-indol-3-yl)-2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)propanoate 
(2.11e)  
 
 
279 
 
(2S,3S)-methyl 2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-3-methylpentanoate (2.11i)  
 
 
280 
 
(S)-2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)-3-phenylpropanoic acid (2.12a) 
 
 
 
281 
 
(S)-2-((S)-3-benzyl-2,5-dioxopiperazin-1-yl)-3-phenylpropanoic acid (2.12b)  
 
 
 
 
282 
 
(S)-3-(1H-indol-3-yl)-2-((S)-3-isopropyl-2,5-dioxopiperazin-1-yl)propanoic acid 
(2.12c)  
 
 
283 
 
(S)-3-benzyl-1-((S)-4-methyl-1-oxo-1-(4-phenylpiperazin-1-yl)pentan-2-
yl)piperazine-2,5-dione (2.14) 
 
 
 
 
284 
 
4-Benzyl-2-methylsulfanyl-pyrimidine-5-carbonitrile (3.2b)   
 
 
285 
 
2-Methylsulfanyl-4-naphthalen-1-ylmethyl-pyrimidine-5-carbonitrile (3.2c) 
 
 
286 
 
4-tert-Butyl-2-methanesulfonyl-pyrimidine-5-carbonitrile (3.3a)    
 
 
287 
 
4-Benzyl-2-methanesulfonyl-pyrimidine-5-carbonitrile (3.3b) 
 
 
288 
 
5-nitro-2,4-diphenylpyrimidine (3.23)  
 
 
289 
 
2,4-diphenylpyrimidin-5-amine (3.24)  
 
 
290 
 
N,N'-Bis(tert-butoxycarbonyl)-S-methylisothiourea (3.35) 
 
 
291 
 
(S)-tert-butyl (((tert-butoxycarbonyl)amino)(2,4-dibenzylpiperazin-1-
yl)methylene)carbamate (3.36) 
 
 
 
 
 
 
 
 
292 
 
(S)-4-benzyl-2-(2,4-dibenzylpiperazin-1-yl)pyrimidine-5-carbonitrile (3.38) 
 
 
293 
 
(S)-methyl 4-methyl-2-(2-(phenylamino)acetamido)pentanoate (4.26a) 
 
294 
 
(S)-methyl 3-phenyl-2-(2-(phenylamino)acetamido)propanoate (4.26b) 
 
 
 
295 
 
(S)-4-methyl-2-(2-(phenylamino)acetamido)pentanoic acid (4.27a) 
 
 
 
296 
 
(S)-3-phenyl-2-(2-(phenylamino)acetamido)propanoic acid (4.27b) 
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(S)-3-isobutyl-1-phenylpiperazine-2,5-dione (4.28a) 
 
 
298 
 
(S)-3-benzyl-1-phenylpiperazine-2,5-dione (4.28b) 
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(S)-1-benzyl-3-isobutylpiperazine-2,5-dione (4.32a) 
 
 
 
300 
 
(S)-1-benzyl-3-isobutylpiperazine (4.33a)   
 
 
 
 
 
 
 
 
 
301 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix C: X-Ray Crystallographic Data  
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ORTEP diagram for compound (2.7e)  
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 ORTEP diagram for compound (2.11g)  
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 ORTEP diagram for compound (3.20a)  
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ORTEP diagram for compound (3.21a)  
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 ORTEP diagram for compound (3.22a)  
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 ORTEP diagram for compound (3.24)  
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 ORTEP diagram for compound (3.25)  
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ORTEP diagram for compound (4.17) 
 
ORTEP diagram for compound (4.19) 
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ORTEP diagram for compound (4.28a) 
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ORTEP diagram for compound (4.27a) 
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 ORTEP diagram for compound (4.27b) 
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